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1. General Introduction 
Summary 
Failure of antimicrobial treatment is observed frequently in hospitalized patients resulting in 
morbidity and mortality, A possible way to improve antimicrobial treatment is the targeted 
delivery of antimicrobial agents, This thesis describes a study on tihe use of long-Circulating 
liposomes for the targeted delivery of antimicrobial agents to sites of bacterial infections, In 
this chapter an introduction is given on the use of targeted drug delivery in infectious 
diseases, which is followed by the aims and outline of this thesis, 
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1. Infectious diseases 
Infectious diseases remain an important cause of morbidity and mortality in the Western 
world, especially in hospitalized patients. The long, invasive, and intensive hospital 
treatments lower the barriers to microbial invasion of host tissues and compromise the 
development of an adequate inflammatory/immune response. In addition, the host response 
may be weakened by administration of immunosuppressants or cytotoxic drugs or as a 
result of a pathology that affects the host defense. Under these circumstances antimicrobial 
treatment frequently fails. This thesis focuses on ways to increase the efficacy of 
antimicrobial treatment against bacterial infections. 
Bacteria are unicellular prokaryotic organisms with a circular double-stranded 
deoxyribonucleic acid (DNA) molecule that bears the genetic information (Salyers, 1994). 
Additional genetic information may be present in the form of plasmids, small 
extrachromosomal, self-replicating, and transferable DNA molecules (Actis, 1999; Davison, 
1999). Some components of the bacterial cell wall, like peptidoglycan, (Iipo)teichoic acid and 
lipopolysaccharide (LPS), are toxic molecules known as endotoxins (Seydel, 2000; Wiese, 
1999; Sriskandan, 1999). In addition, bacteria may also secrete soluble toxic proteins, 
known as exotoxins (Guerrant, 1999; Middlebrook, 1984, Lesieurs, 1997). These toxins have 
detrimental effects on the infected host, as they may destruct host cells or structures and 
may affect host homeostasis. The effects of toxins on host cytokine profiles may lead to 
disseminated intravascular coagulation, severe inflammatory response syndrome and 
ultimately septic shock and multiple organ failure by distorting the balance between pro-
inflammatory and anti-inflammatory stimuli (Bone, 1997; Deitch, 1999; van der Meer, 
1999). 
2. Antimicrobial treatment 
Impediment of bacterial contamination and colonization, for example by sterilization, 
disinfection, or isolation is a way to prevent the development of infectious diseases. Once 
the bacteria have invaded the host, the aspecific and speCific host defense become activated 
to control the infection. For prevention or treatment of bacterial infections antimicrobial 
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agents may be used. Antimicrobial agents are molecules that are (relatively) selectively toxic 
to bacteria, by interfering with essential bacterial metabolic processes. Different classes of 
antibiotics show different modes of action. For example, the S-Iactam class of antibiotics 
(cephalosporins and penicillins) interfere with bacterial cell wall synthesis (Kidwai, 1999), 
whereas the aminoglycosides inhibit bacterial protein synthesis as a result of ribosome 
binding (Forge, 2000). The discovery of antibiotics, early in the 20th century, has had a 
tremendous impact on morbidity and mortality and even, according to some authors, the 
outcome of the Second World War (Bol, 1999; Demain, 1999). Less than a century later, the 
golden age of antibiotics seems to have passed (Trnobranski, 1998; Young, 1985). Clinical 
practice shows that failure of antimicrobial treatment is frequently encountered in 
hospitalized patients (Shlaes, 1993; Cunha, 1995; Sugarman, 1980; Butts, 1994; Barry, 
1999; Sanchez-Navarro, 1999; Liu, 1999; O'Brien, 1997). Three prominent causes of failure 
of antimicrobial therapy can be distinguished: 
>- sub-effective drug concentrations at the infected site (as a result of 
limited drug access to the infected site by unfavorable pharmacokinetics 
of the drug, limited blood fiow (as in osteomyelitis) or the presence of 
barriers (as in intracellular Mycobacterium-infections) 
>- low susceptibility of the microorganism towards the applied antimicrobial 
agent 
>- growing number of immunocompromised patients (as a result of long-
term, invasive, and intensive hospital treatments, administration of drugs 
that affect the host defense, or as a result of a condition that 
compromises the host defense (e.g. human immunodeficiency virus 
infection). 
These causes underlying treatment failure create a need for more efficacious treatment. 
Site-specific drug delivery could improve the therapeutic index by increasing drug 
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concentrations at the target site and by reducing side-effects in case of potentially toxic 
antibiotics. 
3. Drug targeting 
Site-specific drug delivery, or drug targeting, in its broadest sense, is practiced daily by 
millions of people. The application of iodine after a cut (Burks, 1998; Cho, 1998), eye, ear, 
and nose drops for local infection or hay fever (Vajpayee, 2000; Shikiar, 1999; Curran, 
1998; Davies, 1996), or inhalation of drugs for asthma (Dhand, 2000; Volsko 2000) are just 
a few examples. The rationale for this site-specific delivery of drugs may be summarized as 
follows (Tomlinson, 1986): 
>- to administer the drug (almost exclusively) to a specific body 
compartment (to increase therapeutic efficacy) 
>- to protect body and drug from deposition at unwanted -non-target- sites 
(to reduce side effects or drug inactivation) 
>- to control rate and modality of drug delivery to the pathological site 
>- to reduce the amount of drug used 
Whatever the rationale, the examples mentioned on application of iodine, eye, ear, and 
nose drops and inhalation of drugs, share one resemblance: they affect epithelial surfaces. 
In this case, the target site is readily accessible. If it is less acceSSible, drug targeting may 
serve an additional purpose: 
>- to obtain drug access to the pathological site 
To reach the latter goal a drug delivery vehicle, or drug carrier, is generally needed for a 
drug to arrive at the target site. The term drug targeting in scientific literature is generally 
confined to this carrier-mediated drug delivery. The first study employing a drug carrier for 
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targeted drug delivery was published approximately 30 years ago, using antibodies as 
carriers of radioactivity for the specific recognition of tumor cells (Ghose, 1969). 
3.1 Drug carriers 
The ideal drug carrier ensures the timely release of the drug within the therapeutic window 
at the appropriate site, is neither toxic nor immunogenic, is biodegradable or easily excreted 
after acton, and is preferably cheap and stable upon storage (Sinkula, 1988; Tomlinson, 
1986). Many different kinds of drug carriers have been investigated (as reviewed by Pouton, 
1985; Langer, 1998; Mrsny, 1997; Duncan, 1997): 
either soluble macromolecular carriers (as reviewed by Hawiger, 1999; Takakura, 1996; 
Wadhwa, 1995; Rihova, 1997; Felt, 1998; Dubowchick, 1999; Trail, 1999), like proteins, 
lectins, hormones, polysaccharides, or DNA 
or microparticulate carriers (as reviewed by Tomlinson, 1987; Kwon, 1998; Davis, 1997; 
Tenjarla, 1999; Rensen, 1996; Templeton, 1999; Storm, 1997; Yamaguchi, 1994; Allen, 
1998; Tonetti, 1993; Alemany, 1999; Jones, 1999), like liposomes, lipoproteins, emulsions, 
nanoparticles, celis, or viruses. 
The wide variety in investigated drug carriers indicates that ''the ideal drug carrier" does not 
exist. The suitability of a drug carrier is determined by the disease that will be targeted, its 
access to the pathological site, and the carriers ability to achieve appropriate drug retention 
and timely drug release (Tomlinson, 1987). These points will be discussed in relation to the 
research presented in this thesis. 
3.2 DART: Disease.- Access;. Retention, Timing (Tomlinson, 1987) 
Reports on drug carriers with access to or localization at sites of bacterial infection, may be 
categorized according to the approach taken to improve the antibacterial efficacy. Four 
approaches may be distinguished: 
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r Local administration of carriers 
r Passive targeting after i.v. administration of carriers which tend to be taken up by 
phagocytic cells 
r Passive targeting after i.v. administration of carriers with a long-circulation time 
r Active targeting after i.v. administration of carriers 
The first approach is the use of drug carriers to increase the residence time of antibiotics 
after local administration of the drug-carrier complex at the site of infection. Examples are 
polymethylmethacrylate beads (Wahlig, 1978) or tubes (Bircher, 1985), glyceryl 
monostearate implants (Allababidi, 1998) poly-L-Iactic acid conjugates (Teupe, 1992), 
bioerodible polyanhydrides (Laurencin, 1993), fibrin glue/Dacron grafts (Fujimoto, 1997), 
liposomes (Reimer, 1997; lichtenstein, 1995), and nanoemulsions (Hamouda, 1999). These 
carriers are generally investigated with the intention to treat local infections in body parts 
with limited blood flow as in bone, jOint, skin, and cornea. Their use is limited to accessible 
sites of infections with a clear infectious focus. 
The second approach is the use of drug carriers to target intracellular infections. These 
infections are often difficult to treat as a result of limited ability of the antimicrobial agent to 
penetrate into cells. This approach makes use of the recognition of drug carriers as foreign 
material in the bloodstream by the phagocytic cells of the mononuclear phagocyte system 
(MPS), the cell type often infected with microorganisms. Examples of carriers that have 
been shown to be taken up by phagocytic cells are nanoparticles (Youssef, 1988, Fattal 
1989; Pinto-Alphandary, 1994; Peters, 2000; Couvreur, 1991), lactide-glycolide 
microspheres (Barrow, 1998), acetylated low-density lipoproteins (Nicolas, 1990), and 
liposomes (Melissen, 1993; Bakker-Woudenberg, 1989; Majumdar, 1992; Couvreur, 1991). 
Regarding the third and fourth approach, the targeting of infectious foci not restricted to 
MPS-tissues, reports on access of drug carriers to the infected site are mainly derived from 
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imaging studies and are either based on passive or active drug targeting. Passive drug 
targeting makes use of long-circulating drug carriers, whereas active targeting makes use of 
carriers that specifically bind to the infectious organism or host cells involved in the 
infiammatory response. Carriers that have been reviewed are: peptides and proteins 
(Weiner, 1999; Okarvi, 1999; van der Laken, 1998; Nibbering, 1998; Chan, 1999; 
Giacomuzzi, 1999), leukocytes (Chik, 1996), nanoparticles (Becker, 1995), and liposomes 
(Morgan, 1985; Boerman, 1998; Oyen, 1996; Bergers, 1995; Bakker-Woudenberg, 1994). 
In partcular long-circulating liposome systems have been intensively investigated as 
potential drug carriers in infectious or infiammatory pathologies, as substantial liposome 
localization at the target site has been demonstrated in a variety of models of infection and 
infiammation (Morgan, 1981; Dams, 1999; Crommelin, 1999; Rousseau, 1999; Dams, 
1999(11); Klimuk, 1999; Awasthi, 1998; Awasthi, 1998(11); Corvo, 1999; Bakker-
Woudenberg, 1995; Bakker-Woudenberg, 1993; Bakker-Woudenberg, 1992). The target 
localization has been shown to be dependent on the infiammatory response as the 
localization in uninfectedjuninfiamed controls is inSignificant 
In addition, the sufficiency of drug retention and timing of the drug release determine the 
suitability of a drug carrier for targeted drug delivery. The optimal characteristics are to a 
high degree dependent on the class of antibiotics that is to be targeted. A number of papers 
On drug retention and release provided by liposomes show that the retention and release 
profiles can be modulated by variation of liposome characteristics (Kulkarni, 1995; 
Gregoriadis, 1993; Allen, 1998; Gregoriadis, 1988). These results provide further support for 
the choice of long-Circulating liposomes as carriers for the targeted delivery of antibacterial 
agents to sites of bacterial infection. 
3.3 Structure of/{oosomes 
liposomes are spherical vesicles, with particle sizes ranging between 30 nm up to several 
microns, consisting of one (unilamellar vesicle) or more (multi-lamellar vesicle) lipid bilayers 
surrounding an equal number of aqueous spaces (Figure 1). liposomes can either 
incorporate hydrophilic drugs in the aqueous compartment(s), hydrophobic drugs in the lipid 
15 
Chapter 1 
bilayer(s), or amphiphilic compounds that parttion between both phases. The bilayers 
usually consist of (natural or synthetic) phospholipids and cholesterol but incorporation of 
other sterols, fatty acids, glycolipids, and proteins is also possible. The composition of the 
lipid bilayer can be manipulated to infiuence the physicochemical characteristics of the 
liposome (e.g. surface charge, sensitivity to pH changes, and bilayer rigidity) (Vemuri, 1995; 
Jones, 1995; Gregoriadis, 1993). Liposomes were originally investigated as model 
membranes during the 1960's, until, in the early 1970's, the possibility to incorporate drugs 
was appreciated (Gregoriadis, 1971; Gregoriadis, 1973). The result has been an 'avalanche' 
of liposome-focused research. 
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Figure 1. Schematic representation of the structure of liposomes. The lipid bilayer is composed 
of phospholipids, with their hydrophilic head group facing the aqueous spaces. 
3. 4 The search for a prolonged drctJlation time of liposomes 
Information on liposome behavior in vivo is abundant. Soon after liposomes were first 
administered to experimental animals, it appeared that intravenously injected liposomes 
tend to rapidly accumulate in the MPS-cells, most prominently in those in the liver and 
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spleen (Alving, 1983; Kirsh, 1986; Senior, 1987; Gregoriadis, 1989; Kreuter, 1991). The 
efficient uptake of liposomes by this cell type is thought to occur as a result of liposome 
opsonization in the circulation (Patel, 1992; Devine, 1997). Opsonization may be viewed as 
a protective process by which foreign material is coated with proteins facilitating recognition 
and removal of this foreign material from the blood stream by the MPS. As a result, these 
liposomes have a short circulation time and they have only access to the cells of the MPS. 
This conclusion stimulated research on the design of liposomes possessing a prolonged 
circulation time (Senior, 1987; Paphadjopoulos, 1990; Woodle, 1992; Woodle, 1993; Oku, 
1994; Torchillin, 1996). Initially, it appeared that small (approximately 100 nm), neutral 
liposomes composed of rigid lipid bilayers display a prolonged circulation time compared to 
larger, charged liposomes with fiuid lipid bilayers. One of the drawbacks of this approach to 
obtain long-circulating liposomes is that the ability to tailor liposome characteristics for 
optimal drug retention and release profiles is partly lost. 
Subsequent research explored the possibility to increase circulatory half-life by inclusion of 
glycolipids. This method was supposed to mimic the red blood cell's constituents to evade 
uptake by the MPS (Gabizon, 1988; Allen, 1989). However, the apparent species 
dependency of the prolongation of circulation time (Liu, 1995), confinement to a rigid lipid 
bilayer structure, clinical acceptability and costs are important drawbacks in this approach. 
A 'breakthrough' was achieved by coating of the liposome surface with soluble and flexible 
polymers such as poly(ethylene glycol) (PEG) (Klibanov, 1990; Senior, 1991; Allen, 1991; 
Papahadjopoulos, 1991) (Figure 2). The method is based on experience with 
protein:polymer adduds that display reduced plasma clearance compared to the native 
protein (Wieder, 1979; Pyatak, 1980). It is believed that the presence of a dense 
conformational polymer cloud grafted onto the liposome surface sterically hinders the 
adherence of opsonins to the liposome surface (Torchillin, 1996). Such long-circulating, 
PEG-coated, MPS-avoiding, Stealth® or sterically stabilized liposomes (SSL) offer a 
convenient way to obtain liposomes for which long circulation time is to a high degree 
independent of liposome characteristics as size, charge, and bilayer rigidity (Woodle, 1992). 
The value of PEG-coating was first illustrated in tumor models (Gabizon, 1994; Huang, 
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1992; Allen, 1992; Papahadjopoulos, 1991). In these experiments prolonged Iiposomal 
circulation time, increased tumor targeting, and increased therapeutic efficacy were 
demonstrated. 
~~ 
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Figure 2. Structure of sterically stabilized liposomes. The lipid bilayer is composed of 
phospholip·,ds, of which some (usually about 5 mol%) have been grafted with poly(ethylene) glycol. 
4. Aims and outline of this thesis 
The basiS for the present study is the previous work of Bakker-Woudenberg et al. showing 
enhanced target localization of SSL in a rat model of a unilateral pneumonia caused by 
Klebsiella pneumoniae (Bakker-Woudenberg, 1993). The attractiveness of the unilateral K. 
pneumoniae pneumonia rat model for use in drug targeting studies is not only its 
resemblance of the pathology associated with human lobar pneumonia. The ability to 
selectively inoculate bacteria into the left lung, developing into a left-sided pneumonia, 
allows the right lung to serve as an intra-individual control organ. The previously mentioned 
study showed an increase in liposome localization in the infected left lung compared to the 
contralateral non-infected right lung. Moreover, a linear relationship was demonstrated 
between Iiposome left lung localization and infection intensity. Administration of a single 
dose of SSL-encapsulated gentamicin or SSL-encapsulated ceftazidime was shown to have 
an increased therapeutic efficacy compared to an equivalent dose of the free drug (Bakker-
Woudenberg, 1995). 
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In conclusion, these two studies demonstrated that SSL localize preferentially at the site of 
bacterial infection and that the increased therapeutic efficacy of antibiotics was the result of 
encapsulation in SSL. 
These studies have been continued. For optimization of liposome targeting to the site of 
infection it is essential to identify the critical factors that contribute to liposome target 
localization. In addition, in clinically relevant infection models in which antibiotic treatment 
fails, the value of SSL-encapsulated antibiotics should be evaluated. 
Therefore, the present investigations aimed at: 
> identifying the factors (on the side of the liposomes as well as on the side of the 
host) that infiuence the selective target localization of SSL in K. pneumoniae 
infected rat lung tissue 
> evaluating the therapeutic efficacy of these liposomes, when loaded with 
antibiotics, in clinically relevant rat models, in particular addressing the issues of 
impaired host defense and reduced bacterial susceptibility. 
Chapter 2 and 3 describe experiments in which liposome-related factors (Chapter 2) and 
host-related factors (Chapter 3) were studied. Liposome-related factors that were 
investigated were PEG-denSity, particle size, bilayer fiuidity and negative surface charge. 
The investigation of host-related factors focussed on the components of the infiammatory 
response. The conclusions were used to suggest a general model for liposome localization at 
sites of infection based on the equation of Kedem and Katchalsky that describes protein 
infiux into infiammatory tissue (Chapter 4). 
Chapter 5 is a review of preclinical and clinical data on liposome-encapsulated 
aminoglycosides, and provides an introduction to our experiments with gentamicin 
encapsulated in SSL in the next chapters. 
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In Chapter 6 the therapeutic efficacy of two different liposomal gentamicin formulations was 
tested in clinically relevant rat models of serious K. pneumoniae infections. Both the 
clinically encountered problems of a low susceptibility of the bacteria as well as lack of 
adequate host defense were addressed. 
Chapter 7 describes a new concept in the field of antimicrobial drug targeting: the co-
encapsulation of antibiotics, which show synergistic interactions in vitro, in SSL. Therapeutic 
efficacy of site-speCific co-delivered gentamicin and ceftazidime was evaluated in rats 
infected with an antibiotic-susceptible or an antibiotic-resistant strain of K. pneumoniae. 
In Chapter 8 the results, presented in this thesis are summarized, discussed and 
suggestions are made for future research. 
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Klebsiella pneumoniae-infected rat lung tissue: 
influence of liposome characteristics 
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Summary 
Sterically stabilized liposomes are able to localize at sites of infection and could serve as 
carriers of antimicrobial agents. For a rational optimization of liposome localization, the 
blood clearance kinetics and biodistribution of liposomes differing in poly(ethylene) glycol-
density, particle size, bilayer fluidity or surface charge were studied in a rat model of a 
unilateral pneumonia caused by Klebsiella pneumoniae. 
It is shown that all liposome preparations studied localize preferentially in the infected lung 
compared to the contralateral non-infected lung. A reduction of the poly(ethylene) glycol-
density or rise in particle size resulted in a higher uptake by the mononuclear phagocyte 
system, lower blood circulation time and lower infected lung localization. Differences in 
bilayer fluidity did not affect blood clearance kinetics or localization in the infected lung. 
Increasing the amount of negatively charged phospholipids in the liposome bilayer did not 
affect blood clearance kinetics, but did reduce localization of this liposome preparation at 
the site of lung infection. 
In conclusion, the degree of localization at the infected site is remarkably independent of 
the physicochemical characteristics of the PEG-liposomes. Substantial selective liposome 
localization can be achieved provided that certain criteria regarding PEG-density, size, and 
inclusion of charged phospholipids are met. These properties seem to be a direct 
consequence of the presence of the polymer coating operating as a repulsive steric barrier 
opposing interactions with biological components. 
Published in Biochimica et Biophysica Acta 1421 (1999) 329-339 31 
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1. Introduction 
Unfavorable location of an infectious organism, limited susceptibility to the applied 
antimicrobial agent, and/or decreased immune status of the infected host are all major 
factors complicating the efficacy of antimicrobial therapy [1, 2, 3]. The use of a drug carrier, 
like liposomes, could help to improve the efficacy of antibiotic treatment by modifying the 
pharmacokinetics and tissue distribution of the antibiotic. This strategy may increase drug 
concentrations at the target site and/or reduce toxicity to non-target tissues enabling higher 
dosing [4, 5]. 
The location of the infection is an important consideration for the choice of the liposome 
type to be used as targeted antibiotic carrier. As intravenously administered conventional 
liposomes display a high affinity for the mononuclear phagocyte system (MPS), a rapid 
localization ofthese liposomes in MPS-rich organs, most notably in the liver and the spleen, 
is observed. This property makes them appropriate for the speCific targeting of 
antimicrobials to infectious organisms residing within MPS cells in these organs. In addition, 
since the MPS plays an important role in the non-specific defense against infections, MPS-
directed targeting of liposomal immunomodulators may enhance the non-specific host 
resistance. Both strategies have been reviewed [6-7]. 
The limitations of these conventional liposomes as antibiotic carriers are clear, when 
targeting to infections outside the MPS is the main goal. Various strategies have been 
followed to reduce uptake of liposomes by the MPS and consequently to increase their blood 
residence time, allowing interaction with other tissues. At present, coating of the surface of 
liposomes with poly(ethylene glycol), is a popular strategy to increase the circulation time of 
liposomes. It is thought that the poly(ethylene) glycol coating provides a steric barrier 
against opsonization, thereby reducing the interaction with the MPS. Consequently, these 
liposomes, referred to as sterically stabilized liposomes (SSL) exhibit a prolonged circulation 
time (for reviews see [8, 9, 10]). 
Previous studies of our group in a model of acute unilateral pneumonia caused by Klebsiella 
pfJeumofJiae in rats demonstrated that SSL are capable to substantially localize in the 
infected left lung. The presence of a local active infectious process appeared to be required 
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as minimal liposome localization was observed in the contralateral non-infected right lung 
[11,12]. Furthermore, it was shown that encapsulated gentamicin was strongly effective in 
reducing bacterial numbers in the infected left lung as well as preventing mortality, likely 
due to local release of the drug from the SSL at the site of infection [13]. 
The phenomenon of preferential localization of SSL at pathological sites has also been 
described for other infiammatory conditions like adjuvant arthritis in rats, experimental 
colitis in rabbits, focal bacterial infection in the calf muscle of rats, and osteomyelitis in 
rabbits [14, 15, 16, 17]. However, only little information is available on the infiuence of 
liposome characteristics on the degree of localization of SSL at infiammatory foci. Insight 
into the liposomal properties favoring the localization in infiammatory tissue may help to 
optimize liposomal formulations for antimicrobial therapy. The aim of the present study is to 
evaluate the effects of poly( ethylene glycol) surface density, particle size, bilayer fiuidity, 
and surface charge of SSL on circulation kinetics and localization in infected lung tissue. 
2. Materials and Methods 
2.1 Introduction of a Unilateral pneumonia 
Specified pathogen-free female RPjAEurjRijHsd strain albino rats (18-25 weeks of age, weighing 185-
225 g) (Harlan, Horst, The Netherlands) were used in all experiments. Experiments were approved by 
the animal experiments ethical committee of the Erasmus university Medical Center Rotterdam. A 
unilateral pneumonia was induced in the left lung as described previously [18]. In brief, rats were 
anesthetized by an intramuscular injection of 0.1 ml fiuanisone and fentanyl citrate (Hypnorm®) 
(Janssen Animal Health, Saunderton, UK) followed by an intraperitoneal injection of 0.3 ml 1:4 vjv 
diluted pentobarbital (Nembutal®) (Sanofi Sante b.v., Maassluis, The Netherlands). After intubation 
followed by cannulation of the left primary bronchus, 0.02 ml of a saline suspension containing 106 K. 
pneumoniae (ATCC 43816, capsular serotype 2) was inoculated in the lower left lung lobe. Bacterial 
inoculum was checked by culturing appropriate dilutions of the bacterial suspension on tryptone soy 
agar plates (Unipath Ltd., Basingstoke, UK). Following bacterial inoculation, rats received an 
intramuscular injection of nalorphine bromide to recover from anesthesia (Onderlinge Pharmaceutische 
Groothandel, Utrecht, The Netherlands) and were housed individually with free access to water and 
SRMA chow (Hope Farms b.v., Woerden, The Netherlands). 
2.2 iJposome preparabon and cl7aractedzatJon 
Liposomes were prepared as described previously [12]. In brief, appropriate amounts of partially 
hydrogenated egg phosphatidylcholine (PHEPC, iodination value 40) (Asahi Chemical Industry Co. Ltd., 
Ibarakiken, Japan), cholesterol (Chol) (Sigma Chemical Co., St Louis, Missouri), 1,2-distearoyl-sn-
glycero-3-phosphoethanolamine-N-[polyethylene glycol-2000] (PEG-DSPE), egg L-a-phosphatidylcholine 
(EPC), egg L-a-phosphatidylglycerol (EPG) or distearoyl phosphatidylcholine (DSPC) (Avanti Polar Lipids, 
Alabaster, Alabama) were dissolved in chloroform:methanol in a round bottom flask. The solvent was 
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evaporated under reduced pressure in a rotary evaporator and the lipid mixture was dried under 
nitrogen for 15 min, redissolved in 2-methyl-2-propanol (Sigma Chemical Co., St. Louis, Missouri) and 
freeze-dried overnight. The dried lipids were hydrated for 2h in HepesjNaCi buffer, pH 7.4 (10 mM N-
[2-hydroxy ethyl] piperazine-N'-ethane sulfonic acid (Hepes) (Sigma Chemical Co., St. Louis, Missouri) 
and 135 mM NaCi (Merck, Darmstadt, Germany) containing 5 mM of the chelator deferoxamine 
mesylate (DesferaI0) (Novartis, Basel, Switzerland). The chelator was added to enable labeling with 
67Ga (see section 2.3). 
Liposomes of approximately 100 nm (range 80-120 nm) were obtained by sonication of the hydrated 
lipid dispersion for 8 min with an amplitude of 8 IJ using a 9.5 mm probe in an MSE Soniprep 150 
(Sanyo Gallenkamp PLC, Le"lcester, UK). To study the effect of particle size, liposome populations of 
three different mean sizes (i.e. 100, 280, 360 nm) were obtained by multiple extrusion of the hydrated 
lipid dispersion through two stacked polycarbonate membranes (Nuclepore, Pleasanton, california) with 
pore sizes of 100 and 100 nm for the 100 nm liposomes, 400 and 200 nm for the 280 nm liposomes, 
and 600 and 400 nm for the 360 nm liposomes. 
Part"lcle size d"lstribution was measured using dynamic light scattering, detected at an angle of 90° to 
the laser beam on a Malvern 4700 System (Malvern Instruments Ltd., Malvern, UK). The polydispersity 
of the Iip050me population is reported by the system as a value between 0 and 1. A reported value of 1 
indicates large variations in particle size, whereas a value of 0 indicates a complete monodisperse 
system. For allliposome preparations used in the experiments, the polydispersity index value was below 
0.3. 
The ::; -potential of 0, 5, or 30 mol% EPG containing liposomes was measured using a zetasizer equipped 
with PCS v1.35 software (Malvern Instruments Ltd., Malvern, UK). Liposomes were prepared in 5% 
aqueous Hepes/NaCi buffer and the instrument was calibrated with electrophoresis standard latex 
particles. 
23 Uposome labeling 
To remove non-encapsulated deferoxamine, Iiposomes were applied on a Sephadex G-SO column 
(Pharmacia, Uppsalla, Sweden) and eluted with Hepes/NaCl buffer followed by concentration via 
ultracentrifugation at 60,000 rpm for 2h at 4°C in a Beckman ultracentrifuge l-70 (Beckman, Palo Alto, 
california). Liposomes were labeled with 57Ga according to Gabizon et al. [19]. 57Ga-citrate (1 mCijml) 
(Mallinckrodt Medical b.v., Petten, The Netherlands) was diluted 1:10 in aqueous 5 mg/ml 8-
hydroxyquinone (Sigma Chemical Co., St. Louis, Missouri) and incubated for 1 h at 52°C to yield 67Ga-
oxine. 1 ml of this mixture was added per 1000 [.Imol total lipid (TL) of liposomes. Since 57Ga-oxine can 
pass the liposomaJ membrane and has a high affinity for the encapsulated chelator deferoxamine, the 
radioactive label becomes entrapped. 57Ga-deferoxamine is an appropriate label for monitoring intact 
liposomes in the Circulation as it is encapsulated in the liposome interior and it is excreted rapidly via 
the kidneys in case it leaks from circulating liposomes [19]. Free label was removed by gel filtration. 
RadiolabeJed liposomes were concentrated by ultracentrifugation at 60,000 rpm for 2 h at 4 °C in a 
Beckman ultracentrifuge l-70 (Beckman, Palo Alto, callfornia). Resulting speCific activities were 
between 4.104 and 2.105 cpm/[.Imol TL. Phosphate concentration was determined colorimetrically 
according to Bartlett [20]. 
2.4 Blood volume and organ blood content 
Total blood volume of the infected rats was 5.3% of the body weight. This percentage was determined 
by labeling syngeneic erythrocytes with lllIn-oxine according to Kurantsin-MiUs [21]. Briefly, in an 
independent experiment, blood samples were taken at 10 min after injection of the labeled erythrocytes 
assuming that all erythrocytes were still present in the Circulation. The dilution factor of the radioactive 
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lllIn-label allowed calculation of the total blood volume as well as the blood content of the various 
organs. 
2.S Blood drculation kinetics and biodistribution 
Experimental groups consisted of 6 rats. Uposomes were administered Lv. at the selected dose 
(indicated in the text) via the tall vein at 40 h after bacterial inoculation of the left lung. Blood samples 
of approximately 0.3 ml were taken from altemating groups of three rats by retro orbital bleeding using 
heparinized capillaries at 1, 4, 8, 12, and 16 h after liposome injection. All rats were bled at 24 h after 
injection. Blood sample volume was measured and radioactivity was counted in a Minaxi autogamma 
5000 gamma counter (Packard Instrument Company, Meriden, Connecticut) allowing calculation of the 
radioactivity present in the blood (see section 2.5.). 
At 24 h after injectionr rats were sacrificed by CO2 inhalation and infected left lung, right lung, spleen, 
kidneys, liver and heart were dissected. The organs were weighed and radioactivity was counted to 
assess the biodistribution of the liposomes. The contribution of radioactivity in the blood to the 
radioactivity measured in the organs was subtracted (see section 2.5.). 
2.6 Statistical analysis 
Pharmacokinetic studies have shown that SSL exhibit single first-order clearance rates independent of 
dose [9, 22]. Similarly, in our experiments the circulation kinetics of individual animals between 1 and 
24 h after injection could be well described by a linear relationship on a semi-logarithmic plot (0.88 < r 
< 1.00). 
Data were tested for homogeneity of variance using Levene's test. In case of significant differences in 
variance between groups, data were log transformed. Paired t-test was used to compare infected left 
lung and right lung localization. Comparisons between groups were made by one-way analysis of 
variance (ANOVA) corrected for multiple comparisons by the Bonferroni method using SPSS for 
Windows software release 7.5.2 (Statistical Product & Service Solutions Inc., Chicago, USA). 
3. Results 
At 40 h after bacterial inoculation of the left lung, at the time of liposome injection, 3 zones 
could be clearly distinguished in the lobar pneumonia area in the left lung: the early 
infected, hemorrhagic and consolidated zone. Furthermore, limited variation was noted in 
severity of infection between animals. At 40 h after bacterial inoculation, the inoculum of log 
6 bacteria had multiplied to log 9.77 ± 0.24, whereas the original lung weight of 0.36 ±0.07 
g had increased to 1.07 ±0.19 g (mean ± standard deviation, n;9). 
3.1 Effect of PEG-density 
The circulation kinetics and the biodistribution pattern of liposomes containing three 
different levels of PEG-DSPE with an approximate molecular weight of PEG of 2,000 (Le. 1, 
5, or 10 mol%) are shown in Figures 1A and 1B, respectively. 
35 
Chapter 2 
15001 A
f
'00 CJ 1 mo]% PEG-DSPE * ;f!. .,. 
c a • 5 mol% PEG-DSPE a g S'1000 75 
2: 
g 
.a: ~ 0 ='2 
'=0 
.-50 ~ ~ . • c- o 0 
."' .. :;~ .. 0- 0. C E 500 0. g:;, 8:;, 0. 0. 0 ->- 0 f: • ~- • ~ o ~ ~o g 5" ." 250 • c • l.s 0" 0- ~0 1 rnol% PEG-DSPE 0" g. ~ 
• 5 mol% PEG-DSPE 0 c- o 
o 10 mol% PEG-DSPE ~ 
100+---~-_-_-__ ---,-J 
o 4 8 12 16 W ~ u 
time after injection (h) organ 
Figure 1. Effect of PEG~density on blood clearance and biodistribution of liposomes. 67Ga_ 
deferoxamine labeled liposomes were injected Lv. at 40 h after bacterial inoculation of the left lung with 
106 K. pneumoniae at a dose of 75 flmol Tl/kg body weight. The lipid composition was 
PHEPC:Chol:PEG-DSPE 1.85:1:0.15 mol:mol for the 5 mol% PEG-DSPE containing liposome preparation 
(particle size 104 nm, range 91-115 nm, n;8), 1.97:1:0.03 mol:mol for the 1 mol% PEG-DSPE 
preparation (particle size 107 nm, range 98-116 nm, n=2), and 1.7:1:0.3 mol:moi for the 10 mol% 
PEG-DSPE preparation (particle size 98 nm, range 96-100 nm, n;2). 
A. Liposome concentration in nmol TL/ ml blood (left Y-axis) and % of injected dose remaining in the 
circulation (right Y-axis) at indicated time points after injection. Data were calculated from 
radioactivity recovered (n=3, mean±standard deviation). 
B. Blodistribution of liposomes expressed as nmol TLjorgan (left Y-axis) and % of injected 
dose/organ (right Y-axis) at 24 h after injection. Data were calculated from radioactivity recovered 
(n=6, mean±standard deviation). LL=infected left lung, RL=right lung, Spl=spleen, U=liver. 
*=p<O.OS, **=p<O.Ol, ***=p<O.OOl. Significant differences are noted against the 5 mol% PEG-
DSPE containing preparation. 
The 1 mol% PEG-liposomes disappeared from the bloodstream faster as compared to tihe 5 
and 10 mol% PEG-liposomes (p<O.Ol) (Fig. 1A). An increase of the PEG content from 5 up 
to 10 mol% did not affect the circulation kinetics. The biodistribution data show that, for all 
three PEG-liposome preparations, the localization in the infected left lung (ll) at 24 h after 
injection was approximately 3 to 4-fold higher than the corresponding localization in the 
uninfected right lung (Rl) (p<O.OOl) (Fig. 18). Yet, the degree of localization in the infected 
left lung of the 1 mol% PEG-liposomes was somewhat lower (± 20%) compared to the 5 
mol% PEG-liposomes (p<O.OS), while the extent of localization of the 5 mol% and 10 mol% 
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PEG-liposomes in the infected lung was similar. The hepatosplenic uptake of the 1 mol% 
PEG-liposomes was significantly higher than the 5 mol% and 10 mol% PEG-liposomes 
(p<O.OS and p<O.OOS, respectively). The latter two liposome types displayed a similar 
degree of localization in the liver and spleen. Localization in the un infected right lung was 
not significantly different for the three different liposome preparations. Very low levels of 
liposome localization were seen in heart « 40 nmol TL) and kidneys «200 nmol TL) (data 
not shown). 
3.2 Effect or partide size 
The circulation kinetics and tihe biodistribution pattern of liposomes differing in mean size 
(i.e. 100,280, and 360 nm) are shown in Figures 2A and 2B, respectively. 
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Figure 2. Effect of particle size on blood clearance and biodistribution of liposomes. See 
figure 1 for detail5. The lipid composition of the liposomes was PHEPC:Chol:PEG-DSPE 1.85:1:0.15 
mo!:mol. 100 nm formulation particle size 104 nm, range 91·115 nm, n=8; 280 nm formulation particle 
size: 277 nm, range 268-286 nm, n=2; 360 nm formulation particle size: 359, range 331-387 nm, n=2. 
Significant differences against the 100 nm sized liposome preparation are noted. 
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PEG-Iiposomes with a mean size of 100 nm were removed from the bloodstream at a much 
lower rate as compared to the 280 nm and 360 nm liposome formulations (p<O.Ol and 
p<0.05, respectively) (Fig. 2A). Regarding the biodistribution pattern, it was observed that 
the localization in the un infected right lung and the infected left lung was approximately 2-
fold lower in case of the 280 nm and 360 nm liposome preparations compared to the 100 
nm PEG-liposomes (p<O.OOl) (Fig. 2B). Importantly, for each liposome formulation the 
localization in the infected left lung was approximately 4-fold higher than in the un infected 
right lung (p<O.OOl). Splenic uptake appeared to increase considerably with increasing size 
of the PEG-liposomes (p<O.OOl). The distribution to liver, heart (data not shown), and 
kidneys (data not shown) was not significantly different for any of the Iiposome preparations 
in this experiment. 
3.3 Effect or bi/a yer fluidity 
Bilayer fiuidity is determined by the lipid composition of the liposome. Hydrogenated 
phospholipids yield rigid bilayers whereas more unsaturated phospholipids give bilayers a 
more fiuid character [23]. Besides, cholesterol has also been shown to be an important 
modulator of bilayer fiuidity by increasing bilayer rigidity and lateral packing [23]. The 
liposome preparations evaluated here vary, regarding bilayer fiuidity, as follows (in order of 
increasing fiuidity): DSPC:PEG-DSPE, PHEPC:PEG-DSPE, EPC:PEG-DSPE. One liposome 
preparation contains additionally cholesterol (i.e. PHEPC:Chol:PEG-DSPE) to examine the 
effect of inclusion of the steroid. The circulation kinetics and the biodistribution pattern of 
liposomes differing in bilayer fiuidity are shown in Figures 3A and 3B, respectively. 
The circulation times of all four liposome preparations evaluated were similar (Fig. 3A). 
Regarding the biodistribution profile, all four liposome formulations showed an 
approximately 4-fold higher localization in the infected left lung compared to the uninfected 
right lung (p<O.OOl) (Fig. 3B). Tissue distribution patterns of the various liposome 
formulations were not significantly different. 
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Figure 3. Effect of bilayer fluidity on blood clearance and biodistribution of liposomes. See 
figure 1 for details. The lipid composition of the PHEPC:Chol:PEG-DSPE liposome was 1.85:1:0.15 
mol:mol (particle size 104 nm, range 91-115 nm, n=8), of the DSPC:PEG-DSPE 1.9:0.1 mol:mol 
(particle size 114 nm, range 95-133 nm, n=2), of the PHEPC:PEG-DSPE 1.9:0.1 mol:mol (particle size 
121 nm, range 109-133 nm, n=2), and of the EPC:PEG-DSPE preparation 1.9:0.1 mol:mol (particle size 
84 nm, range 76-92 nm, n=2). 
3. 4 Effect or cl7arged phospholipids 
The circulation kinetics and the biodistribution pattern of PEG-liposomes differing in EPG 
content (i.e. 0, 5, and 30 mol%) were determined to study the effect of charged 
phospholipids (Figures 4A and 4S). 
The ,-potentials of the 0, 5, and 30 mol% EPG containing liposomes were measured. 1;-
potential decreased slightly with increasing EPG content, under the experimental conditions 
used, from -10.7 ± 1.1 mV for the 0 mol% EPG containing liposomes via -13.4 ±1.4 mV for 
the 5 mol% EPG preparation to -19.7 ±1.1 mV for the 30 mol% EPG containing liposomes 
(mean ± standard deviation, n=3 preparations). 
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Figure 4. Effect of EPG·level on blood clearance and biodistribution of liposomes. See figure 
1 for details. The lipid composition wa5 PHEPC:Chol:PEG-DSPE:EPG 1.85:1:0.15:0 mol:mol for the 0 
mol% EPG containing liposome preparation (particle size 104 nm, range 91-115 nm, n=8), 
1.7:1:0.15:0.15 mol:mol for the 5 mol% EPG preparation (particle size 93 nm, range 87-99 nm, n=2), 
and 0.95:1:0.15:0.9 mol:mol for the 30 mol% EPG preparation (particle size 82 nm, range 78-86 nm, 
n=2). Significant differences against the 0 mol% EPG containing liposome preparation are noted. 
Inclusion of the negatively charged phospholipid did not appear to influence the circulation 
characteristics of the PEG-liposomes (Fig. 4A). The degree of localization in the infected 
lung was not affected by the inclusion of 5 mol% EPG. Remarkably, inclusion of 30 mol% 
EPG resulted in an approximately 2-fold reduced target localization compared to the PEG-
liposomes containing 0 mol% and 5 mol% EPG (p<O.Ol) (Fig. 4B). But, for all three types of 
PEG-liposomes differing in EPG-content the degree of localization in the infected left lung 
was higher than in the uninfected right lung (p<O.Ol). The 30 mol% EPG containing 
preparation showed a significantly increased splenic localization (p<O.Ol) compared to the 0 
mol% and 5 mol% EPG containing PEG-liposomes. Distribution of the three PEG-liposome 
types to liver, kidneys and heart was not significantly different (heart and kidney data not 
shown). Total accumulation within the infected left lung, right lung, liver and spleen was not 
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significantly different between the liposome formulations differing in EPG-content. (4572 ± 
623,4655 ± 855, 5406 ± 618 nmol TL/tissues for the 0 mol%, 5 mol%, and 30 mol% EPG 
containing liposomes, respectively. Mean ± standard deviation, n=6). 
4. Discussion 
SSL, obtained by coating the liposome surface with PEG via inclusion of PEG-DSPE into the 
liposomes, display a considerably increased circulation time compared to conventional 
liposomes lacking the PEG coating [9, 10, 22, 24]. This long-circulating property has been 
exploited to reach infectious sites localized outside the major MPS organs, the liver and 
spleen [14, 15, 16, 17]. SSL-encapsulated gentamicin showed a superior therapeutic effect 
compared to the free drug in our rat model of acute unilateral pneumonia in the left lung 
caused by Klebsiella pneumoniae [13]. SSL are, therefore, attractive candidates for site-
selective drug delivery of antimicrobial agents. In order to be able to rationally optimize 
liposomal preparations for targeted drug delivery to non-MPS infectious foci, it is important 
to gain insight into the liposome characteristics potentially affecting the process of liposome 
localization at the infected site. In this study the effects of PEG denSity, liposomal size, 
bilayer fluidity and charge on circulation kinetics and biodistribution of liposomes were 
evaluated in our rat pneumonia model. 
Liposomes containing 1 mol% PEG displayed inferior localization at the infected site and a 
shorter circulation time compared to liposomes containing 5 or 10 mol% PEG. It has been 
shown previously in healthy animals that inclusion of 5-7.5 mol% PEG-DSPE is optimal for 
achieving maximal prolongation of the circulation time, in case of PEG with an approximate 
molecular weight of 2,000 [24]. This finding is consistent with the present observations in a 
rat model of bacterial infection, showing lack of effect of increasing PEG density from 5 to 
10 mol% on blood circulation time and tissue disposition (Fig. 1A and 16). Inclusion of 1 
mol% PEG-DSPE is, apparently, less efficient in prolonging the circulation time as compared 
to inclusion of 5 or 10 mol% PEG-DSPE. The lower localization in the infected left lung of 
the 1 mol% PEG-DSPE SSL is most likely related to the faster removal from the bloodstream 
resulting in a reduced possibility to interact with the target site. However, it can not be 
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totally excluded that PEG has a direct effect as we[1. It has been shown in tumor bearing 
mice that PEG-coated [iposomes have an intrinsically higher tumor vascular permeability 
coefficient than conventional [iposomes [25]. In this view, the presence of 1 mo[% PEG-
DSPE may have resulted in a suboptimal PEG-density to facilitate extravasation. Future 
experiments will focus on the relative importance of circulation time versus the presence of 
a PEG-coating. 
A positive correlation between circulation times and infected lung [ocalization is also 
apparent from the experiments on the effect of particle size on circulation kinetics and 
biodistribution of SSL. SSL with mean particle sizes of 280 nm or 360 nm show an 
approximately two-fold [ower target localization compared to the 100 nm PEG-liposomes. 
Again, this may be related to differences in circulation times as 100 nm SSL are cleared 
more slowly from the bloodstream compared to the SSL with larger mean sizes. On the 
other hand, the reduced [ocalization at the site of infection of the two liposome types with 
the larger mean size may also be a direct consequence of the particle size of the [iposomes, 
which may have been too large to achieve equally efficient extravasation compared to the 
100 nm PEG-[iposome preparation. Boerman and co-workers studied the effect of particle 
size of SSL on [iposome localization in a focal infection in the calf muscle of rats. The studied 
particle sizes were between 90 and 220 nm. Their study showed that particle sizes, within 
this range, do not affect the degree of target [ocalization [26]. On the basis of the present 
results, we speculate that a further increase of the particle size to sizes well above 220 nm 
is required to observe a significant reduction in [ocalization at the site of infection. The 
higher splenic uptake of the larger PEG-coated [iposomes, noticed in this study, has also 
been observed by Litzinger and colleagues for SSL of approximately 300 nm, and was 
suggested to be due to a filtration effect within the splenic collagen fiber meshwork [27]. 
A[though the infected lung [ocalization of the two larger SSL is relatively [ow, it can 
nonetheless be argued that these [iposomes are still attractive for the delivery of 
antimicrobials. The present results demonstrate that SSL with a mean particle size up to 360 
nm are still able to [ocalize preferentially in infected tissue, though less efficient in this 
regard than the 100 nm SSL. If the [iposome-associated drug load is increased sufficiently 
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for the larger liposomes, it can be envisaged that the net drug concentration at the target 
site may even be increased, when larger SSL with suboptimal localization characteristics are 
used. 
Since bilayer fiuidity can be an important determinant of the release of liposome-
encapsulated compounds, this liposome characteristic should also be considered regarding 
its effect on SSL localization at the site of infection. Generally, it is reported that release of 
encapsulated compounds increases with increasing fiuidity of the liposome bilayer, which 
has also been shown to affect therapeutic efficacy [28-32]. Minimal variations were noticed 
in circulation kinetics and tissue distribution of the liposome formulations differing in bilayer 
fiuidity. This finding is in agreement with previous results reported by Woodle et al. [10, 
33]. Apparently, bilayer fiuidity of SSL may be chosen to optimize drug retention in the 
blood stream and release profile at the site of infection without compromising target 
localization. 
The only factor that appeared to adversely affect target site localization without 
compromising circulation kinetiCS was incorporation of 30 mol% EPG into the SSL 
formulation. Charged phospholipids are often added to a liposomal preparation to improve 
drug loading and/or stability of the formulation against aggregation during storage. The 
PEG-coating has a distinct effect on liposomal surface charge. The PEG-coating moves the 
hydrodynamic plane of shear from the charged surface of the liposome to the edge of the 
PEG coating. The ,-potential measurements as well as Gouy-Chapman calculations on the 0 
mol%, 5 mol%, and 30 mol% EPG containing PEG-liposomes suggested that in phYSiological 
ionic strength the I; -potential of the 30 mol% EPG SSL would be negligible at 2-3 nm from 
the surface, as the Debye length in this milieu is only 0.8 nm. Estimates for the thickness of 
the PEG-coating, for PEG with a molecular weight of 2,000, range from 3 to 5 nm [34, 35]. 
Therefore inclusion of EPG was not expected to have an effect on the circulation kinetics or 
biodistribution of SSL. However, the biodistribution profile of the 30 mol% EPG-containing 
preparation shows an approximately 2-fold lower target localization compared to the 0 
mol% and 5 mol% EPG-containing liposomes, but similar circulation kinetics as the 0 mol% 
and 5 mol% EPG-containing liposomes. It is speculated that the inclusion of 30 mol% EPG 
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may have conferred a small but detectable negative I; -potential at the edge of the PEG-
coating, allowing interaction with biological components. 
The results of the present study are to a certain degree in accordance with studies on 
pharmacokinetics and target localization of SSL in experimental tumor models. With respect 
to tumor localization of SSL, it is generally accepted that prolongation of Iiposomal 
circulation time is beneficial for target localization [5, 8, 9, 10, 25, 27, 36]. The results 
regarding the effect of PEG-density, particle size and bilayer fluidity in the present study as 
well as previous results point in the same direction [12]. It has been demonstrated that 
tumor localization of SSL is a result of the increased microvascular permeability in malignant 
tissue [9, 25]. As increased capillary permeability is also one of the hall marks of inflamed 
tissue, we suggest that selective SSL localization in infected tissue is a result of a similar 
effect of microvascular permeability changes. 
In conclusion, SSL offer interesting possibilities for delivery of antibiotics to sites of bacterial 
infection localized outside the major MPS-organs. It is shown here that the degree of 
localization at the infected site is remarkably independent of the physicochemical 
characteristics of the PEG-liposomes. Substantial selective liposome localization can be 
achieved provided that certain criteria regarding PEG-density, size, and inclusion of charged 
phospholipids are met. In view of the differences in pharmacodynamics of the different 
classes of antibiotiCS, the rate and extent of release of encapsulated antibiotic from the PEG-
liposome extravasated into the infected site is an important issue. The present findings 
indicate that manipulation of the release profile by variation of the lipid composition may be 
possible without compromising the prolonged circulation and target localization properties. 
These properties seem to be a direct consequence of the presence of the polymer coating 
operating as a repulsive steric barrier opposing interactions with biological components. 
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ABSTRACT 
Purpose. To gain insight into the host factors influencing liposome localization at sites of 
bacterial infection. Methods. In a unilateral Klebsiella pneumoniae pneumonia rat model, 
capillary permeability and number of circulating leukocytes was quantified and related to the 
degree of liposome target localization. Results. Liposome localization was highest in the 
hemorrhagic zone of infection, a zone characterized by markedly increased capillary 
permeability and high bacterial numbers. Both liposome localization and capillary 
permeability correlated positively with severity of infection. Lung instillation of other 
inflammatory stimuli, such as lipopolysaccharide or 0.1 M Hel inducing increased capillary 
permeability, also promoted liposome localization. As liposomal target localization in 
leukopenic rats was similar to that in immunocompetent rats, contribution of circulating 
leukocytes seems limited. Intrapulmonary distribution of liposomes shows that leukocytes at 
the target site are involved in liposome uptake after extravasation. Conclusions. Increased 
capillary permeability plays a crucial role in liposome localization at the infected site, 
whereas contribution of leukocytes is limited. These results suggest the inflammatory 
conditions that could benefit from liposomal drug delivery. The involvement of leukocytes in 
liposome uptake at the target site could be important information in the selection of 
appropriate drugs. 
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1. Introduction 
Targeted delivery of antibiotics may improve antibacterial therapy by increasing the 
concentration of the drug at the site of infection. Liposomes have been investigated as 
targeted drug carriers for this purpose. The avid uptake of conventional liposomes after 
intravenous administration, by the cells of the mononuclear phagocyte system (MPS), has 
been employed to deliver substantial amounts of antibiotics selectively to the cells of this 
system (1-2). However, the prompt uptake by MPS-cells strongly limits the chance of these 
conventional liposomes to interact with sites of infections located outside the major MPS-
organs. 
The development of liposomes coated with poly(ethylene) glycol (PEG), also known as 
sterically stabilized liposomes (SSL), potentially permits liposomal drug delivery to tissues 
beyond the MPS-cells (3-6). SSL display a reduced affinity for the MPS, compared to 
liposomes lacking the PEG-coating. It is believed that the PEG-coating reduces the 
interaction of opsonins with the SSL surface, thereby reducing MPS recognition and uptake. 
As a result SSL display a prolonged circulation time. In experimental models representing a 
variety of infiammatory and infectious foci outside the MPS, substantial SSL localization at 
the site of infection has been demonstrated. The presence of an infectious process is 
essential as SSL localization in uninfected controls is limited (7-13). Previous reports have 
suggested that presence of the long circulation property is also essential to achieve 
significant localization at the target site (5-6, 14). In addition, SSL-encapsulated gentamicin 
showed improved efficacy compared to the free drug in a rat model of Klebsiella 
pneumoniae pneumonia (15). These data warrant further investigations on SSL as carriers 
of antibiotics to sites of infection beyond the cells of the MPS. 
At present, limited information is available on the host factors that are responsible for the 
selective SSL localization at infiammatory sites, compared to non-infected control organs. It 
has been suggested that the increased capillary permeability at infiammatory foci allows SSL 
to extravasate (14). Besides, the infiltration of infiammatory cells may actively or passively 
promote SSL localization, either by taking up liposomes in the circulation and subsequent 
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infiltration into the inflamed tissue, or by facilitating liposome extravasation as a result of 
leukocyte-mediated tissue injury (16). 
The present study was designed to gain more insight into the mechanism of localization of 
SSL at sites of infection. In a rat model of a unilateral pneumonia caused by Klebsiella 
pneumoniae the requirement of increased capillary permeability for achieving SSL 
localization was investigated by correlating the extent of capillary permeability to the degree 
of SSL localization. The correlation was also studied after lung-instillation of other 
inflammatory stimuli (lipopolysaccharide (LPS) and 0.1 M HCI). The involvement of 
leukocytes in SSL extravasation was investigated by leukocyte depletion. Microscopic 
visualization of collOidal-gold labeled SSL was performed to obtain information on the 
intrapulmonary localization of SSL after extravasation in the infected tissue. 
2. Materials and Methods 
2.1 Animals 
RPjAEurjRijHsd strain albino rats, with a speCified pathogen-free status (18-25 weeks of age, weighing 
185-225 g) (Harlan, Horst, The Netherlands), were used in the experiments. Rats were housed 
individually with free access to sterilized water and SRMA chow (Hope Farms, Woerden, The 
Netherlands) 
22 Bactedal inoculation of'the lelt lung 
Bacteria were inoculated in the left lung as described previously (17). Briefly, rats were anaesthetized 
by an intramuscular injection of fluanisone and fentanyl citrate (Janssen Animal Health, Saunderton, 
UK) followed by an intraperitoneal injection of pentobarbital (Sanofi Sante b.v., Maassluis, The 
Netherlands). The left primary bronchus was subsequently intubated and 0.02 ml of a saline suspension 
containing the indicated number of K. pneumoniae (ATCC 43816, capsular serotype 2) was inoculated in 
the lower left lung lobe. Following the inoculation, rats received an intramuscular injection of nalorphine 
bromide as an anesthetic antagonist (Onderlinge Pharmaceutische Groothandel, Utrecht, The 
Netherlands) 
When indicated, leukopenia was effectuated by intraperitoneal injection of 60 mgjkg cyclophosphamide 
(Sigma, St. Louis, MO) every 4 days starting at 5 days before bacterial inoculation, according to 
Leenders et al. (18). Leukopenia was ascertained by measuring leukocyte counts in fresh blood 
samples, obtained by retro-orbital bleeding just before SSL injection. Leukocytes were counted on a 
Cobas Minos Stex (Roche Haematology, Montpellier, France) using Minotrol™ 16 standards (Roche 
HaematoJogy, Montpellier, France) to verify proper functioning of the instrument. 
23 Instillation of' other inllammatory stimuli in the lelt lung 
Rats were anesthetized and intubated as described above. 0.02 ml of a saline solution containing 2 mg 
LPS (from Esc/7edd7ia coli, serotype 0111:B4 (Sigma, St. Louis, MO) or 0.1 ml aqueous 0.1 M Hel 
(Fluka, Buchs, SWitzerland) were instilled in the lower left lung lobe. Nalorphine bromide was injected 
as an anesthetic antagonist. 
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2.4 SSL preparation 
SSL were prepared as described previously (13, 15). In brief, appropriate amounts of partially 
hydrogenated egg phosphatidylcholine (PHEPC) (Asahi Chemical Industry Co. Ltd., Ibarakiken, Japan), 
cholesterol (Chol) (Sigma Chemical Co., St. Louis, MO), and 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[polyethylene glycol-2000] (PEG-DSPE) (Avant polar lipids, Alabaster, 
Alabama) in a molar ratio of 1.85: 1.00:0.15, respectively, were dissolved in chloroform:methanol in a 
round bottom flask, followed by evaporation of the solvent in a rotary evaporator. The lipid mixture was 
dried under nitrogen for 15 min, dissolved in 2-methyl-2-propanol (Sigma Chemical Co., St. Louis, MO) 
and freeze-dried overnight. The resulting lipid film was hydrated for 2 h in Hepes/NaC! buffer, pH 7.4 
(10 mM N-[2-hydroxy ethyl] piperazine-N'-ethane sulfon·,c acid (Hepes) (Sigma Chemical Co., St. Louis, 
MO) and 13S mM NaCI (Merck, Darmstadt, Germany) containing S mM of the chelator deferoxamine 
mesylate (Desferal®) (Novartis, Basel, SWitzerland). SSL were sized by subjeclng the hydrated lipid 
dispersion to a sonication procedure for 8 min with an amplitude of 8 IJ USing a 9.5 mm probe in an 
MSE Soniprep ISO (Sanyo Gallenkamp PLC, Leicester, UK). 
25 Radiolabeling or /iposomes 
Non-encapsulated deferoxamine was removed by gel filtration of the SSL over a Sephadex G-SO column 
(Pharmada, Uppsalla, Sweden) using Hepes/NaCI buffer as an eluens. The SSL were subsequently 
concentrated via ultracentrifugation at 365,000 x g for 2 h at 4 O( in a Beckman ultracentrifuge L-70 
(Beckman, Palo Alto, CA). SSL were labeled with 67Ga according to Gabizon et al. (19). 67Ga-citrate (1 
mCi/ml) (Mallinckrodt Medical, Petten, The Netherlands), diluted 1:10 in aqueous S mg/ml 8-
hydroxyquinone (Sigma Chemical (0., St. Louis, MO), was incubated for 1 h at 52°C to obtain 67Ga-
oxine. 1 ml of this mixture was added per 1000 ]Jmol total lipid (TL) of SSl. 67Ga-oxine can pass the 
liposomal membrane and has a high affinity for the encapsulated chelator deferoxamine, with the result 
that the radioactive label becomes entrapped. 67Ga-deferoxamine is a suitable label for studying intact 
liposomes in the drculation as it is excreted rapidly via the kidneys in case it leaks from the liposomes 
(19). Unencapsulated 67Ga was removed by gel filtration and radiolabeled SSL were concentrated by 
ultracentrifugation. Resulting spedfic activity was approximately 105 cpm/]Jmol TL. 
26 SSL cl7aracterization 
Particle size distribution of the SSL was measured using dynamic light scattering, detected at an angle 
of 90° to the laser beam on a Malvem700 System (Malvern Instruments Ltd., Malvem, UK). The 
polydispersity of the liposome population is reported by the system as a value between a and 1. A 
reported value of 1 indicates large variations in particle sizes, whereas a value of a indicates a complete 
monodisperse system. For all SSL preparations used in the experiments, the mean liposomal size was 
approximately 100 nm and the polydispersity was below 0.3. Phosphate concentration was determined 
calorimetrically according to Bartlett (20). 
2.7 Bacterial cowts 
At indicated time pOints after bacterial inoculation, rats were sacrificed by C02 inhalation, since this 
form of euthanasia does not affect bacterial counts (unpublished observations). The right and left lung 
were excised and kept on ice and the left lung was divided into the three distinct zones of the lobar 
pneumonia: the early infected, hemorrhagiC, and consolidated zone. Lung (zones) were homogenized in 
20 ml of phosphate buffered saline (4'C), appropriate dilutions were cultured (ovemight, 37 'C) on 
tryptone soy agar plates (Oxoid, BaSingstoke, UK) and bacterial colonies were counted. 
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2.8 Evan's blue dye extravasation 
Evan's blue dye extravasation is a measure for the capillary permeability (21-22) and was determined 
as described previously by Zhang et al. (21), A saline suspension of Evan's blue dye (40 mg(kg) (Merck, 
Darmstadt, Germany) was injected in the tail vein at indicated time points after inoculation of the left 
lung. Rats were sacrificed 24 h later. A blood sample was taken via retro-orbital puncture, the lungs 
were exdsed and, when indicated, the left lung was divided into the three distinct zones of the lobar 
pneumonia. Blood sample volume was measured and the right lung and the three zones of the left lung 
were weighed and put in 7 ml of forrnamide (Sigma, St. Louis, MO) to extract the dye. Absorbance was 
measured on an LKB Ultrospec Plus spectrometer (Pharmacia, Uppsalla, Sweden) at a wavelength of 
623 nm. Standards (0-30 f.lg Evan's bluejml) were also dissolved in formamide. Corrections were made 
for the amount of Evan's blue present in the blood (see SSL localization). 
2.9 Lung wet-to-dry weight ratio 
Another measure of capillary permeability is the wet-to-dry weight ratio (23). Animals were sacrificed at 
64 h after bacterial inoculation, the lungs were exdsed and left and right lung weight was determined. 
Lungs were subsequently dried in a stove for 3 days at 70 °C, the dry weight of the lungs was 
determined and the wet-to-dry weight ratio was calculated. 
2.10 SSL localization 
SSL (75 f.lmo! TL/kg) were administered via the tail vein 24 h before the rats were sacrificed by an i.v. 
overdose of pentobarbital, at indicated time points after inoculation of the left lung. A blood sample was 
taken v'la retro-orbital puncture, lungs were excised and, when indicated, the left lung was divided into 
the three distinct zones of a lobar pneumonia. The right lung and the three zones of the left lung were 
weighed and radioactivity was counted in a Minaxi autogamma 5000 gamma counter (Packard 
Instrument Company, Meriden, CT) to assess the degree of localization of the SSL. Blood content of the 
tissues was determined in independent experiments with l1lIn-oxine labeled syngeneic erythrocytes, as 
described by Kurantsin-Mills et ai, (24), Labeled erythrocytes were injected 10 min before the animals 
were sacrificed. Assuming that all erythrocytes are still present in the Circulation, the dilution factor of 
the label allows determination of total blood volume and the blood content of the tissues of interest. 
Blood content values were used to correct for the contribution of labeled SSL in the circulation to total 
tissue radioactivity, 
2.11 Blood cell-associated SSL 
To determine the amount of ce!l-assodated SSL in the circulation, blood samples were obtained from 
infected animals via retro-orbital bleeding in heparanized tubes at indicated time points after injection 
of radioactively labeled SSL Blood cells (0.5 ml sample) were washed three times in 50 ml PBS (4°C) 
by centrifugation at 1500 x g for 10 min (Hettich Rotanta, Germany), Radioactivity of pellet and 
supernatants was counted as described above. 
2.12 Colloidal gold-labeling 01' SSL 
Colloidal gold-labeled SSL were prepared as described by Daemen et ai, (25), Briefly, the lipid film was 
prepared as described above. A 1.1 % (w/v) aqueous solution of AuCIz (Sigma, St Louis, MO) was four-
fold diluted with sodium Citrate (28 mM)( potassium carbonate (7 mM) buffer, filtered (0,2 ~m), and 
used to hydrate the lipid film at 4 0c. SSL were prepared by multiple extrusion of the hydrated lipids 
through two stacked 100 nm membranes (Nuclepore, Pleasanton, CA). The resulting yellow SSL 
suspension was placed at 37 °C, after which the color of the suspension turned purple. Unencapsulated 
colloidal gold was removed by gel filtration of the SSL suspension over a Sephacryl SF S1000 column 
(Pharmacia, Uppsalla, Sweden) using HepesjNaCI buffer as the eluens. 
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213 Localization or colloidal-gold labeled SSL 
Colloidal-gold labeled SSL (approx. S ~mol TL/kg) were injected at 40 h after bacterial inoculation of the 
left lung. 24h after injection both right and left lung were excised, washed in three changes of 2.5 % 
buffered formaldehyde (Merck, Darmstadt, Germany), fixed in 10% buffered formaldehyde and 
embedded in paraffin. 5 !-1m sections were cut on a microtome and mounted on slides. Sections were 
deparaffinized in we changes of xylene and hydrated. Next, colloidal gold was silver-enhanced using a 
Silver-enhancement kit (Sigma, St. Louis, MO) according to the manufacturers instructions. 
Eosinjhaematoxylin was applied as a counterstain, when indicated. 
For the immunohistochemical staining procedure, slides were deparaffinized and hydrated as described 
above. Endogenous peroxidase activity was blocked by incubation of slides for 10 min in 3% HzOz ( 
Merck, Darmstadt, Germany) in methanol (F!uka, Buchs, Switzerland) followed by rinsing with PBS. 
Slides were incubated with 5% goat serum for 30 min. Then 0.4 I-lgjm! of mouse anti-rat CD43 
(Pharmingen, San Diego, CA) was applied and sJldes were incubated overnight at 4 °C in a humid 
container. Slides were rinsed in 3 changes of PBS and the secondary polyclonal horseradish peroxidase 
conjugated goat anti-mouse IgG (10 ~g/ml) (Pharmingen, San Diego, CA) was added, incubated for 30 
min at room temperature and rinsed in 3 changes of PBS. Peroxidase activity was detected using the 3-
amino-9-ethylcarbazole kit (Sigma, St. Louis, MO) according to manufacturers instructions. 
2.14 Statistical analysis 
Indicated statistical analyses were performed using SPSS for Windows software release 7.5.2 (Statistical 
Product & Service Solutions Inc., Chicago, IL). 
3. Results 
3.1 Characteristics oNne lobar K. pl7eumoniae pneumonia 
At 64 h after inoculation of the left lung of the rats with 10' K. pl7eumol7iae a lobar 
pneumonia has developed (Figure 1). Three zones characteristic for this type of pneumonia 
can be clearly distinguished. The consolidated zone (C) is the lower part of the lung where 
the bacterial inoculum was deposited and the infectious process started. As the active 
infection gradually moves upward, the consolidated area is characterized by gray 
hepatization. Microscopic evaluation (data not shown) indicated diSintegration of alveolar 
walls, cellular debris, limited blood fiow and the deposition of connective tissue. The 
hemorrhagic zone (H) is the active area of the infection featured by a dark red appearance. 
Microscopic observations (data not shown) indicate the presence of edema fiuid, a large 
number of bacteria, infiltrating leukocytes, and hemorrhagic areas. The early-infected zone 
(EI) appears macroscopically as normal lung tissue, however, microscopic evaluation (data 
not shown) reveals the presence of bacteria and leukocytes indicates the early involvement 
in the infectious process. As the three zones of the lobar pneumonia can be clearly 
distinguished at 64 h after inoculation, and these zones showed limited variation in size and 
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macroscopic appearance between animals, this time-point was chosen to examine bacterial 
counts, capillary permeability and SSL localization. 
Figure 1. Acute lobar pneumonia in a rat. The consolidated (C), hemorrhagic (H), and early 
infected eEl) zone of an acute lobar pneumonia in the left lung of a rat at 64 h after inoculation of the 
left lung with 106 K. pneumoniae 
As expected, significantly higher bacterial numbers were observed in the infected left lung 
(LL) per gram organ weight compared to the uninfected right lung (RL) at 64 h after 
inoculation. The distribution of the bacteria over the three different zones of the lobar 
pneumonia shows that the number of bacteria was significantly higher in zone H of the 
pneumonia compared to C and EI (Figure 2A). The localization of a marker for capillary 
permeability -Evan's blue- shows a similar pattern at 24 h after injection (Figure 26). A 
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significantly higher level of Evan's blue was seen in the infected left lung compared to the 
contralateral non-infected right lung. The level of Evan's blue in the right lung was 
comparable to the levels measured in lungs of uninfected rats (data not shown). Within the 
infected lung a significantly higher level of Evan's blue was present in zone H compared to C 
and EI. Another measure for capillary permeability is the tissue wet-to-dry weight ratio. The 
wet-to-dry weight ratio was lower for the uninfected right lung (4.81 ± 0.05) compared to 
the infected left lung (5.84 ± 0.06) (mean ± standard deviation, n=10) (p<0.0001, paired t-
test). Localization of 6lGa-labeled SSL shows the same profile at 24 h after injection (Figure 
2C). Significantly higher levels were seen in the infected left lung compared to the right 
lung. Within the infected lung the highest level of SSL localization was seen in zone H 
compared to C and EI. 
3.2 Effect of increase in inoculum size on localization of SSL and Evans blue 
To test whether the severity of infection has an effect on capillary permeability and SSL 
localization, three different inocula of K. paeumoniae were applied and compared to sterile 
buffer-inoculated animals (Figure 3). Tissues were dissected at 48 h after inoculation as the 
highest inoculum already induced mortality at 64 h after inoculation. Evan's blue dye 
localization and 6lGa-labeled SSL localization measured at 24 h after injection, increased 
with an increasing inoculum (r=0.91, p<0.0001, r=0.91, p<0.0001, both Spearman's 
correlation test). 
Figure 2. localization of bacteria (A), Evan's blue (8), and 67Ga·laheled SSl ee) Q 
in right lung (Rl) and infected left lung (ll) (closed bars) (n=6, mean ± standard deviation). 
Localization within the LL in the consolidated (e), hemorrhagic (H) and early infected (EI) zone of the 
lobar pneumonia (open bars) (n=6, mean ± standard deviation). * p<O.05, ** p<O.Ol, ***p<O.OOl, 
left lung compared to right lung (paired t-test), consolidated zone and early infected zone each 
compared to hemorrhagic zone (repeated measures ANOVA corrected for multiple comparisons by the 
Bonferroni method). Tissues were dissected at 64 h after inoculation of the left lung with 105 K. 
pnelfffloniae, at 24 h after injection of liposomes and Evan's blue. 
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Figure 3. Effect of increasing " pneumoniae inoculum on degree of localization of SSL 
(open bars) and Evan's blue (dosed bars) in the inoculated left lung (ll) (n=6, mean ± 
standard deviation). Tissues were dissected at 48 h after bacterial inoculation of the left lung, at 24 h 
after injection of liposomes and Evan's blue. 
3.3 Effect or local administration or LPS and HO on lett lung localization or SSL and Evans 
blue 
LPS, a component of the Gram-negative bacterial cell wall, has been shown to increase 
capillary permeability in lung tissue after local administration (26). To test whether an 
increase in capillary permeability induced by LPS in the absence of living bacteria also 
produces increased 6lGa-labeled SSL localization, 2 mg LPS was inoculated in the left lung. 
After instillation of the LPS a significantly increased localization of 6lGa-labeled SSL and 
Evan's blue in the lung was noted at 24 h after injection (Figure 4). Similarly, inoculation of 
the left lung with 0.1 ml 0.1 M HCI, a model for adult respiratory distress syndrome featured 
by an increased capillary permeability (23), resulted in an increased locali2ation of 6lGa_ 
labeled SSL and Evan's blue at 24 h after injection (Figure 4). 
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Figure 4. Localization of liposomes (open bars) and Evan's blue (closed bars) in right lung 
(RL) and left lung (ll) of rats inoculated with buffer (A), 2 mg LPS per left lung (8), and 0.1 
ml 0.1 M Hel per left lung ee). Uposomes and Evan's blue were injected 15 min after inoculation. 
Tissues were dissected at 24 h after injection of liposomes and Evan's blue. (n=6, mean ± standard 
deviation). * p<O.OS, ** p<O.Ol, ***p<O.OOl compared to right lung (paired t-test). 
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3. 4 Effect oTieukocytes on localization OT SSt 
To investigate whether SSL are taken up by circulating leukocytes, 67Ga-labeled SSL were 
injected Lv. Blood samples were washed three times in PBS by centrifugation. The amount 
of cell-associated radioactivity was determined. In blood samples obtained at 1 h, 4 hand 
24 h after SSL injection 0.28 ± 0.12 %, 0.35 ± 0.16% and 0.17 ± 0.08% of the recovered 
radioactivity was pelletable w',th the blood cell fraction, respectively (mean ± standard 
deviation, n~3). 
To establish whether extravasation of inflammatory cells is a key factor contributing to SSL 
localization in the left lung, the number of leukocytes in the circulation was reduced by Lp. 
injections of cyclophosphamide. As a result of the cyclophosphamide treatment, the number 
of leukocytes in the blood was reduced 6-fold from 5.8 X 109 ± 1 x 109 for the buffer treated 
controls to 1 x 109 ± 8 x 108 for the cyclophosphamide treated rats (mean ± standard 
deviation, n~3) (p<O.Ol, unpaired t-test). Tissues were dissected at 48 h after inoculation 
as the infection produced mortality in the leukopenic animals already at 64 h after 
·,noculation. At 24 h after injection of "Ga-Iabeled SSL, SSL localization in the infected left 
lung of either leukopenic animals or animals with an intact host defense was significantly 
higher compared to 67Ga-labeled SSL localization in the lungs of uninfected animals (Figure 
5). Cyclophosphamide treatment did not result in a significant difference in the degree of 
67Ga-labeled SSL localization in infected animals. 
3.S Microscopic evaluation OT col/oidal gold-labeled SSL within the in/'ected site 
Localization of SSL in infected left lung and uninfected right lung tissue was visualized using 
silver-enhancement of colloidal gold-labeled SSL. Figure 6 A and B show dense clusters of 
silver-enhanced colloidal gold in the connective tissue surrounding the primary bronchus and 
major bronchioles of the infected left lung. These clusters were not observed in the 
un infected right lung. Magnification of these clusters show that the silver-enhanced 
colloidal-gold is present in mononuclear cells (Figure 6 C). These cells stained positive 
immunohistochemically for CD43 (Figure 6 D). One aspect of SSL localization that could only 
be clearly visualized in slides unstained or with just a very light counterstain is the presence 
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Figure S. localization of liposomes in the left lung of uninfected rats with intact host 
defense (1), infected rats with intact host defense (2), and infected leukopenic rats (3) 
(n=6, mean ± standard deviation). Tissues were dissected at 48 h after inoculation of the left lung 
inoculated with 106 K. pneumoniae, at 24 h after i,njection of liposomes and Evan's blue. ** p<O.Ol 
infected rats compared to uninfected rats. No significant differences were noted between leukopenic 
infected rats and infected rats with an intact host defense (ANOVA corrected for multiple comparisons 
by the Bonferroni method). 
of SSL in and around alveolar capillaries. Micrographs show silver granula in and around the 
capillaries in the alveolar walls, most prominent in the hemorrhagic zone of infected left lung 
tissue (Figure 6 E and Fl. Silver granula were not seen surrounding capillaries or alveolar 
walls in the un infected right lung tissue. 
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Figure 6. localization of colloidal gold-labeled liposomes in infected left lung tissue. 
¢ 
B. Magnification of clusters, as shown in A. 
Separate silver-enhanced colloidal gold-labeled 
clusters (arrows) can be clearly distinguished from 
surrounding tissue, in which a bronchiolar lumen 
(circle) and blood vessels (asterisks) are identified. 
Counterstain haematoxylinjeosin. Bar = 450 !-1m. 
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'" A. Presence of silver-enhanced colloidal 
gold-labeled SSL in large clusters (arrows) in the 
connective tissue surrounding the large 
bronchioles and blood vessels (asterisk). 
Inflamed alveolar spaces with high numbers of 
leukocytes surround the connective tissue 
(circles). Counterstain haematoxylinjeosin. Bar 
= 1125 urn. 
'" C. Magnification of clusters, as shown in 
B. Ousters appear intracellular silver-enhanced 
collOidal-gold in a mononuclear cell. Bar = 45 
urn. 
D. Positive immunohistochemical staining 
for C043 of cells containing silver-enhanced 
colloidal gold-labeled SSL (closed arrows). Not 
all positively stained leukocytes show colloidal-
gold accumulation (open arrow). Peroxidase 
activity was detected by 3 amino-9-
ethylcarbazoie . Bar = 45 IJm. 
F. Localization of silver-enhanced colloidal 
gold labeled SSL (arrows) in and around alveolar 
capillaries in the alveolar walls. No counterstain. 
Bar = 45 ~m 
Host factors 
'" 
E. Localization of silver-enhanced colloidal gold-
labeled SSL in and around alveolar capillaries in 
the alveolar walls, surrounding the alveolar spaces 
(asterisks) in a hemorrhagic area of the infected 
lung. Clustered silver-ellhanced colloidal-gold may 
indicate cellular uptake (arrows). Lightly 
cQunterstained with haematoxylinjeosln. Bar = 
450 ~m. 
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4. Discussion 
Preferential localization of SSL at sites of infection or inflammation that have developed 
outside the MPS has been reported by a number of investigators (7-13). Which host factors 
contribute to selective extravasation of SSL at infectious or inflammatory foci is not clear. In 
the present study, the involvement of increased capillary permeability and the role of 
inflammatory cells in the selective localization of SSL in bacterially infected lungs was 
studied in a rat model of unilateral pneumonia caused by K. pneumoniae. 
Three distinct zones of infection characterize the lobar unilateral K. pneumoniae pneumonia: 
the early infected, hemorrhagic, and consolidated zone. When the distribution of bacteria 
was studied at 64 h after inoculation, a higher number of bacteria was present in the 
inoculated left lung compared to the right lung. Within the infected left lung, the highest 
number of bacteria is present in the active hemorrhagic zone of the infection compared to 
the consolidated zone and early-infected zone. It is shown that the high number of bacteria 
in the hemorrhagic zone of the infected lung correlates with a pronounced inflammatory 
response, featured by a significantly increased capillary permeability as reflected by Evan's 
blue dye levels and lung wet-to-dry weight ratio. Furthermore, by raising the bacterial 
inoculum and thereby aggravating the severity of the infection, the increase in capillary 
permeability is enlarged. The increase in capillary permeability was invariably seen along 
with a proportional increase in SSL localization illustrating that capillary permeability is an 
important determinant for SSL extravasation. The observed correlation between capillary 
permeability and SSL extravasation is in line with studies showing preferential accumulation 
of SSL in tumor tissue, possessing angiogenic blood vessels exhibiting increased 
permeability, as has been reviewed (4-6). It also supports the observation of Klimuk et al. 
that increase in vascular permeability and liposome localization occur Simultaneously in a 
model of delayed type hypersensitivity (8). 
Increased capillary permeability has been described after intratracheal administration of LPS 
and HCI in rats (23, 26). Also in our experiments, both inflammatory stimuli promoted an 
increase in capillary permeability as well as SSL localization. Apparently, the nature of the 
inflammatory stimulus is not important for SSL localization as long as a sufficient increase in 
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capillary permeability is effectuated. Preferential SSL localization at the target site has been 
demonstrated in a wide variety of models of experimental infiammation and infection, 
including pathology as a result of administration of guinea-pig spinal cord (allergic 
encephalomyelitis) (7), 2,4-dinitrofiuorobenzene (delayed type hypersensitivity) (8), 
trinitrobenzene sulfonic acid (acute colitis) (9), sodium-morrhuate and Staphylococcus 
aureus (osteomyelitis) (10), Mycobacterium butyricum (adjuvant arthritis) (11), turpentine 
or Staphylococcus aureus (focal infection or infiammation) (12), and K. pneumoniae 
(unilateral pneumonia) (13). These findings strongly suggest that the etiology or location of 
the pathological process is not decisive for achieving SSL localization. Instead, increased 
capillary permeability, as part of the infiammatory response is likely to be the decisive 
parameter. 
Previous studies in models of hypersensitivity, colitis and encephalomyelitis have reported 
preferential SSL localization as well as leukocyte infiux at the site of infiammation (7-9). Also 
in the present model, the infiammatory response involves leukocyte infiltration. It has been 
suggested that there is a correlation between SSL and leukocyte localization (14). In the 
present study, it is shown that the amount of cell-associated SSL-encapsulated radioactivity 
in the circulation is negligible. In addition, a 6-fold reduction of the number of leukocytes in 
the circulation by cyclophosphamide injections, did not result in a reduced degree of SSL 
localization in the infected lung compared to rats with normal levels of leukocytes. In 
addition, Dams et al. showed that SSL still localized preferentially at sites of infection in 
granulocytopenic rats (27). These results strongly suggest that the contribution of 
circulating leukocytes to SSL localization at the site of infection is limited. An important 
implication would be that liposomal drug delivery could also be beneficial to leukopenic 
patients. These patients are highly susceptible to infections that are difficult to treat as a 
result of a reduced support by the host defense (28). 
Microscopic evaluation of silver-enhanced colloidal gold-labeled SSL in lung tissue showed 
that SSL could be visualized principally in the infected left lung. In the left lung, SSL were 
present in dense clusters in the connective tissue surrounding the primary bronchus and 
main bronchioles. These clusters appeared to be uptake by CD43-positive mononuclear 
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leukocytes. SSL were also seen surrounding capillaries in alveolar walls, especially in the 
hemorrhagic zone of infection, supporting the observation that increased capillary 
permeability allows liposome extravasation. To our knowledge, the localization of SSL 
around capillaries and liposome uptake at the site of bacterial infection by leukocytes has 
not been demonstrated before. Our results are in line with studies obtained in other models 
showing that SSL are taken up by infiammatory cells present at the infiamed tissue. In the 
FSN mouse (having a gene mutation producing infiammatory lesions resembling psoriasis) 
(29), in mice having been injected with substance P (30), and in mice overexpressing the 
HIV tatgene showing lesions resembling Kaposi's sarcoma (31), selective SSL localization at 
the target site was demonstrated together with uptake of colloidal gold labeled SSL by 
phagocytiC cells. It is tempting to speculate that phagocytic cells at the pathological site are 
involved in the processing of SSL and release of encapsulated agents. Still, the quantitative 
contribution of SSL uptake by local phagocytes to the fate of SSL localizing within the 
infected area remains unclear. 
In conclUSion, our observations indicate that the selectivity of SSL localization is a result of 
the local infiammatory response, as the locally increased capillary permeability seems 
decisive for SSL localization. The localization process appears independent of the nature of 
the infiammatory stimulus and number of circulating leukocytes. Microscopic observations 
indicate that phagocytes are to a certain extent involved in SSL uptake at the site of 
infection. In addition, extravasation of liposomes is observed in the alveolar walls. Further 
elucidation of the processes that determine the fate of SSL after target site localization, may 
help to design SSL-antibiotic formulations with increased antibacterial activity. 
Acknowledgements 
Research was financially supported by grant 902-21-161 of the Dutch Organization for 
Scientific Research (N.W.O.). Prof. dr. Th. van der Kwast (dept. of Pathology, Erasmus 
university Medical Center Rotterdam) is thanked for helpful comments on colloidal-gold 
labeled liposome localization. 
64 
Host factors 
References 
1. AJ. Schroit, J. Madsen, and R. Nayar, R. L1posome~cell interactions: in vitro discrimination of uptake 
mechanism and in vivo targeting strategies to mononuclear phagocytes, Chem. Phys. LijJlds40:373-393 
(1986). 
2. R. Kirsh, and G. Paste. Uposome targeting to macrophages: opportunities for treatment of infectious 
diseases, Adv. Exp. Ned. 202:171-184 (1986). 
3. G. Storm and D.J.A. Crommelin. Uposomes-Quo vadis? Phaflll. Sci. Tecimol. Today1:19-31 (1998). 
4. M.e. Woodle, M.S. Newman, and P.K. Working. Biological properties of sterically stabilized liposomes. 
In D. Lasic and F.J. Martin (eds), Stealthliposomes, CRe Press, Boca Raton, 1995, pp.103-117. 
5. G. Storm and M.e. Woodle. Long circulating Iiposomes: from concept to clinical reality. In M.e. 
Woodle and G. Storm (eds), Long drcu/ating liposomes: old drugs, new therapellti~ Springer Verlag, 
Germany, 1998, pp. 3-16. 
6. T.M. Allen. Liposomes: opportunities in drug delivery, Drugs54S1:8-14, (1997). 
7. V. Rousseau, B. Denizot, JJ. Le Jeune, and P. Jallet. Early detection of Jiposome brain localization in 
rat experimental allergic encephalomyelitis, Exp. Brain Res. 125:255-264 (1999). 
8. S.K. Klimuk, S.C. Semple, P. Scherrer, and MJ. Hope. Contact hypersensitivity: a simple model for 
the characterization of disease-site targeting by liposomes, Biochirn Biophys. Acta 1417:191-201 
(1999). 
9. E.T. Dams, WJ. Oyen, and O.e. Boerman. Technetium-99m-Iabeled liposomes to image experimental 
colitis in rabbits: comparison with technetium-99m-HMPAO-granulocytes and technetium-99m-HYNIC-
IgG, J. Nuci. Ned. 39:2172-2178 (1998). 
10. V. Awasthi, B. Goins, R. Klipper, R. Loredo, D. Korvick, and W.T. Phillips. Imaging experimental 
osteomyelitis using radiolabeled liposomes, J. Nuc/. Ned. 39:1089-1094 (1998). 
11. M.L Corvo, O.e. Boerman, WJ. Oyen, L. van Blools, M.E. Cruz, DJ.A. Crommelin, and G. Storm. 
Intravenous administration of superoxide dismutase entrapped in long circulating liposomes. II. In vivo 
fate in a rat model of adjuvant arthritis, Bioc/Jim. Biophys. Am 1419:325-334 (1999). 
12. W.J. Oyen, O.e. Boerman, and G. Storm. Detecting infection and infiammation with technetium-
99m-labeled Stealth Iiposomes, J. Nuc/. Ned. 37:1392-1397 (1996). 
13. I.AJ.M. Bakker-Woudenberg, A.F. Lokerse, M.T. ten Kate, J.W. Mouton, M.e. Woodle, and G. 
Storm. Uposomes with prolonged blood Circulation and selective localization in Klebsiella pneumoniae-
infected lung tissue, J. In/' Dis. 168: 164-171 (1993). 
14. WJ. Oyen, O.C. Boerman, CJ. van der Laken, R.A. Claessens, J.W. van der Meer, and F.H. 
Carstens. The uptake mechanisms of inflammation- and infection-localizing agents, Eur. J. Nud Ned. 
23:459-465 (1996). 
15. I.A.J.M. BakJ<er-Woudenberg, M.T. ten Kate, L.E.T. Stearne-Cullen, and M.e. Woodle. Efficacy of 
gentamicin or ceftazidime entrapped in liposomes with prolonged blood circulation and enhanced 
localization in Klebsiella pneumonia~infected lung tissue, J. Inr. Dis. 171:938-947 (1995). 
16. e.A. Owen and E.J. campbell. The cell biology of leukocyte-mediated proteolysis, J. Leukoc Bio/' 
65:137-150 (1999). 
17. I.AJ.M. Bakker-Woudenberg, J.e. van den Berg, and M.F. Michel. Therapeutic activities of cefazolin, 
cefotaxime, and ceftazidime against experimentally induced Klebsiella pneumoniae pneumonia in rats, 
Antimicrob. Agents Chemother. 22:1042-1050 (1982). 
18. A.e. Leenders, S. de Marie, M.T. ten Kate, I.A.J.M. BakJ<er-Woudenberg, and H.A. Verbrugh. 
Liposoma! amphotericin B (AmBisome) reduces dissemination of infection as compared with 
amphotericin B deoxycholate (Fungizone) in a rate model of pulmonary aspergillosis, J. Anbinicrob. 
Chemother. 38:215-25 (1996). 
65 
Chapter 3 
19. A. Gabizon, J. Huberty, R.M. Straubinger, and D. PapahadjopouJos. An improved method for in vivo 
tracing and imaging of !iposomes using a gal1ium 67-deferoxamine complex, J. LJp. Res. 1:123-135, 
(1988). 
20. G.R.l. Bartlett. Phosphorus assay in column chromatography, J. BioI. Cl7em. 234: 466 (1959). 
21. W. Zhang, L. Guo, J.A. Nadel, and D. Papahadjopoulos. Inhibition of tracheal vascular extravasation 
by liposome-encapsulated albuterol in rats. Pharm. Res: 15:455-460 (1998). 
22. G. Thurston, TJ. Murphy, P. Baluk, J,R. Lindsey, and D. McDonald. Angiogenesis in mice with 
chronic airway inflammation: strain-dependent differences. Am. J. PatfJ. 153:1099-1112 (1998). 
23. T. Nagase, E. Ohga, and E. Sudo. Intercellular adhesion molecule-l mediates acid aspiration-
induced lung injury, Am. J. Resp. Dit Care Ned. 154:504-510 (1996). 
24. J. Kurantsin-Mills, H.M. Jacobs, R. Siegel, M.M. cassidy, and loS. Lessin. Indium-ill oxine labeled 
erythrocytes: cellular distribution and effiux kinetics of the label. Int. J. Rad. Appl. Instr. B 16:821-827 
(1989). 
25. T. Daemen, M. Veilnova, and J. Regts. Different intrahepatic distribution of phosphatidylg!ycerol and 
phosphatidylserine liposomes in the rat, Hepat%gy26:416-423 (1997). 
26. J. Tamaoki, E. Tagaya, I. Yamawaki, N. Sakai, A. Nagai, and K. Konno. Effect of erythromycin on 
endotoxin-induced microvascular leakage in the rat trachea and lungs, Am. J. Resp. Crit care Ned. 
151:1582-1588 (1995). 
27. E.T. Dams, MJ. Becker, WJ. Oven, O.c. Boerman, G. Storm, P. Laverman, S. de Marie, J.W. van 
der Meer, LAJ.M. Bakker-Woudenberg, F.H. Carstens. Scintigraphic imaging of bacterial and fungal 
infection in granulocytopenic rats, J. Nud. Ned. 40: 2066-2072 (1999). 
28. B.A. CoJljn and R. RamphaJ. Pneumonia in the compromised host including cancer patlents and 
transplant patients, In!' Dis. Gin. Iv. Am. 12:781-805 (1998). 
29. S.K. Huang, FJ. Martin, G. Jay, J. Vogel, D. Papahadjopoulos, and D.5. Friend. Extravasation and 
transcytosis of ilposomes in Kaposi's sarcoma-like derma! lesions of transgenic mice bearing the HIV tat 
gene, Am. J. Path. 143:10-14 (1993). 
3Q. J. Rosenecker, W. Zhang, and K. Hong. Increased liposome extravasation in selected tissues: effect 
of substance P, PIVC. Nat Acad. Sd. USA93:7236-7241 (1996). 
31. S.K. Huang, F.J. Martin, D.S. Friend, and D. Papahadjopoulos. Mechanism of stealth liposome 
accumulation in some pathological tissues. In D. Lasic and FJ. Martin (eds), Stealth liposomes, CRC 
press, Boca Raton, 1995, pp. 119-125 
66 
4. localization of sterically stabilized liposomes in 
experimental rat Klebsiella pneumoniae pneumonia: 
dependence on circulation kinetics and presence of 
poly( ethylene) glycol-coating 
Raymond M. Schlffelers'l,tI, Irma AJ.M. Bakker-Woudenbergb, Gert Storma 
JDepartment of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences (VIPS), Utrecht University, 
Utrecht, The Netherlands, bDepartment of Medical Microbiology & Infectious Diseases, Erasmus 
univer.s-/CyMedical Center Rotterdam, Rotterdam, The Netherlands 
Summary 
Preferential localization of liposomes at sites of infection or infiammation has been 
demonstrated in a variety of experimental models. Most studies report enhanced localization 
at the target site of poly(ethylene) glycol (PEG)-coated liposomes as compared to 
conventional non-coated liposomes. It is generally accepted that the prolonged circulation 
time of PEG-coated liposomes increases target site exposure, which results in increased 
target localization. A quantitative relationship between circulation kinetics and localization at 
the pathological site has not been defined as yet. Besides, an effect of the PEG-coating itself 
has been suggested, as theoretically the PEG-coating may facilitate liposome extravasation. 
In the present study, in a rat model of an acute unilateral Klebsiella pf7eumof7iae 
pneumonia, circulation kinetics of PEG-coated liposomes were manipulated by incorporation 
of different amounts of phosphatidylserine (PS) and variation of lipid dose, additionally 
allowing evaluation of the saturability of the localization process. In addition, this paper 
addresses the effect of the PEG-coating, by comparing the circulation kinetics and target 
localization of long-circulating 'PEG-free' and PEG-coated liposomes. It is shown that the 
degree of liposome localization at the target site is positively linearly related to the area 
under the blood concentration time curve (AU C) of the liposome formulations, irrespective 
of PEG-coating. This finding is discussed in relation to the equation of Kedem and 
Katchalsky, which describes protein infiux into sites of infection or infiammation. 
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1. Introduction 
In a variety of experimental models of infection or inflammation, liposomes have been 
demonstrated to localize at the pathological site [1-7]. The localization is dependent on the 
inflammatory response as the localization at comparable anatomical sites in un infected 
control animals is generally insignificant. As a result, liposomes have attracted considerable 
interest as targeted drug carriers for application in infection and inflammation. In order to 
maximize the degree of liposome localization at the target site, it is essential to identify 
which factors contribute to the passive targeting of liposomes to inflamed sites. 
With respect to the inflamed target s',te, tih·,s area ',s characterized by an increased blood 
flow, and an increased capillary permeability causing edema. The fluid flux into the target 
site facilitates movement of the phagocytes and promotes plasma protein localization 
supporting the host defense. The influx of plasma proteins into the inflamed site has been 
mathematically described by Kedem and Katchalsky [8] as: 
J, = Jv (l-a) C, + P, S, l1C (1) 
where J, and Jv are the fluxes of the studied protein and of fluid, respectively, a is the 
reflection coefficient (fraction of the protein that is stopped by the microvascular barrier), C, 
is the average protein concentration in the capillary, P, S, is the capillary permeability-
capillary surface area product, and l1C is the protein concentration difference across the 
endothelium. The first term of the equation describes the convective transport component 
(Jv (i-a) C, ), whereas the second term describes the diffusion component (P, S, l1C). 
Assuming that liposome flux into the target site can also be described by this equation, two 
liposome related factors would then determine the degree of liposome localization: the 
ability of the liposomes to cross the vascular endothelium (determ',ned by a) and the 
liposome concentration in the blood (C,). The P, S, l1C component of the equation is 
negligible due to the low diffusion coefficient of particulate systems. The fluid flux (Jv) is not 
related to the particulate system but to the inflammatory response. Therefore, only C, and a 
seem to be the main determining parameters in the liposome localization process. 
Several studies have shown an improved target site localization of liposomes coated with 
poly(ethylene) glycol (PEG), also known as sterically stabilized liposomes (SSL), compared to 
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conventional liposomes lacking the PEG-coating [1-6]. It is generally accepted that the 
higher degree of localization is enabled by the prolonged circulation time of SSL. The 
increased average liposome concentration in the capillaries at the infiamed area, yields 
increased exposure of the target site to the liposomes, suggesting that the liposome 
concentration Cor c,) in time is important for target localization. Besides, permeability 
studies in tumor tissue suggest that the PEG-coating itself can promote target localization 
[9]. A less interactive Iiposome surface, conferred by the PEG-coating, which could also be 
interpreted as a reduced refiection coefficient Cor 0-), may facilitate their extravasation at 
sites of increased capillary permeability. 
Up to now, a limited number of qualitative studies has appeared on the relationship 
between circulation kinetics (i.e. involvement of the C, parameter) and degree of localization 
of SSL in the pathological target tissue, as has been discussed by Storm and Woodle [10]. 
In the present study, this relationship is explored in more detail. In a rat model of an acute 
unilateral Klebsiella pneumoniae pneumonia in rats, SSL circulation kinetics were 
manipulated by incorporation of different amounts of phosphatidylserine CPS) [11, 12]. 
Circulation kinetics were also manipulated by variation of lipid dose, additionally allowing 
evaluation of the saturability of the localization process. A relationship between liposomal 
circulation time and target site localization was established on the basis of the collected 
data. In addition, this paper addresses the effect of the PEG-coating itself (Le. involvement 
of the 0- parameter) by comparing the circulation kinetics and target localization of long-
circulating 'PEG-free' liposomes and SSL. 
2. Materials and Methods 
21 Uposome preparation and clJaractenzation 
Uposomes were prepared as described previously [2] using appropriate amounts of the following lipids: 
partially hydrogenated egg phosphatidylcholine (PHEPC) (Asahi Chemical Industry Co. Ltd., Ibarakiken, 
Japan), cholesterol (Chol), L-(-phosphatidyl-L- serine (PS) (Sigma Chemical Co., St. Louis, Missouri), 
1,2 -distearoyl-sn-glycero-3-phosphoetha nola mi ne-N -[polyethylene glycol· 2000] (PEG-DSPE), or 
distearoy! phosphatidylcholine COSPC) (Avanti Polar Uplds, Alabaster, Alabama). In brief, lipids were 
dissolved in a mlxture of chloroform and methanol. The solvent was evaporated and the lipids were 
dried, redissolved in 2-methyl-2-propanol (Sigma Chemical Co., St. Louis, Missouri), frozen, and freeze-
dried overnight. The resulting lipid film was hydrated in Hepes/NaCi buffer, pH 7.4 (10 mM N·[2· 
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hydroxy ethyl] piperazine-N'-ethane sulfonic acid (Hepes) (Sigma Chemical Co., St. Louis, Missouri), 13S 
mM NaCI (Merck, Darmstadt, Germany), and 5 mM of the chelator deferoxamine mesylate (Desferal ®) 
(Novartis, Basel, SWitzerland). 
The liposome dispersion was sonicated for 8 min with an amplitude of 8 IJm using a 9.5 mm probe in an 
MSE Soniprep 150 (Sanyo Gallenkamp PLC, Leicester, UK) to obtain liposomes with a mean particle size 
of 100 nm. Dynamic light scattering, detected at an angle of 900 to the laser beam on a Malvern 4700 
System (Malvern Instruments Ltd., Malvern, UK), was measured to evaluate the particle size 
distribution. In addition to the mean particle size, the system reports a polydispersity index (a value 
betv'leen a and 1). A polydispersity index of 1 indicates large variations in particle size, a reported value 
of a means that size variation is absent. All liposome preparations used had a polycflspersity index 
below 0.3. The DSPC:Chol preparation with a mean size of 80 nm was obtained by multiple extrusion at 
60 °C of the liposome dispersion through two stacked polycarbonate membranes (Nuc!epore, 
Pleasanton, california) with a final pore size of 50 nm. Mean particle size was 80 nm. 
22 Radlolabellng of Ilposomes 
Uposomes were radiolabeled with 67Ga, as described previously [2]. In brief, non-encapsulated 
deferoxamine was removed by gel filtration. Uposomes were concentrated via ultracentrifugation. 57Ga_ 
citrate (1 mCijml) (Mallinckrodt Medical b.v., Petten, The Netherlands) was diluted 1:10 in aqueous 5 
mg/ml 8-hydroxyquinone (Sigma Chemical Co., St. Louis, Missouri) and incubated for 1 h at 52°C to 
yield 57Ga-oxine. 1 ml of this solution was added per 1000 lJmol total lipid (TL). 67Ga-oxine can pass 
the llposomal membrane and form a complex with the entrapped chelator deferoxamine. The complex 
is an appropriate label for monitoring intact liposomes in the Circulation as it is rapidly renally excreted 
once it is released from circulating liposomes [l3]. Free label was removed by gel filtration and labeled 
Iiposomes were concentrated by ultracentrifugation. Resulting specific activities were between 1*104 
and 2*105 cpm/lJmol TL. Phosphate concentration was determined spectrophotometrically according to 
Bartiett [14]. 
23 UflI/ateral pnel/moflla 
The animal experiments ethical committee of the Erasmus university Medical Center Rotterdam 
approved the experiments described in this study. Female albino RP/AEurjRijHsd strain albino rats, 18-
25 weeks of age, body weight 185-225 g (Hartan, Horst, The Netherlands) with a specified pathogen 
free status were used. A left-sided unilateral pneumonia was induced as described previously [IS]. In 
brief, rats were anesthetized and the left primary bronchus was intubated. Through the tube, 0.02 ml of 
a saline suspension containing 106 K. pneumonlae (ATCC 43816, capsular serotype 2) was inoculated in 
the left lung lobe. Rats were housed individually with free access to water and SRMA chow (Hope Farms 
b.v., Woerden, The Netherlands). 
24 Blood clearance and biodlstrlbubon 
Experimental groups conslsted of 6 rats. At indicated tlme points after bacterial inoculation of the left 
lung, liposomes were injected at the indicated dose in the tail vein. At indicated tlme-points after 
injection blood samples of approximately 0.3 ml were taken, by retro-orbital puncture, from alternate 
groups of 3 rats. After measuring sample volume, radioactivity was counted in a Minaxi autogamma 
SOOO gamma counter (Packard Instrument Company, Meriden, Connecticut). To determine the tlssue 
distribution of the liposomes, rats were sacrificed by CO2 inhalation. Subsequently, organs were 
dissected, weighed and radioactivity was counted. Organ radioactivity was corrected for radioactivity 
present in the blood (see below). 
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2.5 Total blood volume and blood content or tissues 
Total blood volume of infected rats was determined, in an independent experiment, as being 5.3% of 
the total body weight. Syngeneic erythrocytes labeled with lllIn-oxine according to Kurantsin-Milis were 
used [16]. Blood samples were taken at 10 min after injection of the labeled erythrocytes assuming that 
all erythrocytes were still present in the drculation. The dilution factor of the radioactive label allowed 
calculation of the total blood volume. Sample volume and blood volume allowed calculation of total 
blood radioactivity content. This technique was also used to determine blood content of the tissues at 
appropriate time-points after inoculation. 
26 Statistical analysis 
SSL display single first-order clearance rates, independent of dose [17, 18]. Similarly, in our study blood 
clearance profiles of individual animals could be well described by a linear relationship on a semi-
logarithmic plot (0.88 < r < LaO), which allowed estimation of individual area under the blood 
concentration-time curve (AUC) values. 
Uposome localization data were tested for homogeneity of variance using Levene's statistic. Data were 
log transformed in case of significant differences. Infected left lung and right lung localization was 
compared using the paired t-test. Comparisons between groups were made by one-way analysis of 
variance (ANOVA). The Sonferroni method was used to correct for multiple comparisons. All analyses 
were performed using SPSS for Windows software release 7.5.2 (Statistical Product & Service Solutions 
Inc., Chicago, USA). 
3. Results 
3.1 Manipulation of Aue by incorporation of PS and effect on degree of infected left lung 
localization of SSL 
Incorporation of PS was used to manipulate the circulation time of SSL, as PS is a strong 
recognition signal for macrophage uptake, which cannot be prevented by the presence of 
PEG-DSPE at the usually applied amount of 5 mol% [11, 12]. The circulation kinetics and 
biodistribution profiles of SSL containing either 0, 1, or 10 mol% PS in the bilayer are shown 
in Figure 1 A and S, respectively. The AUCo.24h of the 1 and 10 mol% PS-SSL was 2.0-fold 
and 2.6-fold lower, respectively, compared to that of the 0 mol% PS-SSL. Regarding the 
biodistribution profile at 24 h after injection, the three liposome preparations displayed an 
approximately 4-fold higher localization in the infected left lung compared to the uninfected 
right lung (p<O.OOl, Fig. 1 S). The degree of localization in the infected lung was 2.5-fold 
higher for the 0 mol% PS containing SSL compared to the 1 and 10 mol% PS containing SSL 
(p<O.OOl). The differences in localization in the right lung between the SSL types showed a 
similar pattern (p<0.05; p<O.OOl, respectively). 
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Figure 1. Effect of incorporation of 0, 1, or 10 molo/o PS on blood clearance and degree of 
localization of SSL in infected left lung and right lung tissue. 67Ga-Jabeled I1posomes were 
injected i.v. at 40 h after bacterial inoculation of the left lung at a dose of 75 ~mol TL/kg. Upid 
composition was PHEPC:Chol:PEG-DSPE:P5 1.85:1.00:0.15:0 mol:mol for the 0 mol% PS containing 
liposomes, 1.82:1.00:0.15:0.03 for the 1 mol% PS preparation, and 1.55:1.00:0.15:0.30 for the 10 
mol% PS preparation. 
A. nmol TLjml blood was calculated from radioactivity recovered (n=3, Mean ± S.D.) 
B. nmol TLjlung at 24 h after injection was calculated from radioactivity recovered (n=6, mean ± 
standard deviation). 
p<O.OS, **p<O.Ol, ***p<O.OO1. Significant differences versus the 0 mol% PS preparation are 
indicated. 
3.2 Manipulation or Aue by variation oTlipid dose and effect on degree or inrected lett lung 
localization or SSL 
SSL were injected Lv. at lipid doses from 25 up to 375 ~mol TLJkg. The resulting values for 
AUc,,'24h and corresponding infected left lung localization at 24 h after injection are 
presented in Figure 2 A and B, respectively. The AUc,,-24h value as well as degree of left lung 
localization increased linearly with escalating dose. For all doses tested, the localization in 
the infected lung was approximately 3-fold higher than the localization in the right lung 
(data not shown, p<O.OOl). 
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Figure 2. Effect of lipid dose on AUCo-24h (A) and degree of left lung localization (8) of 67Ga_ 
labeled SSL. Lipid composition was PHEPC:Chol:PEG-DSPE 1.85:1.00:0.15 mol:mol. See the legend of 
Figure 1 for experimental conditions. 
3.3 Effect or PEG-coaang on degree oTinrected leff lung localizaaon or liposomes 
To assess whether the presence of a PEG-coating has a facilitating effect on target site 
extravasation, two liposome types were studied: 1- long-circulating small rigid liposomes 
(LCL) without a PEG-coating (DSPC:Chol, 2:1, mol:mol) and 2- SSL (PEG-DSPE:PHEPC:Chol 
0.15:1.85:1.0 mol:mol). The circulation kinetics and biodistribution profiles are shown in 
Figure 3 A and B, respectively. The slow clearance profiles of the long-circulating PEG-free 
liposomes and the SSL were similar, as is reflected by approximately equal AUCo.24h-values. 
In line with these results, the degree of localization in the infected left lung was similar for 
both long-circulating liposome types. Both formulations demonstrated an approximately 3-
fold higher degree of localization in the infected left lung compared to the degree of 
localization in the un infected right lung (p<O.OOl, Fig. 3 B). 
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Figure 3. Blood clearance (A) and degree of lung localization (B) of SSl and lel. Blood 
clearance and degree of localization in infected left lung and right lung tissue of 67Ga-JabeJed SSL (lipid 
composition PHEPC:Chol:PEG-DSPE 1.85:1.00:0.15 mol:mol) and PEG-free small rigid long-drculating 
liposomes (LCL) (lipid composition DSPC:Chol 2:1 mol:mol). See the legend of Figure 1 for experimental 
conditions. 
3. 4 Correlation between AUCo-24h and degree of infected left lung localization of liposomes 
Collected data regarding AUCo-24h-values and regarding degree of infected lung localization 
in individual animals taken from Figures 1, 2 and 3, are presented in Figure 4. A positive 
linear correlation was obtained (r=0.92, p<O.OOl) 
3.5 Relationship between infected left lung weight; AUe; and degree of infected left lung 
localization of SSL versus time after bacterial inoculation 
An implication of Iiposome concentration as a driving force for target localization would be 
that the driving force gradually weakens in time as a result of reduced blood levels due to 
liposome clearance. Therefore, left lung weight (as a measure of fluid influx), Iiposomal. 
AUC, and degree of infected left lung localization of SSL was determined at different time-
points after liposome injection (Figure 5 A-C). To obtain a clear effect of Iiposome clearance 
from the bloodstream, of these long-circulating SSL, data had to be collected over a 48 h 
period. To be able to collect data over this time period, Iiposomes were injected at 24 h 
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after bacterial inoculation as some animals died shortly after 72 h after inoculation. Figure 5 
A shows that the increase in left lung weight is linear in time (r=0.92, p<O.OOl). Both 
liposomal AUC and degree of liposome left lung localization show a hyperbolic curve (Fig 5 B 
and C, respectively). Over 70% of the liposome AUC and degree of left lung localization is 
achieved in the first 24 h. 
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Figure 4. Relationship between AUCO_24h M values and corresponding degree of left lung 
localization of individual animals for indicated liposome formulations. 
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Figure 5. Infected left lung weight (A), degree of infected left lung localization of liposomes 
(B), and AUC-value ee) of SSl at different time points after liposome injection. 67Ga~labeled 
I1posomes were injected Lv. at 24 h after bacterial inoculation of the left lung at a dose of 75 j.Jmol 
Tljkg. Rats were dissected at indicated time-points and left lung weight, degree of SSL left lung 
localization, and SSL blood concentration was determined. The AUC-values were calculated from 
individual blood clearance kinetics. n = 3-6 animals per time-point. Mean ± S.D. 
4. Discussion 
Similarly as plasma proteins, long-circulating SSL have been shown to localize preferentially 
at sites of infection or inflammation [1-7]. The equation of Kedem and Katchalsky (see 
Introduction) has been used to describe the influx of proteins into inflamed areas [8]. If the 
same equation also applies to liposome influx into inflammatory fOCi, then target localization 
would be dependent on the ability of liposomes to cross the vascular endothelium, 
determined by the reflection coefficient (a), and liposome concentration in the bloodstream 
(,). SSL with prolonged circulation times generally show a higher degree of target site 
localization compared to non-coated liposomes with shorter circulation times, which points 
at the involvement of (, [1-6]. In addition, the PEG-coating of SSL may have a promoting 
effect on target site localization itself by conferring a less interactive surface to the 
liposome, which implies a reduction of a [9]. At present, a systematic investigation of the 
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effect of circulation time and PEG-coating on the degree of [iposome localization at infiamed 
areas is lacking. The approach taken in the present study to investigate the effect of 
circulation kinetics of SSL on target localization was to incorporate PS in SSL and to vary SSL 
dose. The effect of PEG-coating was studied by comparing circulation kinetics and degree of 
target site localization values of long-circulating liposomes without PEG-coating to those of 
SSL. 
The rate of SSL removal from the blood increased with an increasing amount of PS in the 
[iposoma[ bi[ayers. A similar PS-effect has been observed by Boerman et al. [11]. Increased 
clearance from the circulation was paralle[ed by a diminished target site accumulation. The 
incorporation of PS could have an intrinsic effect on SSL biodistribution as a result of 
increased negative surface charge or induction of defects in the PEG-coating. More likely the 
reduced circulation time of PS-containing SSL reduces the number of [iposomes able to 
interact with the target site over time (reduction in c,), leading to a diminished target site 
[ocalization. The results reveal that the reduction in AUC is directly proportional to the 
reduction in degree of target [ocalization. 
Liposoma[ AUC was also manipulated by variation of lipid dose. The rise in AUC-va[ues was 
proportional to the increase in administered lipid dose, showing that the pharmacokinetics of 
SSL are independent of dose between 25 and 375 ~mo[ TL/kg. Dose-independent 
pharmacokinetics have also been observed earlier by Allen et a[. [18]. Here we show that 
the degree of target site [ocalization increases proportionally to the administered dose, 
which points out that saturation of target localization does not occur within the dose range 
of 25 to 375 ~mo[ TL/kg and further supports the notion that the liposome concentration (or 
C,) 'drives' the localization in the infected [eft lung. 
It has been argued that the presence of a PEG-coating facilitates [iposome extravasation at 
sites of increased capillary permeability, which could be interpreted as a reduction of the 
refiection coefficient (cr). This issue was addressed by comparing the circulation kinetics and 
target site localization values of long-circulating liposomes without a PEG-coating to SSL. 
Since the long-circulating liposome formulation lacking the PEG-coating shows similar AUC 
and target localization values as the SSL formulation, it appears that the presence of a PEG-
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coating does not contribute significantly to the degree of liposome localization at the site of 
infection and that the value for 0 is equal for both Iiposome types. Experiments, similar to 
those described by Waypa et al. [19] to measure the actual value of 0 for liposomes in 
infiammatory conditions could yield important information to maximize the degree of 
liposome target localization. 
The linear relationship obtained by plotting the AUC-values of the Iiposome formulations 
tested and corresponding target localization values in individual animals emphasizes that 
liposome concentration is the prime determinant of liposome extravasation at the target site 
and supports the usefulness of the Kedem and Katchalsky equation for describing Iiposome 
influx at the site of infection. 
Uposome concentration as a driving force for target localization implies that the Iiposome 
infiux at the target site gradually slows down as a result of Iiposome clearance. 
Experimental support for this notion was obtained by determining lung weight, and degree 
of left lung localization of SSL at different time-points after injection and calculation of the 
AUC-values between Iiposome injection and tissue dissection. It is shown that the lung 
weight increase is linear in time, which indicates that fluid infiux into the site of infection (Jv) 
occurs at an approximately constant rate (r=0.92, p<O.OOl). Both cumulative AUC and 
Iiposome localization show a hyperbolic curve, indicating that a gradual decrease in 
Iiposomal blood concentration results in a proportional decrease in target localization, which 
again confirms that AUC is the main factor driving the passive targeting effect. 
A theoretical implication of the Kedem and Katchalsky equation is that, during fiuid fiux into 
the site of infection (Jv>O) and a Iiposomal refiection coefficient that allows passage through 
the vascular endothelium (0<1), target localization of long-Circulating Iiposomes will occur 
and will not be saturable. Therefore, the design of liposomes with a longer circulation time 
compared to that of the Iiposome formulations used in the present study can be expected to 
provide for a higher degree of target localization, indicating that there is still room for 
improvement. Our results deviate from those of Longman and co-workers who investigated 
the localization of i.v. administered liposomes with various circulation times in peritoneal 
fiuid [20]. Localization of long-circulating Iiposomes in peritoneal fiuid was not increased 
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compared to conventional liposomes, despite significant differences in circulation times. 
Limited fluid transport (J,) due to an intact microvascular barrier in the abdomen 
(possessing a high reflection coefficient (a)) likely explains these results. 
In conclusion, the present study clearly shows for the first time that the blood concentration 
is the primary factor driving localization of liposomes into the K. pl7eumol7iae-infected target 
site. In addition, the PEG-coating itself does not contribute significantly to the degree of 
liposome target localization. The design of liposomes with longer circulation times as 
compared to those of the SSL used in this study can be predicted to result in a higher 
degree of target localization of liposomes. 
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Summary 
Liposome-encapsulated amikacin has recently entered clinical trials. The rationale for 
liposome-encapsulation of aminoglycosides is the possibility to increase the therapeutic 
index of this class of antibiotics by increasing aminoglycoside concentrations at the site of 
infection and/or by reducing the toxicity of these drugs. Three approaches can be 
distinguished: the use of liposomes as a depot formulation for local drug administration, 
targeting of (relatively) short circulating conventional liposomes to the cells of the 
mononuclear phagocyte system (MPS) for treating intracellular bacterial infections, and 
targeting of long-circulating Iiposomes to infectious foci localized outside the MPS. This 
review discusses the preclinical and clinical data in connection with recent developments in 
liposome technology. 
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1. Aminoglycosides 
After the introduction of streptomycin in 1944, aminoglycosides developed into an important 
class of antibiotics. Their wide antimicrobial-activity, post-antibiotic effect, synergism with S-
lactam antibiotics, rapid concentration-dependent bactericidal activity, low rate of 
resistance, and low cost contributed to their success [1-4]. However, the poor oral uptake of 
aminoglycosides requires parenteral administration. Moreover, the pharmacodynamics in 
relation to the dose-related adverse effects on kidneys and audio-vestibular apparatus 
demand that the plasma concentrations are maintained within a narrow therapeutic window 
[5-8]. Therefore, aminoglycosides are currently used for treating severe (nosocomial) Gram-
negative and Gram-positive infections, especially in immunocompromised patients, and for 
treating mycobacterial infections [9-12]. 
A drug delivery system may help to increase the therapeutic index of the aminoglycosides 
by increasing the concentration of the drug at the site of infection and/or reducing the 
nephro- and ototoxicity. With regard to drug delivery, liposomal encapsulation of 
aminoglycosides has attracted considerable interest. 
2. liposomes 
Liposomes are spherical vesicles, with particle sizes ranging between 30 nm up to several 
microns, consisting of one or more lipid bilayers surrounding aqueous spaces. Hydrophilic 
drugs, like aminoglycosides, can be encapsulated in the internal aqueous compartment, 
whereas hydrophobic drugs may bind to or are incorporated in the lipid bilayer. The bilayers 
are usually composed of (natural or synthetic) phospholipids and cholesterol but the 
incorporation of other lipids (and derivatives) as well as proteins is also possible [13-15]. 
The physicochemical characteristics of the liposome, like particle size, surface charge, 
sensitivity to pH changes, and bilayer rigidity, can be manipulated. Manipulation of these 
characteristics can have marked effects on the in vivo behavior of liposomes and therefore 
have a major impact on therapeutic success. Uposomes have also been studied as model 
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membranes regarding the interaction of aminoglycosides with phospholipids in relation to 
aminoglycoside toxicity [16-19]. The present review will exclusively focus on liposomes as a 
drug delivery system for aminoglycosides. 
3. In vitro data 
3.1 Extracellular bacteria 
The first literature, reporting on liposome-encapsulated aminoglycosides, appeared 
approximately twenty years ago. Regarding the antibacterial activity of Iiposomal antibiotics 
against extracellular bacteria, variable results have been reported. It is generally shown that 
the concentration of the liposome-encapsulated aminoglycoside to obtain growth inhibition 
and killing needs to be substantially higher compared to the free drug [20-22]. The 
encapsulation of the antibiotic reduces the antibacterial activity, because the bacteria are 
separated from the antibiotic by the liposomal bilayer. The variability in the in vitro data is 
probably the consequence of the variations in liposome lipid compositions used, leading to 
various release profiles for the encapsulated agents. 
In contrast to this generally observed reduction of antibacterial activity, Beaulac et aJ. 
reported that a liposome formulation composed of dipalmitoylphosphatidylcholine and 
dimyristoylphosphatidylglycerol encapsulating tobramycin showed a considerable 
antibacterial effect against a range of Gram-positive and Gram-negative bacteria at 
concentrations below the minimum inhibitory concentration of the free antibiotic in vitro 
[23]. They reported that the enhanced antibacterial effect may be due to a fusion 
mechanism of this liposome formulation with bacteria [24]. 
3.2 Intracellular bacteria 
In vitro studies using intracellularly infected phagocytic cells demonstrated that the 
phagocytOSiS of aminoglycoside-Ioaded liposomes yielded therapeutic intracellular drug 
concentrations [25], and consequently enhanced killing of intracellular micro-organisms such 
as Staphylococcus aureus [26, 27], Escherichia coli [28], 8rucella abortus [29-31], 8rucella 
canis [30], and Mycobacterium avium complex (MAC) [32-35]. A recent report addressed 
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the possibility to further improve liposomal drug efficacy towards infected cells. Liposomes 
encapsulating gentamicin composed of pH-sensitive dioleoylphosphatidylethanolamine-
based bilayers, showed an improved antibacterial effect against intracellular Salmonella 
typhimurium and Listeria monocytogenes in murine macrophage-like J774A cells as 
compared to non pH-sensitive liposome formulations [36]. It is believed that the pH-
sensitivity of the liposomes promotes drug release in the acidic environment of the 
lysosomes after phagocytosis by the infected cells. 
4. local application 
Local application of large, multilamellar aminoglycoside-containing liposomes exploits the 
possibility to utilize liposomes as a reservoir from which the encapsulated dnug can be slowly 
released, resulting in therapeutically active drug concentrations that are present at the site 
of infection for prolonged periods of time. Research in this area has focussed on intravitreal 
or subconjunctival injection or topical application of liposomes for treatment of bacterial 
endophtalmitis or keratitis [37-43). All studies reported prolonged presence of therapeutic 
aminoglycoside concentrations compared to administration of the free drug, offering the 
opportunity to reduce the number of injections necessary for successful treatment. Besides, 
systemic drug levels remained low. Research has been done mainly in rabbits but a single 
study reported excellent therapeutic results regarding eye-infections in AIDS patients [44). 
Similar results, as obtained in the ophthalmiC studies, were reported after (prophylactic) 
application of aminoglycoside-loaded liposomes in models of soft tissue infection, burn 
wounds, prosthetic vascular grafts or surgical wound infections [45-50), and 
intrabronchial/intratracheal administration of liposomal aminoglycosides in rodents [51-54). 
After intrabronchial administration, liposome-encapsulated tobramycin was shown to 
eradicate mucoid Pseudomonas aeruginosa in a model of chronic pulmonary infection [53). 
Interestingly, treatment results were dependent on the lipid composition of the liposomal 
formulation. Free tobramycin as well as tobramycin encapsulated in liposomes with rigid 
lipid bilayers showed no bactericidal effect, whereas tobramycin in liposomes composed of 
fiuid lipid bilayers was able to eliminate the bacteria. These data are in agreement with data 
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from in vitro experiments that have shown that fiuid liposomes tend to release encapsulated 
aminoglycosides faster compared to their rigid counterparts [54]. 
5. Intravenous administration 
5.1 Conventional liposomes 
5.1.1 Circulation kinetics and Tissue distribution 
Extensive research on liposome behavior after i.v. administration has shown that many 
liposome types rapidly accumulate in the cells of the mononuclear phagocyte system (MPS), 
particularly in the liver and spleen [55-57]. It is believed that the relatively rapid clearance 
of the liposomes is the result of opsonization in the bloodstream facilitating MPS-recognition 
and uptake [58, 59]. Such liposomes are generally termed 'conventional' liposomes. The 
rate by which conventional liposomes are taken up by the MPS can be manipulated by 
controlling the liposome dose, but also by variation of liposomal characteristics such as 
charge, size, and lipid composition. Generally, large, charged liposomes composed of fiuid 
lipid bilayers tend to accumulate in the MPS more rapidly than small, neutral, rigid liposomes 
[60]. With the objectve to reduce the MPS-uptake of conventional liposomes, it has been 
shown that by increasing the liposome dose, the amount of liposomes that remain in the 
circulation can be increased due to saturation of MPS-uptake [61]. However, saturation of 
the MPS needs to be avoided as it will impair the system's ability to clear infectious 
organisms from the circulation, which is exceedingly important in patients with severe 
infectons [62, 63]. 
The pharmacokinetics of i.v. administered conventional liposome-encapsulated 
aminoglycosides generally show that plasma half-lifes are prolonged compared to the free 
drug [64-68]. The blood levels reported in some representative studies of (liposomal) 
aminoglycosides are shown in figure 1. Free and liposome-encapsulated drug were 
administered at equivalent doses. It is important to realize that when injected in the free 
form the aminoglycoside is completely therapeutically active, while after injection of the 
liposome-encapsulated form only the released part is expected to show antimicrobial 
activity. The tissue distribution of aminoglycosides is remarkably changed upon liposomal 
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encapsulation as is illustrated in figure 2, again free and liposome-encapsulated drug were 
administered at equivalent doses. Renal concentration of aminoglycosides is approximately 
similar after administration in either the free or liposome-encapsulated form, whereas much 
higher concentrations are observed in liver and spleen after injection of the liposome-
encapsulated aminoglycosides. The absolute uptake of the liver exceeds that of the spleen 
considering its weight. Swenson et al. reported measurable gentamicin levels in liver and 
spleen up to 2 and 15 weeks after injection of a single dose of 20 mg/kg liposomal 
gentamicin, respectively [66]. Concentrations in other organs achieved with these 
conventional liposomes are generally insignificant. However, a few reports indicated 
increased concentrations in the lung [65, 68]. Interestingly, Ladigina and Vladimirski 
showed that in the lungs of mice infected with Mycobacterium tuberculosis, a six-fold 
increase in the amount of drug localizing in the infected lungs was seen for the liposome-
encapsulated aminoglycoside [65]. However, absolute drug concentrations remained low. 
It has been suggested that after liposome uptake and processing by the MPS-cells, the drug 
may be released in the blood, prolonging drug blood levels. Bermudez et al. showed that 
substantial urinary excretion of amikacin continued for up to 7 days after injection of 50 
mg/kg liposomal amikacin, whereas mice that received an equivalent dose of the free drug 
excreted most of the administered dose within the first day and had an undetectable level in 
the urine by day 4 [69]. Similar results were obtained by Swenson et aI., showing increasing 
cumulative gentamicin urinary excretion up to 10 days after injection of 20 mg/kg liposomal 
gentamicin. Even at that time pOint, only 80% of the injected dose was cumulatively 
excreted [66]. 
5.1.2 Safety 
Considering the prolonged presence of aminoglycosides in the body, it is unfortunate that 
studies on nephro- or ototoxicity of 'conventional' liposomal formulations of aminoglycosides 
are lacking. There are, however, reports comparing the acute toxiCity (characterized by 
convulsions or death as a result of neuromuscular blockade) of free versus liposome-
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encapsulated aminoglycosides. Without exception all studies showed a substantial reduction 
in acute toxicity for the liposome-encapsulated drug [67, 69-71]. 
-.--CL·G 
-Y- free G } 20 mg/kg 
........ Cl-A } 40 mg/kg 
-o-freeA 
time after injection (hours) 
c::Jspleen 
!EZ'3liver 
_kidney 
formulation 
Figure 1. A (left). Circulation kinetics of conventional liposome (el)-encapsulated 
aminoglycosides (closed symbols) and free aminoglycosides (open symbols). Mean 
aminoglycoside concentrations at indicated time-points after injection of a single dose of 20 mg/kg 
gentamicin in rats (triangles), 40 mg/kg amikacin in mice (circles), or 5.1 mgjkg gentamicin in AIDS-
patients (squares). Adapted from references [66, 68, 80], respectively. 
B (right). Tissue distribution of conventional liposome (el)-encapsulated 
aminoglycosides and free aminoglycosides. Mean concentrations in tissues at 24 h after injection 
of a single dose of 20 mgjkg gentamidn (G) in rats and 40 mgjkg amikacin (A) in mice. Adapted from 
references [66, 68], respectively. 
5.1.3 Therapeutic efficacy 
Generally, aminoglycosides are not the drug of choice for treating intracellular infections 
inside phagocytic cells due to their polar character. However, conventional liposomes readily 
accumulate in the MPS [72-74]. Therefore, aminoglycoside-Ioaded conventional liposomes 
were initially studied in in vivo models of intracellular infections inside the MPS-cells. An 
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overview of treatment results achieved with conventional liposome formulations is presented 
in Table 1-
Promising results are reported regarding a bactericidal effect in the liver and spleen in 
intracellular infectons caused by Mycobacterium spp., Salmonella spp., and Brucella spp. 
[26, 67-71, 75-87]. A pH-sensitive liposome formulation further increased therapeutic 
efficacy in liver and spleen in a murine intracellular Salmonella typ/Jimurium infect on [88]. 
In some studies a reduced bacterial load in lungs, blood, and/or kidneys was also reported, 
but the antibacterial effects in these organs were always less pronounced and were only 
achieved at higher dosages. These results illustrate the 'strength and weakness' of 
conventional liposomes as carrier system of antibiotics. On the one hand, liposome-
encapsulated aminoglycosides are very efficiently transported into the MPS-cells in liver and 
spleen and consequently high intracellular concentrations can be achieved resulting in good 
therapeutic efficacy as shown by prolonged survival and the opportunity to increase the 
dosing interval. On the other hand, due to the relatively fast and efficient uptake of the 
liposomes by the MPS-cells relatively low therapeutically active drug levels are seen in 
organs outside the liver and spleen. As a result, only moderate therapeutic effects are 
observed in these organs. 
A limited number of reports describe the therapeutic efficacy of conventional liposomes 
encapsulating aminoglycosides directed against infectious foci outside the cells of the MPS. 
The prolonged presence of drug in the body after administration of conventional liposome-
encapsulated aminoglycosides has been the rationale to study the prophylactic actvity 
against extracellular bacterial infections. Swenson et al. showed that the dose of liposome-
encapsulated gentamiCin needed for protection against a lethal i.p. infection caused by 
Klebsiella pneumoniae or Escherichia coli was substantially lower than for the free drug, 
when administered from 7 up to 2 days before bacterial inoculation [66]. This result is not 
surpriSing, as the free drug is almost completely excreted within 24 h after injection. In a 
single dose study in a murine model of a Klebsiella pneumoniae a single dose of 20 mg/kg 
liposome-encapsulated gentamicin was more effective than an 80 mg/kg dose of free drug 
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[89]. The prolonged residence time of gentamicin in the body by liposome-encapsulation is 
probably responsible for the enhanced efficacy. 
5.2 Long-drcu/ating /iposomes 
5.2.1 Circulation kinetics and Tissue distribution 
To enable the liposomes to reach infectious sites outside the major MPS-organs, such as the 
liver and spleen, it is necessary to decrease the liposome uptake by the phagocytic cells. 
One way to reduce MPS uptake is to prepare small, neutral vesicles with a rigid bilayer. 
Using this approach, NeXstar Pharmaceuticals (currently Gilead Sciences Inc.) have 
developed MiKasome®, a small (approx. 50 nm) unilamellar liposome formulation containing 
amikacin. This formulation is currently in clinical trials. Another approach to prolong 
circulation time of liposomes is the incorporation of poly( ethylene glycol) (PEG) coupled to 
phosphatidylethanolamine in the liposome bilayers. It is believed that the hydrophilic PEG 
provides a layer of steric hindrance around the liposome reducing liposome opsonization and 
thereby rapid recognition and uptake by the MPS-cells. These liposomes are therefore 
termed 'sterically stabilized liposomes' (SSL). The low MPS-uptake of the SSL is to a high 
degree irrespectve of liposome lipid compOSition, which is an important advantage when 
tuning the liposome lipid composition for optimal targeting, retention, and release [90-97]. 
Using this approach in our laboratory, we have developed a long-circulating sterically 
stabilized liposome formulation containing gentamicin [98]. In the case of MiKasome®, such 
fiexibility in tailoring the liposome characteristics does not apply, as the lipid composition of 
MiKasome® is restricted to a rigid membrane structure to retain its long-circulation 
behavior. 
Studies with aminoglycosides encapsulated in both types of LCL show that drug plasma half-
lifes are markedly prolonged. Blood levels obtained for MiKasome® and SSL-gentamicin are 
shown in Figure 3. Studies in rats receiving 50 mg/kg MiKasome® demonstrated that the 
AUC in plasma is increased approx. 130-fold compared to the AUC of an equivalent dose of 
free amikacin [99]. These findings were generalized to rabbits, dogs, rhesus monkeys and 
humans [100, 101]. In man, the plasma half-life is 114 h. After 1 week of daily dosing with 
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2.5 mgjkgjd or 5 mgjkgjd plasma concentrations were 120 and 215 ~gjml, respectively. 
One week later, plasma concentrations stll amounted to 10-20 ~gjml. Yet, the 
concentrations of free amikacin released from the liposome never exceeded 4 ~gjml. Our 
experimental studies with SSL-gentamicin showed a similar picture: a 70- to 130-fold 
increase in AUC compared to the free drug in rats [98]. 
The tissue distribution of aminoglycosides is remarkably changed after administration in the 
formulation 
Figure 3. A (left). Circulation kinetics of long-circulating liposome (lel)-
encapsulated aminoglycosides (closed symbols) and free aminoglycosides (open symbols). 
Mean aminog[ycoside concentrations at indicated time-points after injection of a single dose 5 mgjkg 
gentamicin in rats (circles) or 50 mgjkg amikacin in rats (squares). Adapted from ref [98, 99], 
respectively. 
B (right). Tissue distribution of long-circulating liposome (lel)-
encapsulated aminoglycosides and free aminoglycosides. Mean concentrations in tissues at 24 h 
after injection of a single dose of 5 mg/kg gentamicin (G) in rats (data are based on liposome 
distribution, note the increased liposome levels in the infected lung tissue; organs shown are the only 
organs investigated) or 50 mg/kg amikacin (A) in rats. Adapted from ref [98, 99] respectively. 
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liposome-encapsulated form for both types of LCL, as is illustrated in Figure 4. Equivalent 
doses of free and liposome-encapsulated drug were administered. Relatively high tissue 
concentrations are seen in the liver and spleen compared to free drug. In addition, higher 
drug concentrations are observed in other organs as bone marrow, lungs, intestine, lymph 
nodes, skin, and heart. MiKasome® has been recovered from microvacuolated macrophages 
in most tissues after injection, which suggests that phagocytic cells could serve as a depot 
of amikacin. The urinary recovery of unchanged amikacin after injection in the MiKasome® 
formulation is dramatically reduced compared to that in case of the free drug. Whereas 
practically all amikacin is excreted within 24 h after injection of the free drug, MiKasome® 
showed less than 40% recovery in urine by day 10 [100]. 
In addition to the reduced affinity of LCL for the MPS and increased localization in other 
organs, it was demonstrated in our laboratory by Bakker-Woudenberg et al. that in a rat 
model of a unilateral pneumonia caused by Klebsiella pneumoniae, the localization of SSL in 
the infected left lung was approximately 4-fold higher than the localization in the 
contralateral non-infected right lung [102]. In the same model, lO-fold lower levels of 
infected lung localization were observed when liposomes with a relatively short circulation 
time were used [103]. Recent studies, indicate that a prolonged liposomal circulation time 
is essential for substantial target site localization. An increase in AUC of the liposome 
formulation, achieved by tuning the lipid composition, was refiected by a proportional 
increase in localization at the infectious focus [97]. Similar findings of selective liposome 
localization at the target site in models of infiammation such as adjuvant arthritis, 
osteomyelitis, intraabdominal abscesses, colitis, allergic encephalomyelitis, focal thigh 
infection, and contact hypersensitivity have been reported [104-113]. The selectivity of the 
localization of LCL at the site of infection or infiammation is mediated by the locally 
increased capillary permeability as a result of the infiammatory response [114-116]. The 
nature of the inflammatory stimulus seems not important as lung instillation of HCI and 
lipopolysaccharide also induced increased capillary permeability and effected liposome 
localization [116]. A contribution of infiltrating inflammatory cells to selective liposome 
target site localization has been suggested by some authors [105, 115]. Studies in the 
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unilateral K. pneumoniae model indicate that the contribution of infiltrating inflammatory 
cells is not required for substantial liposome target site localization, as the degree of 
localization was similar in leukopenic rats as well as in immunocompetent rats [116]. This is 
an important observation as these results would indicate that targeted liposomal drug 
delivery could also be beneficial to immunocompromised patients, who suffer from severe 
infections and show a high risk of antimicrobial treatment failure. 
5.2.2 Safety 
Regarding the safety of long-circulating liposomal aminoglycosides, much work has been 
done on MiKasome®. Parameters tested in a one month study witih daily or every tihird day 
injection of MiKasome® in Beagle dogs were based on clinical chemistry, hematology, urine 
analysis, and coagulation together witih body weights, clinical observations, and vital signs. 
Gross necropsy and histopathologic examination of tissues was performed at tihe end of the 
study period [100]. Daily doses of 20 mg/kg or every third day doses of 60 mg/kg were not 
associated with the occurrence of adverse effects despite steady state plasma 
concentrations above 750 ~g/ml and trough levels above 600 ~g/ml. Surprisingly, kidney 
concentrations above 1 mg/g did not lead to elevation of blood urea nitrogen or creatinine 
concentrations. The study shows that the ratio of cortical to medullary amikacin was 
substantially reduced by liposome encapsulation compared to the free drug. Therefore, it 
appears that liposome-encapsulation results in a different kidney localization, preventing 
aminoglycoside-induced nephrotoxicity [100]. 
A clinical safety-study in HIV-positive patients showed that after one week of daily dosing of 
2.5 mg/kg and 5 mg/kg, plasma levels were approximately 120 ~g/ml or 215 ~g/ml, 
respectively. Plasma amikacin levels of 10-20 ~g/ml persisted for two weeks after the last 
dose. However, no renal or audiovestibular toxicity was noted in any of the subjects 
participating in the study [100]. 
Administration of SSL-gentamicin in rats, showed acute toxicity after a single dose of 40 
mg/kg, characterized by convulsions. A similar dose of SSL-gentamicin showed no acute 
toxicity [117]. 
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5.2.3 Therapeutic efficacy 
Results of the treatment studies with aminoglycosides encapsulated in LCL are shown in 
Table 2 [117-122]. The overall conclusion is that the efficacy of LCL-encapsulated 
aminoglycosides is superior over the free drug or conventional liposome-encapsulated 
aminoglycosides. Most studies relate to the use of MiKasome®. The long half-life of LCL in 
the circulation allows for prolonged dosing intervals or even single dose treatments. A 
clinical trial in urinary tract infection (UTI) patients shows that a single dose of 40 mgjkg 
MiKasome® produced a high cure rate and the efficacy was comparable to seven daily 
infusions of 10 mgjkg [118]. In two rabbit models of endocarditis, it was shown that single 
daily doses of MiKasome® improved survival and were as efficient in reducing bacterial 
numbers as twice daily doses of the free drug [119, 120]. In contrast, the rate of vegetation 
sterilization was higher in the animals treated with the free drug, probably as a result of the 
complete therapeutic availability of the free drug in the circulation. In immunocompromised 
mice, the relatively high tissue concentrations of MiKasome® are probably responsible for 
the enhanced prophylactic activity of the liposomal drug in prolongation of survival and 
reduction in bacterial numbers (also outside the liver and spleen) [121]. The studies related 
to SSL-gentamicin demonstrated in a rat Klebsiella pneumoniae pneumonia model that the 
therapeutic efficacy was clearly superior to the free drug in a Single dose schedule [98]. 
Evaluation of its efficacy in a multidose schedule in leukopenic rats showed that addition of 
a single dose of SSL-gentamicin to free gentamicin treatment showed complete survival, 
using a 7-fold lower cumulative amount of gentamicin compared to treatment with free 
gentamicin alone. In leukopenic rats infected with low gentamicin-susceptible K. 
pneumoniae, free gentamicin at the maximum tolerated dose did not result in survival. 
Addition of SSL -gentamicin was needed for therapeutic success. Complete survival was 
obtained adding an SSL-gentamicin formulation with a fiuid lipid bilayer, adding a rigid SSL 
gentamicin formulation showed only 50% survival. The increased gentamicin release from 
the fiuid liposomes, improved rat survival, thus showing the importance of liposome lipid 
composition for therapeutic efficacy [117]. 
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Tabie 1. Clinical and preclinical therapcutic cfficacy of ftJ11inoglycosidcs in cOlH'entionalliposomcs. 
INFECTION STUDIED IN DRUG USED RESULT COMMENTS 
Intracellular Bmcella Swiss mice {3O, Gentamicin [86, Compared to free drug: reduction of Empty cationic Iiposomes did also 
canis [30J, ll. 86, 87J, Hartley 87], Streptomycin number ofhacteria in spleen [30, 87J, prolong survival [86J 
abortlls [30, 86], and strain guinea pigs [30J liver [87J and other organs [30], 
B. melitensis [87J [30J prolongcd survival [86J, and high drug 
liver and spleen) levels in liver and s~lcen [87] 
---
Intracellular BALBle [66,71], Gentamicin [66, Compared to free drug: prolonged No rcduction of number ofbactcria 
Salmonella Swiss [85], 71], Streptomycin survival [66,67,71,85], reduced acutc in lung compared to frce dmg [85] 
typhimlirilllll [66], S. C57BLl6 [67] [67,851 toxicity [67, 71J, and high drug levels in 
dublin [71], and S. mice liver and spleen [851 
enteritidis [67, 85] 
liver and spleen) '" 
Klebsiella (ncutropenic) CD- Gentamicin [66, Compared to free dmg: enhanced Similar cnicacy of free and 
pllellll/Ol/iae sepsis, 1 mice [66, 89] 89J therapeutic cfl1cacy in Klebsiella liposomal drug when administered 
pneumonia, and pllelllJlolliae pneumonia and thigh immediately after inoculation [66J 
thigh infection [66, infection in neutropenic animals [89], 
89] Escherichia coli prolonged survival when administered 
sepsis [66] prophylactically [66J, prolonged dosing 
interval allowed [891 
Intracellular AIDS patients [80, Gentamicin [69, Compared to free drug: reduction of No reduction of number of bacteria 
M)'cobaCleril/llJ 811, Beige [68, 69, 76,79-81 J, number of bacteria in liver, spleen [68- in lung [68,70,75-79,82, 83 J or 
avitllll-ilitracelililare 75-79J, SCIL) [821, Amikacin [68,69, 70,75-79], blood [80], lung [84J and lymph nodes 175]. Transient renal 
complex [68, 69, 75- C57BU6 [82, 83J, 75,79,82,83J, kidneys [75, 84], prolonged survival [70, insufi1cicncy in I patient [80], no 
841, At. tuberculosis BAWle [70, 82, Streptomycin [70, 82, 83], reduced acute toxicity [69, 70J, reduction of number of bacteria in 
f70] (lung, liver, 84J CBB6FI [70J 77,78J, prolonged dosing interval allowed [82, any of the bone marrow core biopsy 
Ispleen) mice Kanamycin r 841 831 r~duction in Eulmona!1lesions [8.41 specimens [811 
g lip 
vegetation dcnsity, relapse, 
of renal and splenic abscesses 
19,120] 
amikacin used in thesc studies was MiKasome ®. 
activity, 
in liver 
and long-circulating 
equipotent in reduction of 
bacteria in spleen, liver and 
myocardial 
Rate of vegetation 
Isteri1izati~n \~as higher for free drug 
liposome-eneapsulated 
limes not 
[122] 
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Only one single study failed to show a superior effect of LCL-encapsulated aminoglycoside 
compared to conventional liposomal drug in the treatment of MAC infection [122]. 
Unfortunately, the preparations used in this study were not characterized with respect to 
their circulation time as well as their tissue distribution, so the underlying cause of the 
disappointing results cannot be traced. 
6. Concluding remarks 
Liposome-encapsulated aminoglycosides offer interesting prospects to increase the 
therapeutic index of this class of antibiotics. The local application of liposomes may provide 
a reservoir to prolong therapeutic drug concentrations at the site of infection. Accessible 
infected tissues such as eye, wound, and lung could benefit from this local administration. 
In order to optimize therapeutic efficacy it is of importance to balance drug release from 
and drug retention in the liposome. SpeCific liposome compositions may enhance bacterial 
killing by interacting with the infectious organism. 
As the largest number of conventional liposomes is taken up by the MPS after intravenous 
administration, the targeted delivery of drugs to MPS-cells in the liver and spleen seems to 
be the most relevant application of this liposome type. Treatment of intracellular infections 
in the MPS-cells may benefit from the high amounts of aminoglycosides that can be 
delivered intracellularly. By making liposomes pH-sensitive, the therapeutic availability of the 
liposome-encapsulated phagocytized drug may even be increased. Research is needed on 
the nephro- and ototoxicity of conventional liposomal aminoglycosides, with respect to their 
prolonged presence in the body. This research should also include the potential danger of 
promoting microbial resistance as a result of the prolonged exposure of the resident 
microbial fiora to the drug. 
In case the infectious focus is located outside the MPS, conventional liposomes are of 
limited use. Therefore, research has been aimed at decreasing the MPS-uptake of liposomes 
and consequently increasing their circulation time. LCL were the result of these efforts. 
Intravenous administered LCL potentially offer dnug targeting to sites of infection not 
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restricted to the MPS. A number of reports have demonstrated enhanced therapeutic 
efficacy of LCL -encapsulated aminoglycosides compared to free drugs or conventional 
liposomes. Unfortunately however, most studies with liposome-encapsulated 
aminoglycosides have, up to now, been performed in animal models with an intact host 
defense infected with high antibiotic-susceptible bacteria. Treatment failure in clinical 
practice, however, particularly occurs in patients having an impaired host defense or in 
patients infected with a low antibiotic-susceptible infectious organism. A single study 
addressed both issues in determining the efficacy of SSL-gentamicin [117]. These issues 
should be incorporated more in animal models to demonstrate the value of liposomes in 
clinically relevant settings. So far, MiKasome has shown an excellent safety profile. Yet, 
Similarly as for the conventional liposome formulations, the effects that the prolonged tissue 
drug concentrations have on development of resistance need to be addressed. The results 
that have been reviewed sketch promising prospects for liposome-encapsulated 
aminoglycosides and warrant further clinical investigations into the use of these formulations 
for the treatment of severe infections. 
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Summary 
Long-circulating liposomes may be used as targeted antimicrobial drug carriers as they 
localize at sites of infection. As a result, liposome-encapsulated gentamicin (LE-GEN) has 
demonstrated superior antibacterial activity over the free drug (GEN) in a single dose study 
in immunocompetent rats with a Klebsiella pnellmoniae pneumonia. In the present study, 
the therapeutic efficacy of LE-GEN was evaluated, by monitoring rat survival and bacterial 
counts in blood and lung tissue, in clinically relevant models, addressing the issue of 
impaired host defense and low bacterial antibiotic susceptibility. Results show that in 
immunocompetent rats infected with the high gentamicin-susceptible K. pnellmoniae, a 
single dose of LE-GEN is clearly superior over an equivalent dose of free GEN. Yet, complete 
survival can also be obtained with multiple dosing of free GEN. In leukopenic rats infected 
with the high gentamicin-susceptible K. pnellmoniae, free GEN at the maximum tolerated 
dose (MTD) was needed to obtain survival. However, with addition of a single dose of LE-
GEN to free GEN-treatment complete survival can be obtained using a 7-fold lower 
cumulative amount of gentamicin compared to free GEN-treatment alone. In leukopenic rats 
infected with low gentamicin-susceptible K. pnellmoniCie, free GEN at the MTD did not result 
in survival. The use of LE-GEN is needed for therapeutic success. Increasing LE-GEN bilayer 
fiuidity, resulted in an increased gentamicin release from the liposomes and hence improved 
rat survival, thus showing the importance of liposome lipid composition for therapeutic 
efficacy. These results warrant further clinical studies of liposomal formulations of 
aminoglycosides in immunocompromised patients with severe infections. 
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1. Introduction 
Clinical practice shows that failure of antimicrobial treatment is not uncommon. Two major 
risk factors can be identified: an impaired host defense and a moderate to low antibiotic-
susceptibility of the infectious organism(s) (4, 6, 8, 18). An impaired host defense increases 
the patients' susceptibility to infections. In addition, a limited ability of the host defense to 
support antimicrobial treatment increases the chance of treatment failure (15). A low 
antibiotic-susceptibility of bacteria can result in sub-effective drug concentrations at the site 
of infection despite high drug doses (8). 
Targeted antibacterial drug delivery may increase dnug concentrations at the infectious 
focus and therefore help to reduce the treatment failure risks imposed by the impaired host 
defense or low bacterial susceptibility. Besides, in case of potentially toxic antibiotics, 
toxicity to non-target tissues may be reduced which enables the use of higher doses. 
Liposomes have attracted considerable interest as targeted drug carriers in infectious 
diseases. A number of studies have convincingly demonstrated that so-called long-
circulating liposomes tend to localize preferentially at foci of infection or inflammation after 
intravenous administration (1, 9, 11, 17, 19). The preferential localization appears to be the 
result of the inflammatory response provoking a locally increased capillary permeability 
allowing liposome extravasation. Generally, intravenously administered liposomes that are 
rapidly opsonized and taken up by the mononuclear phagocyte system (MPS), hardly 
localize at foci of infection outside the MPS. By coating the liposomal surface with 
poly(ethylene) glycol (PEG), opsonization and subsequent MPS-uptake is reduced thus 
prolonging circulation time and interaction with the infectious target site. As a result, these 
long-Circulating PEG-coated liposomes (LCL) show superior target localization characteristics 
(19). Therefore, LCL have attractive prospects for the site-speCific delivery of antimicrobial 
agents. Previous research has shown that LCL-encapsulated gentamiCin (LE-GEN) 
demonstrates superior antibacterial efficacy compared to free gentamicin (free GEN) in a 
single dose study in rats with an intact host defense with a unilateral Klebsiella pneumoniae 
pneumonia (3). 
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In the present study, the antibacterial efficacy of LE-GEN was evaluated in clinically more 
relevant models addressing the issue of impaired host defense and low antibiotic 
susceptibility. Rat survival and bacterial counts in lung tissue and blood were monitored in 
immunocompetent as well as leukopenic rats with a pneumonia caused by high or low 
gentamicin-susceptible Klebsiella pneumoniae. 
2. Material and Methods 
2.1 Uposome preparabon and charactenzation 
Uposomes were prepared as described previously (3). In brief, appropriate amounts of partially 
hydrogenated egg phosphatidylcholine (PHEPC) (Asahi Chemical Industry Co. Ltd., Ibarakiken, Japan), 
cholesterol (Choi) (Sigma Chemical Co., St. Louis, Missouri), and 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[polyethylene glycol-2000] (PEG-DSPE) (Avanti Polar Upids, Alabaster, 
Alabama), in a molar ratio of 1.85:1:0.15 respectively, were dissolved in a mixture of chloroform and 
methanol to obtain 'rigid' liposomes. To obtain 'fluid' liposomes, egg phosphatidylcholine (EPC) (Asahi 
Chemical Industry Co. Ltd. Ibarakiken, Japan) and PEG-DSPE were dissolved in a molar ratio of 
2.85:0.15, respectively. After evaporation of the solvent under constant rotation and reduced pressure, 
the llpid mixture was dried under nitrogen, dissolved in 2-methyl-2-propanol (Sigma Chemical Co., St. 
LouiS, Missouri) frozen, and freeze-dried ovemight. The resulting lipid film was hydrated for 2 h in 2.5 
ml aqueous 200 mgjml gentamicin (Duchefa Biochemie b.v., Haarlem, The Netherlands), subsequently 
7.5 ml Hepes/NaCI buffer (10 mM Hepes) (Sigma Chemical Co., St. Louis, Missouri) and 135 mM NaCI 
(Merck, Darmstadt, Germany)) pH 7.4 was added. The hydrated lipids were sonicated for 8 minutes 
with amplitude of 8 ~ using a 9.5 mm probe in an MSE Soniprep 150 (Sanyo Gallenkamp PLC, Leicester, 
UK). Dynamic light scattering, detected at an angle of 90° to the laser beam on a Malvern 4700 System 
(Malvern Instruments Ltd., Malvern, UK), was used to evaluate the partide size distribution. Liposomes 
were obtained with a mean partide size of 100 nm. In addition to the mean partide size, the system 
reports a polydispersity index (a value between a and 1). A polydispersity index of 1 indicates large 
variations in particle size, a reported value of 0 means that size variation is apparently absent. AU 
liposome preparations used had a polydispersity index below 0.3. Non-encapsulated GEN was removed 
by ultracentrifugation in two changes of Hepes/NaCi buffer at 265,000 x g for 2 h at 4 °C in a Beckman 
ultracentrifuge L-70 (Beckman, Palo Alto, california). Phosphate concentration was determined 
spectrophotometrically according to Bartlett (5). Total (encapsulated and free) and unencapsulated 
(free) GEN was measured using a diagnostic sensitivity test agar (Oxoid, Basingstoke, UK) diffusion test 
with SfaphylococcusaureusOxford strain (ATCC 9144) as the indicator organism and standards ranging 
from 4 ~g/ml to 0.25 ~g/ml GEN, as described previously (3). For total (unencapsulated and 
encapsulated) GEN measurements, liposomes were destructed by 0.1 % v/v (final concentration) Triton 
X-100 (Janssen Chimica, Geel, Belgium). Less than 10% of the GEN in the liposome dispersion was 
shown to be unencapsulated after ultracentrifugation. Specific activity was between 70-80 I-Ig GEN/I-lmol 
total lipid. 
22 Bacteda/ strains 
The high gentamicin-susceptible K. pneumoniae (ATCC 43816, capsular serotype 2, MIC=0.5 ~g/ml) 
was used. The MIC was determined by plating an inoculum of 104 cfu per spot on MueJler-Hinton (MH) 
agar (Difco laboratories, Detroit, MI, USA) plates containing two-fold dilutions of gentamicin, according 
to Woods et al. (20). The low gentamiCin-susceptible K. pneumoniae (MIC=4 ~g/ml) was obtained by 
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culturing the high-susceptible strain in Mueller-Hinton (MH) broth (Diteo laboratories, Detroit, MI, USA) 
in the presence of increasing concentrations of gentamicin. The low gentamicin-susceptible strain 
appeared to be stable in vitro after repeated culture in antibiotic-free MH-broth. 
23 Unilateral pneumonia 
The animal experiments ethical committee of the Erasmus university Medical Center Rotterdam 
approved the experlments described in this study. Female RPjAEurjRijHsd strain albino rats, 18-25 
weeks of age, body weight 185-225 g (Harlan, Horst, The Netherlands) with a specified pathogen free 
status were used. When indicated, rat host defense was impaired by Lp. injection of 60 mgjkg 
cyclophosphamide (Sigma, St. louis, Missouri) every 4 days, starting at 5 days before bacterial 
inoculation. The leukopenic status of cyclophosphamide-treated animals was ascertained in separate 
experiments by measuring leukocyte counts in fresh blood samples, obtained by retro-orbital bleeding 
in EDTA-coated tubes. White blood cells were counted on a Cobas Minos Stex (Roche Haematology, 
Montpellier, France) using MinotrolTM 16 standards (Roche Haematology, Montpellier, France) to verify 
proper functioning of the instrument. As a result of the cyclophosphamide treatment, the number of 
leukocytes in the circulation at the day of bacterial inoculation was reduced 6-fold from approx. 6 x 109 
± 1 x 10' (buffer treated controls) to 1 x 10' ± 8 x 10' (mean ± standard deviation, n=3, P<O.Ol). 
Leukocyte counts remained reduced throughout the study period. 
From 5 days to 1 day before bacterial inoculation, drinking water of the leukopenic rats was 
supplemented with 1 gil cephalexin monohydrate (Dopharma, Raamsdonksveer, The Netherlands) to 
prevent superinfections. Drinking water in the remaining study period, and drinking water of 
immunocompetent rats was autodaved water pH 3. At the time of bacterial inoculation, cephalexin 
concentrations were less than 1 IJg/ml in the blood and lung tissue of rats that had received the 
drinking water supplemented with cephalexin (n=3 rats), as measured by agar diffusion test using an 
BcI7endJia collas the indicator organism, as described previously (3). 
A left-sided unilateral pneumonia was induced as has been described in detail elsewhere (2). In brief, 
rats were anesthetized and the left primary bronchus was intubated. Through the tube, 0.02 ml of a 
saline suspension of K. pneumoniaewas inoculated in the left lung lobe. Inoculated bacteria were in the 
logarithmic phase of growth. Inoculum was adjusted such that the median sUlVival of rats was 
comparable between the models. Rats with intact host defense were inoculated with 105 high 
gentamicin-susceptible K. pneumoniae (ATCC 43816, capsular serotype 2), leukopenic rats were 
inoculated with 105 high gentamicin-susceptible K. pneumoniae, or 107 low gentamicin-susceptible K. 
pneumoniae The cephalexin-containing water did not have an effect on rat sUlVival and did not have 
an effect on bacterial outgrowth. Rats were housed individually. In vivo stabillty of the phenotype of the 
low-susceptible K. pneumoniae was checked by culturing dilutions of homogenized left lung tissue 
obtained at 24 h after bacterial inoculation (the starting point of treatment) on MH-pJates. Colonies 
were isolated and MIC was determined on MH-plates as described above (20). All out of 100 tested 
colonies had a stable low gentamicin susceptible phenotype after inoculation in vivo. The same 
procedure was applied to bacteria isolated at the end of the study period (after death of the rats or 
after 14 days). None of the treatments in this study resulted in a change of the MIC of the K. 
pneumomaestrains pre- and post-exposure. 
2.4 Antimicrob/al treatment 
Indicated treatments were started at 24 h after bacterial inoculation. GEN was administered twice daily 
every 12 h (q12h) and LE-GEN was administered once daily every 24 h (q24h). The formulations were 
injected intravenously in the tail vein. 
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2.S Survival 
10 rats were used per experimental group. Survival of rats was examined every day until 14 days after 
bacterial inoculation. Blood of dead rats was cultured on Columbia III agar supplemented with 5 % 
sheep blood (Beckton-Dickinson) overnight at 37°C. Substantial numbers of, exclusively, K. 
pneumoniaewere recovered in the blood samples of dead rats. 
26 Quantificabon of bactedal numbers in blood 
At indicated time points after bacterial inoculation, blood samples were taken via retro-orbital bleeding 
in heparinized tubes on ice. Serial dilutions were prepared on ice and 0.2 ml of each dilution was 
applied on tryptone soy agar (TSA)-plates. Plates were incubated overnight at 37°C and colonies were 
counted. 
2.7 Quantification of bacterial numbers in left lung tissue 
At indicated time points after bacterial inoculation, rats were sacrificed by COrinhalation. The infected 
left lung was dissected and homogenized in 20 ml PBS (4°C), supplemented with aminoglycoside 
acetylating enzyme, and 2 mM acetyl coenzyme A (sodium salt) (Sigma Chemical Co. St Louis, USA) to 
inactivate residual gentamicin present in the tissues, according to Den Hollander et al. (13). Serial 
dilutions were prepared and 0.2 ml of each dilution was applied on TSA-plates. Plates were incubated 
overnight at 37°C and colonies were counted. 
28 Pharmacokinebcs and tissue concentrabons of/ree GEN or L£-GEN 
Free GEN or LE-GEN was injected Lv. in healthy rats at the indicated doses, used in the survival 
experiments, via the tail vein. Blood samples were taken at indicated time-points after injection from 
alternate groups of 3 rats via retro-orbital bleeding under CO2-anaesthesia. Blood samples were 
collected in heparinized tubes and after centrifugation the plasma was collected. Drug concentrations 
were analyzed using the agar diffusion test as described above. The sample was divided into two 
portions, one was analyzed directly to determine the free (i.e. non-Iiposomal) drug concentration. The 
other was incubated with Triton X-lOO, as described above, to disrupt the Iiposomes in order to 
determine total (free + encapsulated) drug concentrations. Both liposome types used in the study did 
not show substantial drug leakage when mixed with plasma, and subsequently brought in agar wells 
and incubated overnight at 37 0(, As a result, free gentamicin concentrations could accurately be 
determined separately from the total gentamicin concentrations. 
Total GEN-concentrations in lung tissue at different time-points after injection were analyzed by 
dissection of the infected left lung and uninfected right lung, homogenization of the tissue in PBS and 
subsequent incubation with 0.1 % Triton X-100 (final concentration) followed by agar diffusion test as 
described above. 
2.9 Statistical analysis 
Survival between experimental groups and controls was compared by the log-rank test (Graph Pad 
software Inc., San Diego, CA, USA). 
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3. Results 
3.1 Rats witIJ intact host del'ense inl'ected witIJ t1Je high gentamidn-susceptible K. 
pneumoniae 
In the first model, rats with an intact host defense were infected with the high gentamicin-
susceptible K. pneumoniae (MIC=0.5 ~gjml). Treatment with either free GEN or LE-GEN 
was started at 24 h after bacterial inoculation. The survival rates are shown in Figure 1. 
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Figure 1. Effect of free GEN and lE-GEN on survival of rats with intact host defense 
infected with a high gentamicin-susceptible IC pneumoniae. Treatments: control (no drug 
treatment) CD), free GEN 5 mg/kg single dose Cm), free GEN 5 mg/kg/d q12h for 3 days ce), or LE-
GEN 5 mg/kg single dose CO). 
untreated control animals died between day 3 and day 5 after bacterial inoculation. A single 
dose of free GEN 5 mgjkg slightly prolonged survival (P<O.Ol compared to controls) but all 
animals still rapidly died before day 8. An equivalent dose of LE-GEN yielded 70% survival 
after two weeks (P<O.OOl, compared to a single dose free GEN 5 mgjkg). The difference in 
efficacy between these two treatments is paralleled by the differences in gentamicin 
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concentrations in the lung tissue after injection. Already at 5 h after a single dose of GEN 5 
mg/kg, gentamicin levels are below 1.5 ~g/Iung in either infected left lung or uninfected 
right lung. In contrast, an equivalent dose of LE-GEN results in total gentamicin 
concentrations of 7.9±0.8 ~g/Ieft lung and 4.0±2.1 ~g/right lung at 5 h after injection. At 
24 h, concentrations of 12.9±4.3 ~g/Ieft lung versus 5.5±1.2 ~g/right lung were noted, 
whereas after 48 h concentrations were 16.2±3.9 ~g/Ieft lung versus 3.3±2.8 ~g/right lung 
(mean ± S.D., n~5 to 9 rats per time point). 
Treatment of rats with free GEN 5 mg/kg/d 2 daily doses every 12 h (q12h) for 3 days 
resulted in 100% survival. 
3.2 Leukopenic rats infected with the high gentamicin-susceptible K. pneumoniae 
Rat host defense was impaired, in the second model, by cyclophosphamide injections 
resulting in a 6-fold reduction in number of circulating white blood cells. These leukopenic 
rats were infected with the high gentamicin-susceptible K. pneumoniae (MIC~0.5 ~g/ml). 
Treatment with either free GEN, LE-GEN, or a combination of both was started at 24 h after 
bacterial inoculation. The survival rates are shown in Figures 2 and 3. 
Figure 2 shows that, similarly as in the previous model, untreated control animals died 
between day 2 and 4 after bacterial inoculation. The therapeutic regimen that resulted in 
complete survival in the previous model (free GEN 5 mg/kg/d q12h for 3 days) hardly 
prolonged survival in leukopenic rats. Free GEN 5 mg/kg/d q12h for 5 days prolonged 
survival during treatment, but after termination of treatment only 10% of the rats survived 
up to 14 days (P<O.OOOI compared to control animals). Increasing the dose of free GEN to 
20 mg/kg/d q12h for 5 days, showed 70% survival on day 14. A further increase to 40 
mg/kg/d q12h for 5 days, which is the maximum tolerated dose (MTD), resulted in complete 
survival. 
Figure 3 shows that addition of a single dose LE-GEN 5 mg/kg on day 1 to a 5-day 
treatment with free GEN 5 mg/kg/d q12h also resulted in 100% survival. The complete 
survival, obtained with that therapeutic regimen, is the result of the addition of liposomal 
gentamicin as the addition of free GEN on day 1 to the 5-day treatment with free GEN 
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showed only 30% survival on day 14 (P<O.OOl, addition of free GEN versus addition of LE-
GEN). Treatment with LE-GEN only at 5 mgjkgjd once daily (q24h) for 5 days was not 
effectve as the majority of rats already died during treatment. 
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Figure 2. Effect of free GEN on survival of leukopenic rats infected with a high gentamicin-
susceptible K.. pneumoniile. Treatments: control (no drug treatment) (0), free GEN 5 mgjkgjd q12h 
for 3 days (II), free GEN 5 mg(kg(d q12h for 5 days (0), free GEN 20 mg(kg(d q12h for 5 days (.), or 
free GEN 40 mg(kg(d q12h for 5 days (V). 
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Figure 3. Effect of GEN and LE-GEN on survival of leukopenic rats infected with.a high 
gentamicin-susceptible K. pneumoniae. Treatments: control (no drug treatment) (D), free GEN 5 
mgjkgjd q12h for 5 days CO), free GEN 5 mgjkgjd q12h for 5 days plus a single dose of LE-GEN 5 
mgjkg on day 1 (,V), free GEN 5 mgjkgjd q12h for 5 days plus a single dose of free GEN 5 mgjkg on 
day 1 Ce), or LE-GEN 5 mgjkgjd q24h for 5 days CIII). 
The median number of bacteria (± range) recovered from the left lung and blood on day 0, 
1, 6, 10, and 14 after bacterial inoculation of leukopenic rats infected with the high-
gentamicin-susceptible K. pneumoniae are shown in Table 1. Rats received as-day 
treatment with free GEN 5 mg/kg/d q12h with addition of either a single dose of LE-GEN 5 
mg/kg or free GEN 5 mg/kg on day 1. Median bacterial counts, 24 h after the last dose (day 
6), in the left lung of rats treated with the combination free GEN + LE-GEN were 10-fold 
lower compared to rats treated with equivalent doses of only free GEN. In the following 
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days complete bacterial killing was achieved in rats treated with free GEN + lE-GEN, 
whereas the majority of rats treated with only free GEN died. Bacterial counts in blood on 
day 6 were apprOXimately lOO-fold lower for free GEN + lE-GEN treated animals compared 
to rats treated with only free GEN. Median bacterial blood counts stab·liized in the following 
days in the rats that received free GEN + lE-GEN. Examination of bacterial counts in 
consecutive blood samples of individual rats revealed that the bacteremia was episodic in 
nature. The gentamicin-susceptibility of K. pneumoniae recovered from dead or surviving 
animals was not changed compared to the inoculated bacteria. 
Table 1. Number of high gentamicin-susceptible K. pneumoniae in left lung and 
blood. Number (#) of bacteria (median and range) in left lung (ll) and blood in leukopenic 
rats infected with the high gentamicin-susceptible K. pneumoniae, receiving the indicated 
combination treatments, at different time-paints after inoculation. 
Day Free GEN 5 mg/kg/d q12h for 5 days Free GEN 5 mg/kg/d q12h for 5 days 
+ rigid LE-GEN 5 mg/kg day 1 + free GEN 5 mg/kg day 1 
Log # baeteria/LL Log # baeteria/ml blood Log # baeteria/LL Log # baetena/ml blood 
Median Range Median Range Median Range Median Range 
o 5.0 0.0 5.0 0.0 
1 8.9 8.6-9.3 1.7 1.0-2.2 8.9 8.6-9.3 1.7 1.0-2.2 
6 5.7 3.0-8.2 1.8 0.0-2.0 6.7 3.9-7.7 3.5 3.1-4.3 
10 3.2 0.0-5.0 2.2 0.0-3.4 ~ " 
14 0.0 0.0-3.1 1.2 0.0-2.5 'D' 'li 
'8' bacteria! counts are not presented as the majority of rats had died. 6 animals were used per 
experimental group. 
3.3 LeukopeniC rats intected with the low gentamidn-susceptibie K. pneumoniae 
The third model combines the clinically encountered problems of an impaired host defense 
and low bacterial antibiotic-susceptibility. leukopenic rats were infected with the low 
gentamicin-susceptible K. pneumoniae (MIC~4 ~g/ml). Treatment consisted either of free 
GEN or a combination of free GEN and lE-GEN, and was started at 24 h after bacterial 
inoculation. The survival rates are shown in Figure 4. 
Untreated control animals died, similarly as in the previous models, on day 3 and 4. Free 
GEN given at the MTD of 40 mg/kg/d ql2h for 5 days, which resulted in complete survival 
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Figure 4. Effect of GEN and rigid LE-GEN or fluid LE-GEN on survival of leukopenic rats 
infected with a low gentamicin-susceptible K., pneumoniae. Treatments: control (no drug 
treatment) (D), free GEN 40 mg/kg/d q12h for 5 days (III), free GEN 40 mg/kg/d q12h for 5 days plus 
rigid LE-GEN 20 mg/kg/d q24h for 5 days (0), ar free GEN 40 mgjkgjd q12h far 5 days plus fluid LE-
GEN 20 mg/kg/d q24h for 5 days (e). 
in the previous model, was unsuccessful. Higher doses of free GEN produced acute 
mortality. Addition of LE-GEN 20 mgjkgjd q24h for 5 days to 5-day treatment with free GEN 
at the MTD, increased survival up to 50% (P<O.Ol compared to treatment with only free 
GEN), without producing acute mortality. 
So far, only a rigid LE-GEN formulation has been used, as it proved highly effective. In the 
present model, the maximum dose of free GEN + rigid LE-GEN was only partially successful 
(50% survival). Therefore, a fluid LE-GEN formulation was investigated, as it has been 
shown that bilayer fluidity can influence the therapeutic efficacy of liposome-encapsulated 
aminoglycosides (7). A previous study already demonstrated that the fluid and rigid LE-GEN 
115 
Chapter 6 
localize with the same targeting efficiency at the target site (19). Addition of the fluid LE-
GEN 20 mgjkgjd for 5 days instead of equivalent doses of rigid LE-GEN to the 5-day free 
GEN-treatment at the MTD resulted in complete survival (P<0.05, compared to free GEN + 
rigid LE-GEN). 
The median number of bacteria (± range) recovered from the left lung and blood on day 0, 
1, 6, 10, and 14 after bacterial inoculation of leukopenic rats infected with the low 
gentamicin-susceptible K. pneumoniae is shown in Table 2. Rats received 5-day treatment 
with free GEN 40 mgjkgjd q12h with addition of rigid LE-GEN or fluid LE-GEN 20 mgjkgjd 
q24h for 5 days. Median bacterial counts, 24 h after the last dose (day 6), in the left lung of 
rats treated with free GEN + fluid LE-GEN were 10-fold lower compared to rats treated with 
equivalent doses of free GEN + rigid LE-GEN. In the following days the median number of 
bacteria in the left lung of rats treated with free GEN + fluid LE-GEN was reduced further to 
zero. 50% of the rats treated with the rigid LE-GEN combination died in this period. Median 
number of K. pneumoniae in blood of rats treated with the GEN + fluid LE-GEN remained 
zero throughout the study period, whereas bacteria were present in the blood of rats 
treated with GEN + rigid LE-GEN. The gentamicin-susceptibility of K. pneumoniae recovered 
from dead or surviving animals was not changed compared to the inoculated bacteria. 
Table 2. Number of low gentamicin-susceptible K.. pneumoniae in left lung and 
blood. Number (#) of bacteria (median and range) in left lung (LL) and blood in leukopenic 
rats infected with the low gentamicin-susceptible K. pneumoniae, receiving the indicated 
combination treatments, at different time-points after inoculation. 
Day Free GEN 40 mgjkgjd q12h for 5 days Free GEN 40 mgjkgjd q12h for 5 days 
o 
1 
6 
10 
14 
+ rigid LE-GEN 20 mgjkgjd g24h for 5 days + ftuid LE- GEN 20 mgjkgjd g24h for 5 days 
Log # baetenajLL Log # baeteriajml blood Log # baetenajLL Log # baeteriajml blood 
Median Range Median Range Median Range Median Range 
7.0 M ~O 0.0 
10.0 8.6-10.3 1.7 1.0-2.2 10.0 8.6-10.3 1.7 
7.3 3.3-8.3 0.7 0.0-2.7 6.4 4.6-7.8 0.0 
'"' '"' 5.4 4.1-6.8 0.0 
'"' '"' 1.0 0.0-4.9 0.0 
1.0-2.2 
0.0-1.2 
0.0-1.5 
0.0-2.4 
<G' bacterial counts are not presented as the majority of rats had died. 6 animals were used per 
experimental group. 
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3. 4 Pharmacokinetics 
The time course of blood concentrations of therapeutically available gentamicin or total 
(therapeutically available plus liposome-encapsulated) gentamicin after injection of free 
GEN, fluid LE-GEN, or rigid LE-GEN are shown in figure 5 A and B. The pharmacokinetics of 
free GEN are independent of dose in the range of 2.5 mg/kg to 20 mg/kg, as the gentamicin 
concentrations in the circulation in time were approximately proportional to the injected 
dose. Disappearance of free GEN from the bloodstream was relatively rapid, with a half-life 
of approximately 20 min. At 8 h after injection of the highest dose (20 mg/kg) blood levels 
were already below 0.1 ~g/ml. 
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Figure 5. Left: Time course of gentamicin concentrations in plasma of rats after 
injection of a single dose of free GEN 2.5 mg/kg (0), 5 mg/kg (e), 10 mg/kg (D), or 20 mg/kg 
(.).3 animals per experimental group (mean ± S.D.) 
Right. Time course of gentamicin concentrations in plasma of rats after 
injection of a Single dose of rigid LE-GEN or fluid LE-GEN. Open symbols indicate 
microbiologically active (Le. not liposome-encapsulated) gentamicin concentrations after a single dose 
of rigid LE-GEN 5 mg/kg (D), rigid LE-GEN 20 mg/kg (0), fiuid LE-GEN 20 mg/kg ('7). Filled symbols 
indicate total (Le. microbiologically active and liposome-encapsulated) gentamicin concentrations after 
a single dose of rigid LE-GEN 5 mg/kg (_), rigid LE-GEN 20 mg/kg (e), fiuid LE-GEN 20 mg/kg ('1'). 3 
animals per experimental group (mean ± S.D.) 
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Encapsulation of gentamicin in rigid Iiposomes resulted in dramatically increased total 
gentamicin concentrations in the circulation after injection. Even at 24 h after injection 15-
20% of the injected dose was still present in the bloodstream. Fluid LE-GEN showed a 
completely different picture. Less than 5% of the injected dose was present in the 
circulation at 24 h after injection. As rigid and fluid liposomes exhibit similar blood clearance 
kinetics, as has been demonstrated previously (19), the difference between the two 
Iiposome types is the result of faster drug release from the fluid Iiposomes, as can also be 
deduced from the higher free gentamicin levels after injection of the fluid liposomes. It is 
not the result of renal impairment, as administration of the highest doses of free GEN, rigid 
LE-GEN, or fluid LE-GEN used in this experiment did not result in Significantly different blood 
creatinin or blood urea nitrogen levels between these three experimental groups at 24 h 
after administration (data not shown). 
4. Discussion 
The preferential localization of Iiposomes at sites of infection offers an attractive way to 
selectively increase antibacterial drug concentrations at the target location, with the 
intention to increase therapeutic efficacy of antimicrobial treatment. Most studies in this 
field have, up to now, been performed in animal models with an intact host defense with 
high antibiotic-susceptible bacteria. However, in clinical practice, two important complicating 
factors should be taken into account. Particularly patients having an impaired host defense 
carry a high risk of treatment failure, which further increases when the infectious organism 
is moderate to low susceptible to the applied antimicrobial agent. Generally, the studies in 
animals with an intact host defense report enhanced therapeutic efficacy of the liposomal 
formulation compared to the free drug (3, 7, 16, 21). The same conclusion can be drawn 
from the present study in the intact host defense model of a high gentamicin-susceptible K. 
pneumoniae pneumonia. As a result of the local delivery of the antibiotic by LE-GEN, a 
single dose of the liposome-encapsulated drug dramatically improves survival compared to 
an equivalent dose of free GEN. Increasing the dose of LE-GEN may improve survival to 
100%. Yet, the clinical relevance of this approach is limited as a relatively short course of 
118 
Therapeutic efficacy 
treatment for only 3 days with free GEN 5 mg/kg/d q12h already yields in complete survival. 
Therefore, the present study was undertaken to investigate the therapeutic potential of LE-
GEN in clinically more relevant models of infection, that are difficult to treat with 
conventional antibiotics as a result of an impaired host defense and low antibiotic-
susceptibility of the inoculated bacteria. 
In leukopenic rats, inoculated with the high-susceptible K. pnellmoniae, approximately 10 to 
100 bacteria per ml blood were present already at 24 h after injection. Thus, in these 
leukopenic rats, antimicrobial therapy should not only be directed towards the bacteria at 
the infectious focus (the left lung) but also towards the rapidly occurring bacteremia. The 
survival experiments in the leukopenic model of a high gentamicin-susceptible K. 
pnellmoniae pneumonia show that antimicrobial treatment is far less effective as a result of 
impaired host defense. Treatment with free GEN 5 mg/kg/d q12h for 3 days, that produced 
complete survival in the rats with an intact host defense, hardly prolongs survival in the 
leukopenic animals. Continuing treatment up to 5 days, prolonged survival during 
treatment. However, after termination of treatment only 10% survives up to 14 days. Doses 
of free GEN have to be increased up to 40 mg/kg/d for 5 days (MTD) to obtain complete 
survival. These data illustrate why in clinical practice aminoglycosides are used in 
combination with other classes of antibiotics to increase the therapeutic efficacy in these 
conditions. 
Addition of a single dose of LE-GEN 5 mg/kg on day 1 to the 5-day treatment with free GEN 
5 mg/kg/d q12h appeared to confer substantial therapeutic benefit. All rats survived, and 
the cumulative amount of gentamicin administered was 7-fold lower compared to the 
amount of free GEN (40 mg/kg/d for 5 days) needed to obtain complete survival. This 
reduction in gentamicin exposure may reduce the risk of the well-known toxicity of 
gentamicin on kidney and audiove5tibular apparatus. On the other hand, the altered tissue 
distribution in general and increased gentamicin concentrations at the site of infection in 
particular as a result of the liposome-encapsulation might change the toxicity profile. Yet, 
previous studies in Beagle dogs with liposome-encapsulated amikacin suggest a favorable 
safety profile of liposome-encapsulated aminoglycosides as doses of 20 mg/kg/day for one 
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month did not result in adverse effects despite steady-state plasma concentrations of 750 
~gjml (14), Rats treated with only LE-GEN 5 mgjkg for 5 days already show mortality during 
treatment, The blood clearance kinetics of free GEN and LE-GEN offer an explanation for the 
superior efficacy of the combination of free GEN + LE-GEN, Free GEN is therapeutically 
active in the circulation against the bacteremia, but is rapidly cleared after injecton with a 
half-life of approximately 20 min, Activity in the infected left lung is expected to be limited, 
When encapsulated in liposomes, on the other hand, the drug is only slowlY leaving the 
circulation, LE-GEN hardly releases gentamicin in the bloodstream, and consequently shows 
limited activity against the bacteremia, but localizes substantially in the infected left lung 
(3), Release of gentamicin from the liposomes localizing in the infected lung leads to the 
efficient bacterial killing seen, As a result, combination of free GEN + LE-GEN reduces the 
numbers of bacteria in left lung tissue and blood 10-fold and 100-fold more efficiently 
compared to the treatment with free GEN alone, respectively, These numbers are further 
reduced to zero in the remaining study period, In contrast, the majority of rats treated with 
free GEN or LE-GEN alone die during this period, The third model addresses an additional 
factor complicating clinical antimicrobial therapy, i,e, low antibiotic-susceptibility of the 
bacteria, The 8-fold increase in MIC clearly had an effect on the efficacy of treatment, as 
free GEN at the MTD was no longer effective and all rats died, Addition of LE-GEN 20 
mgjkgjd q24h for 5 days to the 5-day treatment with free GEN at the MTD resulted in 50% 
survival on day 14 without producing acute toxicity, Probably, as a result of the low 
gentamicin-susceptibility of the K. pneumoniae, the therapeutic availability of gentamicin 
released from this rigid liposome formulation in the infected lung is insufficient to obtain 
100% survival. As fiuid liposomes have been reported to release encapsulated 
aminoglycosides more easily than their rigid counterparts (7), a fiuid LE-GEN formulation 
was investigated, Cholesterol was omitted from the liposome formulation as cholesterol has 
a major rigidifying effect on liposomal bilayers (10), Furthermore, the partially hydrogenated 
phospholipid (PHEPC) was replaced by EPC as bilayer rigidity increases with the degree of 
hydrogenation of the phospholipids in the bilayer, Addition of fiuid LE-GEN instead of rigid 
LE-GEN to 5-day free GEN treatment at the MTD, resulted in an increase in therapeutic 
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effect: complete survival was obtained. The blood clearance kinetics of fiuid LE-GEN show 
that gentamicin is released in the circulation to a larger extent from this liposome 
formulation compared to rigid LE-GEN. As a result, higher therapeutically active drug 
concentrations were measured in the bloodstream. Yet, a sufficient amount of gentamicin 
remained liposomally encapsulated to be delivered to the left lung to control the local 
infection, as is supported by the efficient bacterial killing in the left lung observed. These 
results show that lipid composition is an important determinant of therapeutic efficacy. A 
careful balance must be sought between release of antibiotic in the circulation to obtain 
sufficiently high drug levels in the circulation versus liposomal retention of the drug in order 
to achieve sufficiently high levels of (locally released) antibiotic at the infectious focus. 
In conclusion, in rats with an intact host defense infected with high gentamicin-susceptible 
K. pneumoniae LE-GEN is clearly superior over free GEN treatment. Yet, the clinical 
relevance is limited as complete survival can also be obtained with multiple dosing of the 
free drug. In leukopenic rats infected with high gentamicin-susceptible K. pneumoniae, 
addition of LE-GEN to free GEN treatment shows substantial therapeutic benefit. Complete 
survival can be obtained using a 7-fold lower amount of gentamicin compared to 
administration of the free GEN alone. In leukopenic rats infected with low gentamicin-
susceptible K. pneumoniae, free GEN at the MTD shows 0% survival. The use of LE-GEN is 
a strict requirement for achieving therapeutic success. It appears that the increased release 
of gentamicin by fiuid LE-GEN compared to rigid LE-GEN is more favorable. These results 
warrant further clinical studies of liposomal formulations of aminoglycosides in 
immunocompromised patients with severe infections. 
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Abstract 
Antimicrobial agents may act synergistically when both drugs are present at the site of 
infection at sufficiently high concentrations for an adequate period of time. Co-
encapsulation of drugs in a drug carrier may ensure parallel tissue distributions and increase 
drug concentrations at the infectious focus. Therapeutic efficacy of liposome-co-
encapsulated gentamicin and ceftazidime was examined by monitoring survival rate in rat 
models of an acute unilateral pneumonia caused by antibiotic-susceptible and antibiotic-
resistant Klebsiella pneumoniae. It is shown in both models that combination of gentamicin 
with ceftazidime in the free form as single dose or as 5-day treatment twice daily failed to 
display synergy but resulted in an additive therapeutic effect. In contrast, targeted delivery 
of the liposome-co-encapsulated drugs resulted in a synergistic effect of the antibiotics in 
both models. Consequently, liposome co-encapsulated antibiotics allowed a shorter course 
of treatment and lower cumulative doses compared to administration of the unencapsulated 
antibiotics. 
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1. Introduction 
Administration of combinations of antimicrobial agents is frequently employed in clinical 
practice to increase therapeutic efficacy. Efficacy may be increased by broadening the 
antimicrobial spectrum of the treatment, preventing the emergence of resistant strains, 
reducing toxicity, eliminating multiresistant micro-organisms, and/or enhancing bacterial 
killing by exploiting the synergistic interaction of a specific drug combination [1-3]. To 
ensure a synergistic drug interaction in vivo, the drugs should both be present at the site of 
infection at sufficiently high concentrations for an adequate period of time [4-7]. Due to the 
differences in physicochemical properties between the various antimicrobial agents, the 
pharmacokinetics and tissue distributions of these agents vary substantially. A significant 
interaction of antibiotics at the infectious focus resulting in a synergistic activity is therefore 
not guaranteed. The use of a drug carrier containing both antibiotics could enforce a parallel 
tissue distribution of both of the encapsulated agents. In addition, the use of a targeted 
drug carrier (including liposomes) may increase the concentrations of the drugs at the site 
of infection, which would further strengthen the synergistic drug interaction. In this respect, 
co-encapsulation of antibiotics in liposomes may open up new perspectives. 
Uposomes have been widely investigated as targeted drug carriers in infectious 
diseases. Liposomes have been shown to localize selectively at the infected target site in a 
variety of experimental models of infection [8-13]. The selective localization appears to be 
the result of the locally increased capillary permeability allowing local liposome 
extravasation [14-15]. Up to now, only liposomes containing a single antimicrobial agent 
have been investigated. In the present study, we have co-encapsulated two antibiotics, 
gentamicin and ceftazidime, that have documented synergy in vitro [16] into liposomes. The 
therapeutic efficacy in vivo was examined by monitoring survival in a rat model of an acute 
unilateral Klebsiella pneumoniae pneumonia. Both an antibiotic-susceptible and an 
antibiotic-resistant K. pneumoniae strain was studied. 
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2. Material and Methods 
21 i.JjJosome preparabon 
Poly(ethylene) glycol (PEG)-coated LCL were used as previous studies have demonstrated that this 
liposome type shows substantia! localization at the site of infection in the investigated model [8]. 
Uposomes were prepared as described previously [8]. Appropriate amounts of the indicated lipids 
partially hydrogenated egg phosphatidylcholine (PHEPC) (Asahi Chemical Industry Co. Ltd., Ibarakiken, 
Japan), cholesterol (Chol) (Sigma Chemical Co., St. Louis, Missouri), 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[polyethylene glycol-2000] (PEG-DSPE) (Avanti Polar lipidS, Alabaster, 
Alabama) in a molar ratio of 1.85:1.00:0.15, respectively, were dissolved in a mixture of chloroform and 
methanol. After evaporation of the solvent under constant rotation and reduced pressure, the lipid 
mixture was dried under nitrogen, dissolved in 2-methyl-2-propanol (Sigma Chemical Co., St. Louis, 
Missouri) frozen by immersing in ethanol (-40 0c), and freeze-dried ovemight. The resulting !ipid film 
was hydrated for 2 h in aqueous solutions of appropriate concentrations of ceftazidime (CZ) (Glaxo-
Wellcome, Zeist, The Netherlands) or gentamidn (GEN) (Duchefa Biochemie, Haarlem, The 
Netherlands). For co-encapsulation of the drugs in liposomes, the CZ-solution was added first, followed 
by the GEN solution. Upid concentration was diluted to a final concentration of 100 IJmol total lipid/ml 
using Hepes/NaG buffer pH 7.4 (10 mM N-[2-hydroxy ethyl] piperazine-N'-ethane sulfonic acid (Hepes) 
(Sigma Chemical Co., St. Louis, Missouri) and 135 mM NaG (Merck, Danmstadt, Germany). The lipids 
were sonicated for S minutes with an amplitude of 8 IJm using a 9.5 mm probe in an MSE Soniprep 150 
(Sanyo Gallenkamp PLC, Leicester, UK) to obtain LCL with a mean particle size of 100 nm. Particle size 
distribution was measured using dynamic light scattering, detected at an angle of 900 to the laser beam 
on a Malvern 4700 System (Malvern Instruments Ltd., Malvern, UK). In addition to the mean particle 
size, the system reports a polydispersity index (a value between ° and 1). A polydispersity index of 1 
indicates large variations in particle size, a reported value of ° means that size variation is apparently 
absent. All liposome preparations used had a polydispersity index below 0.3. Unencapsulated GEN 
and/or CZ was removed by ultracentrifugation of the liposomes in two changes of Hepes/NaCi buffer at 
265,000 x g for 2 h at 4 0c. Phosphate concentration was determined spectrophotometrically according 
to Ba~ett [17]. Total (iiposome-encapsulated and free) and free (unencapsulated) GEN and/or CZ was 
measured USing a diagnostic sensitivity test agar (Oxoid, Basingstoke, UK) diffusion test with 
SlaphylococcusaureusOxford strain (ATCC 9144) (CZ-resistant) and an Escherichia colistrain (clinical 
isolate, GEN-resistant) as the indicator organism for GEN and CZ, respectively, as described previously 
[18]. For total (unencapsulated and encapsulated) drug measurements, liposomes were disintegrated 
by 0.1% v/v (final concentration) Triton X-lOa (Janssen Chimica, Geel, Belgium). Less than 10% of the 
GEN and/or CZ was shown to be unencapsulated after ultracentrifugation. The validity of the agar 
diffusion test for the determination GEN and CZ concentrations in the combination was ascertained in a 
separate experiment. Enzymatic inactivation of GEN using aminoglycoside acetylating enzyme [19] or of 
CZ using B-Jactamase (Koch-Ught Ltd. Haverhill, UK) yielded similar inhibitory zones as without 
deactivation of either one of the antibiotics, thus showing the possibility to measure one drug at a time 
in the combination. 
22 Bacterial strains 
The susceptible K. pneumoniae (ATCC 43816, capsular serotype 2, MIC=0.5 ~g/ml for both GEN and 
CZ) was used. The MIC was determined by plating an inoculum of 104 cfu per spot on Mueller~Hinton 
(MH) agar (Difco laboratories, Detroit, MI, USA) plates containing two-fold dilutions of GEN or CZ, 
according to [20]. The resistant K. pneumoniae (MIC=32 ~g/ml for GEN and 16 ~g/ml for CZ) was 
obtained by culturing the susceptible strain in Mueller-Hinton (MH) broth (Difco laboratories, Detroit, 
MI, USA) containing increasing concentrations of CZ. The MIC was determined according to the method 
described above. The resulting CZ-resistant strain was conjugated with an Escherichia coliR176 strain 
127 
Chapter 7 
(clinical isolate) that produced a plasmid encoding for an aminoglycoside-acetylating enzyme. In this 
way, a _in resistant to both GEN and CZ was obtained. The stability of the GEN/CZ resistant 
phenotype in vitro was checked by culturing the bacteria 5 times in succession in antibiotic-free 
medium, followed by determination of the MIC. All out of 100 tested bacterial colonies remained 
resistant to both antibiotics. 
2.3 Checkerboard tilTctions 
Checkerboard titrations were performed with GEN and/or CZ at the indicated concentrations in MH-
broth of 37°C in a total volume of 3 ml. An inoculum of 5 x 105 susceptible or resistant K. pneumoniae 
cfujml in the logarithmic phase of growth was used. Tubes were incubated for 24 h at 37 °C, and (the 
absence of) microbial growth was determined macroscopically. Each titration was performed in 
triplicate. 
24 77me-kill curves 
Time-kill curves were performed with GEN and/or CZ at the indicated concentrations in MH-broth of 37 
°C in a total volume of 3 ml. An inoculum of 5 x 105 susceptible or resistant K. pneumoniae cfu/ml in 
the logarithmic phase of growth was used. Samples were taken at 0, 1, 2, 4, 6, and 24 h after addition 
of the inoculum. Number of bacteria in the samples was determined by making serial dilutions in 
phosphate buffered saline (PBS) 4 °C. 200 ~I of each dilution was plated on byptone soy agar (TSA)-
plates and incubated overnight at 37 0c. Colonies were counted. Each curve was determined in 
triplicate. 
25 Unilateral pneumonia 
The animal experiments ethical committee of the Erasmus university Medical Center Rotterdam 
approved the experiments described in this study. Female albino RP/AEur/RijHsd strain albino rats, 18-
25 weeks of age, body weight 185-225 g (Harlan, Horst, The Netherlands) with a specified pathogen 
free status were used. A left-sided unilateral pneumonia was induced as described previously [21]. In 
brief, rats were anesthetized and the left primary bronchus was intubated. Through the tube, 0.02 ml 
of a saline suspension containing 1015 susceptible K. pneumoniae were inoculated. Inoculated bacteria 
were in the logarithmic phase of growth. For the resistant K. pneumoniae strain the inoculum was 
adjusted to 2 X10B to establish a median survival of untreated controls that was comparable between 
both models. Rats were housed individually. In vivo stability of the phenotype of the K. pneumoniae 
was checked by culturing dilutions of homogenized left lung tissue obtained at 24 h after bacterial 
inoculation (the starting point of therapy) on MH-plates. Colonies were isolated and MIC was 
determined as described above on MH-plates. All out of 100 tested colonies of both the susceptible and 
resistant strain had a stable phenotype, regarding GEN and CZ-susceptibility, after inoculation in vivo. 
Treatment was started at 24 h after bacterial inoculation. Controls were left untreated. GentamiCin was 
administered at two-fold increasing doses ranging from 1.25 to 40 mg/kg. ceftazidime was 
administered at two-fold increasing doses ranging from 0.4 to 400 mg/kg dose. In the model of the 
susceptible K. pneumoniae, gentamicin doses administered were 1.3, 1, 0.8, or 0.6 mg/kg/d because of 
the steep dose-response curve in this model. GEN and/or CZ were administered either as a single dose 
or as multiple doses every 12 h. In case of combination of GEN and CZ, the drugs were injected with 
an interval of 5 min. Uposome-encapsulated gentamicin or ceftazidime (LE-GEN or LE-CZ, respectively) 
or liposome-co-encapsulated gentamicin and ceftazidime (lE-GEN-CZ) was administered either as a 
single dose or as multiple doses every 24 h. The formulations were injected intravenously into the tail 
vein. Survival of rats was examined every day until 14 days after bacterial inoculation. The MIC of the 
K. pneumoniae bacteria recovered from deceased rats was determined as described above and similar 
to that of the inoculated bacteria. 
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26 Statistical analysis 
To identify synergy, in vitro and in vivo, the effect of a drug combination was compared to the 
expected effect for each of the drugs alone. This method to identify synergy, also known as the isobole 
or iso-effect curve-method, has been validated by Berenbaum [22]. The method is based on the 
equation: 
do/D, + do/Db = 1 
where Da and Db are the doses of agent A alone and agent 8 alone, respectively, needed to produce a 
desired effect. The terms da and db are the doses in a combination of agent A and agent 6, 
respectively, that produce the same effect (iso-effect). If no interaction between agent A and agent B is 
present, or in other words the effects of agent A and agent B are additive, da/Da + dJDb = 1. 
Deviations from the equanon indicate synergy (d,/D, + do/Db < 1) or antagonism (do/D, + do/Db> 1). 
Curves, resulting from the checkerboard titrations were compared to lines describing absence of drug 
interaction using the F-test. Survival between experimental groups was compared by the log-rank test. 
Area under the nme-kill curve (AUKC) was calculated using the trapezoid rule. Analyses were perfonmed 
using Graph Pad Prism 3.00 software (Graph Pad Software Inc., San Diego, CA, USA). AUKC's were 
compared by one-way analysis of variance CANOVA) corrected for multiple comparisons using the 
Bonferroni method. 
3. Results 
3.1 Checkerboard titrations 
The results of the checkerboard titrations with the susceptible strain and resistant strain are 
shown in figure 1 A and B, respectively. The shape of the best-fitted curve in figure 1 A as 
well as 1 B is concave up and describes the relationship significantly better than the line 
that would represent the relationship in absence of drug interactions CF-test, p<O.OOOl for 
both curves). Thus, CZ and GEN act synergistically against both K. pneumoniae strains. 
3.2 lime-kill curves 
The time-kill curves of the susceptible strain and the resistant strain are shown in figure 2 A 
and B, respectively. Bacterial density for both strains rapidly increased to a plateau of 109 
bacteria/ml in absence of antibiotics. For the susceptible strain, GEN alone, at a 
concentration of 0.3 ~g/ml, initially reduced bacterial numbers. After 4 h incubation >99% 
of bacteria were killed. However, between 6 and 24 h incubation, bacterial outgrowth was 
observed to 10' bacteria/ml. Similar results were obtained with CZ alone at a concentration 
of 0.3 ~g/ml. Incubation of 0.15 ~g/ml GEN and 0.15 ~g/ml CZ in combination reduced 
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bacterial numbers more efficiently, After 4 h of incubation >99,99% of bacteria were killed, 
whereas after 24 h 
0,50 20 
A B 
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Figure 1. Checkerboard titrations of gentamicin (GEN) and ceftazidime CCZ) against the 
susceptible /C pneumoniae CA) and the resistant f{" pneumoniae (B). The symbols represent 
the lowest concentrations of GEN and CZ that resulted in absence of bacterial growth. The curve shows 
the best fit through the symbols, whereas the dotted line represents the relationship that would be 
obtained in absence of drug interactions. Both experiments were performed in triplicate. 
of incubation the bacterial density was lOs-fold lower compared to the single agent 
incubations, The AUKC-values of the time-kill curves are shown in table L As the AUKC-
value of the combination is significantly lower than the AUKC's of the single agent 
incubations CANOVA, p<O,OS for both GEN and CZl, and thus dGErJDGEN + dczfDcz < 1, it 
can be concluded that GEN and CZ display a synergistic interaction against the susceptible 
K. pneumoniae [20], 
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Figure 2.Time-kill curves of the susceptible /C pneumoniae (A) and the resistant IC 
pneumoniae (8). In figure A the susceptible bacteria were incubated without antibiotics CC&), 0.3 
~g/m[ GEN C.6.), 0.3 ~g/m[ CZ CA), or 0.15 ~g/m[ GEN in combination with 0.15 ~g/m[ CZ CO). In 
figure B the resistant bacteria were incubated without antibiotics Ce), 16 ~g/m[ GEN C.6.), 8 ~g/m[ CZ 
CAl, or 8 ~g/m[ GEN in combinatiOn with 4 ~g/m[ CZ CO). Both experiments were performed in 
triplicate. 
Table 1. Area under the time-kill curve (AUKC)-values for the susceptible and the 
resistant f{, pneumoniaestrain. 
Susceptible Resistant 
Drug AUKC· Drug AUKC· 
(~g/m[) ([og # bacteria x h/m[) (~g/m[) ([og # bacteria x h/m[) 
Control 10.4 ± 0.1*** Control 10.2 ±0.1 *** 
GEN (0.3) 8.9 ± 1.7* GEN (16) 9.9 ± 0.1*** 
CZ (0.3) 8.2 ± 0.6* CZ (8) 8.3 ± 0.1*** 
GEN/CZ (0.15/0.15) 5.9 ± 0.2 GEN/CZ (8/4) 7.0 ± 0.2 
Bacteria were incubated with indicated concentrations of GEN and/or CZ. Experiment was performed in 
triplicate. ""Results are expressed as mean ± S.D. Significant differences against the combination are 
noted as *** p<O.OOl, * p<O.OS. 
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For the resistant strain, GEN alone, at a concentration of 16 ~g/ml, initially stabilized 
bacterial numbers, but at 24 h after incubation bacterial density had increased to the control 
level. CZ alone, 8 ~g/ml, also stabilized bacterial counts initially, but eventually bacterial 
outgrowth was observed to 10' bacteria/ml after 24 h incubation. The combination of GEN 
and CZ at concentrations of 8 and 4 ~g/ml, respectively, initially killed and then stabilized 
bacterial counts throughout the study period of 24 h. As the AUKC-value for the 
combination was significantly lower compared to those of the single agent incubations 
(AN OVA, p<O.OOl), and thus dGEN/DGEN + dczfDcz < 1, GEN and CZ showed synergistic 
interaction against the resistant K. pneumoniaeCTable 1). 
3.3 Rat survival in the susceptible K. pneumoniae pneumonia model 
The results of the in vivo survival experiments with rats infected with the susceptible K. 
pneumoniae are shown in Figure 3. Maximum survival after a single dose of free GEN alone 
or free CZ alone was 50% (Figure 3A). The maximum dose for free GEN alone was 20 
mg/kg and for free CZ alone 200 mg/kg, because 2-fold higher doses caused acute toxicity 
(local irritation at the site of injection for CZ and convulsions for GEN). As the combination 
of free GEN and free CZ did not increase survival compared to an equivalent dose of free 
GEN alone or free CZ alone, dGENIDGEN + dczfDcz > 1, which would suggest antagonism. 
However, as the single dose treatment never resulted in survival > 50%, these data seem 
more indicative for the conclusion that treatment is too short to have sufficiently prolonged 
concentrations at the site of infecton for the drugs to exert their maximum effect on rat 
survival. 
By prolonging treatment to 5 days and administration of the antibiotics every 12 h, survival 
is increased (Figure 3 B). Free GEN alone showed a steep dose response relation between 
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¢:IiJFigure 3. Percentage of rat survival at 14 days after inoculation of the susceptible f(, 
pneumoniaein the left lung. Rats were treated at 24 h after bacterial inoculation with a single dose 
of free gentamicin (GEN) (open bars), or free ceftazidime (CZ) (hatched bars) or GEN and CZ (closed 
bars) (A), 10 doses every 12 h of GEN (open bars), or CZ (hatched bars) or GEN and CZ (closed bars) 
(6), single dose of liposome-encapsulated gentamidn (LE-GEN) (open bars), or Iiposome-encapsulated 
ceftazidime (LE-CZ) (hatched bars), or Iiposome-co-encapsulated gentamicinjceftazidime (LE-GEN-CZ) 
(closed bars) (C). Number of animals per experimental group in italics. 
0.63 mgjkgjd (0% survival) and 1.25 mgjkgjd (100% survival), explaining why 
intermediate drug doses were also studied. Free CZ alone showed a response of 0% 
survival up to 100% at doses ranging from 12.5 mgjkgjd to 100 mgjkgjd dose. Looking at 
iso-effective doses of free GEN alone and free CZ alone (e.g. 1.05 mg GENjkgjd and 50 mg 
CZ/kgjd) each resulting in 60-70% survival, shows that combination of half of these iso-
effective doses for free GEN and free CZ (i.e. 0.53 mg GENjkgjd combined with 25 mg 
CZjkgjd) results in a similar survival percentage (60%). As a result, dGENjDGEN + dczlDcz ~ 1, 
134 
Uposome-co-encapsulated gentamicin and ceftazidime 
indicating that there is no interaction between free GEN and free CZ in vivo at the 5-day 
treatment schedule. 
Using the liposome-encapsulated antibiotics, the survival data obtained with single doses of 
either LE-GEN alone, LE-CZ alone, or co-encapsulated LE-GEN-CZ were completely different 
(Figure 3 C). A single dose of LE-GEN alone produced a dose response with 0% survival at a 
dose of 1.25 mg/kg increasing to complete survival for the 20 mg/kg dose. Whereas, with 
LE-CZ 0% survival was obtained after administration of 0.38 mg/kg. Survival increased 
gradually to 100% for 12 mg/kg. Looking at iso-effective doses for LE-GEN and LE-CZ alone 
(e.g. 5 mg LE-GEN/kg or 3 mg LE-CZ/kg) each resulting in 60-67% survival, shows that co-
encapsulation of half of these iso-effective doses (i.e. LE-GEN-CZ 2.5/1.5 mg/kg, 
respectively) showed a Significantly better survival (100%) (Log-rank test, p<0.05). 
Consequently, dlE-GErJDlE-GEN + dl£.cz/DlE-cz < 1, revealing a synergistic interaction of 
liposome-co-encapsulated GEN and CZ. 
3.4 Rat survival in the resistEnt K. pneumoniae pneumonia model 
The results of the in vivo survival experiments with rats infected with the resistant K. 
pneumoniae are shown in Figure 4. Administration of single doses of the free drugs, alone 
or in combination, at the maximum tolerated dose did not yield survival (data not shown). 
Prolongation of treatment to 5 days with the free drugs administered every 12 h, increased 
survival (Figure 4 A). Yet, free GEN alone at the maximum tolerated dose of 40 mg/kg/d 
showed only 40% survival. With free CZ alone a nearly complete dose-response relation 
could be obtained at doses ranging from 50 mg/kg/d (0% survival) to 400 mg/kg/d (90 % 
survival). Looking at iso-effective doses of free GEN alone and free CZ alone (e.g. 40 mg 
GEN/kg/d or 100-200 mg CZ/kg/d) each resulting in 30-50% survival, shows that 
combination of half of these iso-effective doses of GEN and CZ (i.e. 20 mg GEN/kg/d 
combined with 50 or 100 mg CZ/kg/d) did not increase the survival percentage significantly 
(20-70%). Consequently, dGErJDGEN + dcz/Dcz ~ 1, indicating that there is no interaction 
between free GEN and free CZ. 
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¢:I Figure 4. Percentage of rat survival at 14 days after inoculation of the resistant J{, 
pneumoniae in the left lung. Rats were treated at 24 h after bacterial inoculation with 10 doses 
every 12 h of free gentamicin (GEN) (open bars), or free ceftazidime (CZ) (hatched bars) or GEN and 
CZ (dosed bars) (A), two doses every 24 h of liposome-encapsulated gentamicin (LE-GEN) (open bars), 
or liposome-encapsulated ceftazldime (LE-CZ) (hatched bars), or Iiposome-co-encapsulated 
gentamicin/ceftazidime (LE-GEN-Cl) (closed bars) (6). Number of animals per experimental group in 
italiCS. 
In contrast, treatment for only two days with LE-CZ alone showed 0% survival at a dose of 
3 mg/kg/d, and complete survival was already obtained at a dose of 24 mg/kg/d (Figure 4 
B). LE-GEN alone at the maximum administered dose of 40 mg/kg/d did not prevent death 
of the rats. However, at this dose of 40 mg/kg LE-GEN rats survived significantly longer 
compared to the controls (p<O.Ol). Liposomal co-encapsulation of GEN and CZ improved 
survival compared to LE-GEN alone or LE..cz alone. LE-GEN-CZ, at a dose of 10 and 12 
mg/kg/d, respectively, already produced complete survival, which was obtained for LE-CZ 
alone at 24 mg/kg/d and for LE-GEN alone at a dose that exceeded 40 mg/kg/d (probably 
by far). Consequently, dLE.GErJDLE-GEN + d,E-CZID'E-cz < 1, thus showing a synergistic 
interaction of liposome-co-encapsulated GEN and CZ. Similar reasoning shows a synergistic 
interaction for LE-GEN-CZ at doses of 10 combined with 6 mg/kg/d as well as 10 combined 
with 3 mg/kg/d CZ, respectively. 
4. Discussion 
Treatment with a combination of antimicrobial agents may improve therapeutic efficacy over 
single agent treatment as a result of synergistic drug interactions. Synergistic drug 
interaction in vitro has been clearly shown for various drug combinations. For a synergistic 
drug interaction to occur in vivo, the drugs in the combination should be present at the site 
of infection at sufficiently high concentrations for an adequate period of time. Theoretically, 
simultaneous drug delivery to the target site could strengthen synergistic interactions. 
Interestingly in this respect, targeted liposomal delivery of single antimicrobial agents has 
demonstrated superior therapeutic efficacy over conventional antimicrobial treatment in a 
number of experimental infection models, as has been reviewed previously [23-25]. The 
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superior efficacy is attributable to the increased concentration of the drug at the site of 
infection as a result of the targeted drug delivery. Up to now, only single agent liposome 
preparations have been investigated. The present study aimed to investigate the 
therapeutic efficacy of liposome-co-encapsulated antimicrobial agents in vivo in a rat model 
of pneumonia caused by an antibiotic-susceptible strain or antibiotic-resistant strain of K. 
pneumoniae. The results of the present study show that targeted liposomal delivery of GEN 
and CZ results in a synergistic interaction of these antibiotics in vivo. Importantly, the 
synergistic interaction was present in the animals infected with the susceptible strain as well 
as the animals infected with the resistant strain. In contrast, administration of the 
combination of the antibiotics in the free form, although showing synergy in vitro, displayed 
only an additive effect in both in vivo models. Synergy in vivo was not observed. As a result, 
by use of liposome-co-encapsulated GEN and CZ, 100% survival can be obtained using a 
shorter treatment schedule and lower cumulative doses compared to treatment with the 
free drugs. 
The interaction between GEN and CZ against both the susceptible and resistant K. 
pneumoniae was first examined in vitro by performing checkerboard-titrations and time-kill 
experiments. Both in vitro assays show that GEN and CZ acted synergistically against both 
the susceptible strain and the resistant K. pneumoniae strain. The in vitro synergistic 
interaction of GEN and CZ, or more in general aminoglycosides and B-Iactam antibiotics, has 
been reported earlier. The interaction is suggested to be due to the limited penetration of 
aminoglycosides into bacteria to effect bacterial killing and the ability of beta-Iactams to 
increase that penetration [26]. 
To investigate whether GEN and CZ can act synergistically in vivo, rats were infected with 
either the susceptible or the resistant K. pneumoniae strain, and survival was monitored for 
14 days. At single doses of either free GEN alone or free CZ alone a maximum survival of 
50% could be obtained in rats infected with the susceptible strain. Combination of single 
doses free GEN and free CZ did not improve survival compared to an equivalent single dose 
of either free GEN alone or free CZ alone. Likely, treatment at a single dose of GEN and CZ 
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is too short and thus adequate concentrations at the site of infection are too transient for 
synergistic interactions to have an effect on survival. 
To increase therapeutic efficacy, treatment with the free drugs was prolonged to 5 days and 
both antibiotics were administered every 12 h. Using this dosing schedule, complete survival 
could be obtained with either free GEN alone or free CZ alone against the susceptible K. 
pneumoniae infection. The effects of free GEN combined with free CZ on rat survival in this 
5-day treatment schedule, however, are merely additive. Synergism was not detected. This 
result was unexpected as, in vitro, GEN and CZ acted synergistically against both K. 
pneumoniae strains and synergism between aminoglycosides and 6-lactams in vivo has 
been reported [27-28]. The discrepancy between in vitro and in vivo data is possibly the 
result of the rapidly changing concentrations of the antibiotics at the site of infection in the 
rats as compared to the constant drug concentrations in the in vitro incubations [5-6]. 
Seemingly, the pharmacokinetics and tissue distributions of free GEN and free CZ in rats 
[29-32] do not provide adequate drug concentrations at the site of the K. pneumoniae 
infection in a timely fashion for synergistic drug interactions to occur. Consequently, the 
assessment of in vitro synergistic interactions does not guarantee in vivo synergy to occur 
predictably. 
The results obtained with the liposome-encapsulated antibiotics contrast favorably with the 
results obtained with the free antimicrobial agents. Single doses of LE-GEN alone or LE-CZ 
alone were shown to be highly effective, as complete survival could be obtained in the 
susceptible K. pneumoniae infection. Apparently, the simultaneous targeted delivery of LE-
GEN-CZ results in higher GEN and CZ concentrations at the target site for prolonged periods 
of time, enabling synergistic drug interactions to occur. A single dose of liposomal co-
encapsulated agents produced complete survival at a comparable GEN-exposure and a 170-
fold reduced CZ body exposure, compared to 10 injections of the free drug combination. 
To investigate the strength of the synergistic drug interaction after administration in the co-
encapsulated form, comparative studies were also performed in rats infected with the K. 
pneumoniae strain resistant to both antibiotics. In this model, survival in a 5 day treatment 
schedule could only be obtained with doses of free GEN alone or free CZ alone that were 
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well over the clinically recommended doses. Combinations of free GEN with free CZ were 
again just additive. In contrast, administration of two doses of LE-CZ alone of 24 mg/kg/d 
already resulted in complete survival. LE-GEN alone was less effective as two doses of 40 
mg/kg/d failed to increase survival. Yet, liposome-co-encapsulation of GEN and CZ resulted 
in significantly improved survival compared to the expected efficacy based on the dose-
response relations of LE-GEN alone and LE-CZ alone, demonstrating that the synergistic 
interaction was strong enough to overcome infection with a resistant K. pneumoniae 
infection. Two doses of liposome-co-encapsulated GEN and CZ produced complete survival 
at a lO-fold lower GEN-exposure and 40-fold lower CZ-exposure compared to 10 injections 
of the free GEN-C2 combination. 
In conclusion, the present study demonstrates that targeted delivery of GEN and CZ by 
liposome-co-encapsulation results in synergistic drug interactions in a susceptible as well as 
resistant K. pneumoniae pneumonia model. In these models, synergistic interaction of a 
combination of free GEN and free CZ could not be demonstrated. Probably as a result of the 
synergistic interaction, administration of liposome-co-encapsulated gentamicin and 
ceftazidime allowed a shorter course of treatment as well as lower cumulative doses to 
obtain complete therapeutic efficacy compared to administration of the drugs in the free 
form. The reduced drug exposure may also reduce the risk of the development of microbial 
resistance. The observed synergism of liposome-co-encapsulated antibiotics may open up 
new perspectives for targeted drug delivery in serious infectious diseases. 
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8. Summary 
Failure of antimicrobial treatment is observed frequently in hospitalized patients resulting in 
morbidity and mortality, The long, invaSive, and intensive hospital treatments lower the 
barriers to microbial invasion of host tissues and compromise the development of an 
adequate inflammatory/immune response, In addition, the host response may be weakened 
by administration of immunosuppressants or cytotOXiC drugs or as a result of a pathology 
that affects the host defense, Under these circumstances antimicrobial treatment is often 
not successful. The possibility to increase therapeutic efficacy of antibiotics by targeted 
delivery of antimicrobial agents is discussed in Chapter 1, With regard to targeting of 
antibiotics to bacterial infections, Bakker-Woudenberg et al. demonstrated that 
intravenously injected sterically stabilized liposomes (SSL) localize preferentially at the site 
of infection in a rat model of a unilateral Klebsiella pneumoniae pneumonia in the left lung 
(Bakker-Woudenberg, 1993), An improved therapeutic effect of a single dose of SSL-
encapsulated gentamicin or SSL-encapsulated ceftazidime was achieved compared to a 
single equivalent dose of the free drug in this model (Bakker-Woudenberg, 1995), For 
optimization of liposome targeting to the site of infection it is essential to: 
,. identify the critical factors (on the side of the liposomes as well as on the side of 
the host) that contribute to target localization of SSL in K. pneumoniae infected rat lung 
tissue (Chapter 2-4) 
,. evaluate the value of SSL-encapsulated antibiotics in Clinically relevant infection 
models, addressing in particular the issue of impaired host defense and reduced bacterial 
susceptibility (Chapters 6-7), 
These have been the aims of the present thesis, 
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Chapter 2 to 4 are devoted to the first aim of the project. In Chapter 2 the effect of 
Iiposome characteristics (particle size, PEG-density, bilayer fiuidity, and degree of negative 
surface charge) on liposome localization at the site of the Klebsiella pneumoniae pneumonia 
were investigated. It is shown that all liposome preparations studied, localize preferentially 
in the infected left lung compared to the contralateral non-infected right lung. However, the 
degree of left lung localization differed for the various Iiposome preparations. Decreasing 
circulation time, as observed by reducing PEG-density (from 5 to 1 mol%) and increasing 
particle size (from 100 nm to 280 nm or 360 nm) yielded a reduced degree of target 
localization. Interestingly, incorporation of a high amount of negatively charged 
phospholipids (30 mol% EPG) reduced target localization without a reduction in Iiposome 
circulatory half-life. Increase in PEG-density from 5 to 10 mol%, variation of liposome 
bilayer fiuidity, or incorporation of 5 mol% EPG in the Iiposome bilayer did not affect 
liposome circulation time nor liposome target localization. These results show that SSL 
localize to a high degree at the target site, compared to conventional liposomes. The 
highest degree of target localization can be achieved USing PEG-coated, small and neutral 
Iiposomes. It is concluded that the degree of liposome localization at the infected site is 
relatively independent of the physicochemical characteristics of the SSl. This is important 
for the tailoring of SSL to achieve an optimal therapeutic effect of the encapsulated drug. It 
will often be required to create a balance between the best properties with respect to target 
localization, drug incorporation efficiency, drug retention and drug release, which will 
probably differ for the various classes of antibiotics. 
Chapter 3 is focused on the factors on the side of the host that are important for Iiposome 
target localization. Liposome localization appeared to be highest in the hemorrhagic zone of 
the infected lung, a zone characterized by markedly increased capillary permeability and 
high bacterial numbers. Both liposome localization and capillary permeability correlated 
positively with the severity of the infection, supporting the central role of increased capillary 
permeability in the selective liposome target localization. Lung instillation of infiammatory 
stimuli that increased capillary permeability other than viable bacteria (i.e. 0.1 M HCI or LPS) 
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also promoted liposome localization, showing that the nature of the inflammatory agent is 
not critical. This finding is in line with other reports that show enhanced Iiposome 
localization at the inflamed site as a result of various inflammatory and infectious agents 
(Dams, 1999ajb; Rousseau, 1999; Klimuk, 1999; Corvo, 1999; Awasthi, 1998ajb; Oyen, 
1996; Morgan, 1981). 
As liposomal target localization in leukopenic rats was similar to that in immunocompetent 
rats, contribution of Circulating leukocytes seems of minor importance. This would suggest 
that liposomal drug targeting could be feasible in immunocompromised patients. These 
patients suffer a high risk of antibiotic treatment failure (Reynolds, 1999) and could 
therefore particularly benefit from targeted drug delivery. 
Intrapulmonary distribution of Iiposomes shows that phagocytes at the target site take up 
extravasated liposomes. The extent of liposome uptake by phagocytes as well as the 
contribution of phagocytes to liposome processing and drug release is still unclear and 
deserves future investigation. The involvement of phagocytes in Iiposome uptake at the 
target site could, for example, be important information in the selection of appropriate (e.g. 
non-pH-sensitive) drugs, to prevent intracellular drug degradation. 
In conclusion, increased capillary permeability plays a crucial role in Iiposome localization at 
the infected site, whereas contribution of infiltrating leukocytes is limited. The observation 
that liposomes are taken up by phagocytes at the target site could be important information 
in drug selection. 
In Chapter 4, the results presented in the preceding chapters and additional experimental 
data are used to propose a general mechanism behind Iiposome localization at sites of 
infection or inflammation. The mechanism is based on an equation by Kedem and 
Katchalsky describing the natural accumulation of plasma proteins at sites of increased 
capillary permeability as a result of a local inflammatory response [Kedem and Katchalsky, 
1967]. 
The simplified equation describing Iiposome flux into the target site is: 
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> JL=JvC,(l-cr) 
Or in words, the liposome fiux into the target site (JL) is determined by the fiuid fiux into the 
target site across the capillary endothelial barrier (Jv), the concentration of liposomes 
therein (C,), and the refiection coefficient (cr) for that given liposome formulation. 
Regarding the fiuid fiux term, Bakker-Woudenberg et al. already demonstrated that SSL 
localization in the infected left lung is linearly related to the intensity of the K. pneumoniae 
infection (as measured by the increase in left lung weight) (Bakker-Woudenberg, 1993). As 
the weight increase is the result of fiuid flux into the lung as a result of increased capillary 
permeability (as confirmed by Evan's blue dye extravasation and lung wet-to-dry-weight 
ratio, described in Chapter 3) these results support the equation and the view that the 
nature of the inflammatory stimulus is not important as long as an adequate fluid flux is 
generated. Present investigations in our department together with Lorna Stearne and Inge 
Gyssens in a murine abscess model, also show a positive relationship between abscess 
weight and liposome target localization (unpublished observations), which supports the 
general validity of the equation. 
The term C, refers to the liposome concentration in the circulation. SSL showing prolonged 
circulation times have been demonstrated to show an increased localization at the site of 
infection compared to liposomes with shorter circulation times (Bakker-Woudenberg, 1993). 
This term in the equation explains the relationship between circulation time and degree of 
left lung localization obtained in Chapter 2 and earlier studies (Bakker-Woudenberg, 
1993/1992). In addition, it explains why long-circulating liposomes (LCL) without a PEG-
coating but with similar circulatory half-lifes as SSL, show a similar degree of liposome 
target localization. It must be stressed that SSL have the advantage of allowing tailoring of 
liposome properties without compromiSing liposome circulation time and degree of liposome 
target localization (Chapter 2), which is not expected to be valid for LCL without a PEG-
coating (Woodle, 1992). As a result, SSL properties can be manipulated to optimize the 
retention and release of the encapsulated drug. The equation states that the liposome 
concentration term (C,) is proportional to the degree of target localization (JJ. As a result it 
146 
Summary 
is suggested that liposome localization can be improved by designing liposomes with even 
longer circulation times. However, to our knowledge, these liposomes have not been 
designed as yet. 
The term C, cannot explain why incorporation of a high mole % of EPG does not affect 
blood circulation time but does affect liposome target localization. It can be explained by 
assuming an increased refiection cqefficient (cr) for SSL containing a high mol% of EPG. Yet, 
the nature of this increase in refiection coefficient for this liposome type is not clearly 
understood. Experiments to determine the value of cr for liposomes should be carried out, as 
such experiments could indicate if liposome target localization can be improved by reduction 
of Iiposomal cr. 
Chapter 5 provides an overview of the literature on therapeutic efficacy of liposome-
encapsulated aminoglycosides. Liposome-encapsulation offers interesting prospects to 
increase the therapeutic index of this class of antibiotics. The local application of liposomes 
may provide a drug reservoir to prolong therapeutic drug concentrations at the site of 
infection. Specific liposome lipid compositions may enhance bacterial killing by interacting 
(e.g. fusing) with the infectious organism (Sachetelli, 2000). 
The main role of intravenously administered conventional liposomes is established in the 
targeted delivery of drugs to cells of the MPS, primarily those in the liver and spleen. 
Treatment of intracellular infections in the MPS-cells may benefit from the high amounts of 
aminoglycosides that can be delivered intracellularly. Research is needed on the nephro-
and ototoxicity of conventional liposomal aminoglycosides as liposomal aminoglycoside 
administration results in prolonged drug exposure. In addition, it should be investigated 
whether this leads to an increased risk of the development of microbial drug resistance 
(Hyatt, 2000; Baquero, 1997). 
Intravenous administration of long-circulating Iiposomes potentially offers drug targeting to 
sites of infection not restricted to the MPS. Indeed, some reports have demonstrated 
enhanced therapeutic efficacy of long-circulating Iiposome-encapsulated aminoglycosides 
compared to free drugs or conventional Iiposomes. Up to now, most studies with liposome-
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encapsulated aminoglycosides have been performed in animal models with an intact host 
defense infected with high antibiotic-susceptible bacteria. Treatment failure in clinical 
practice, however, particularly occurs in patients having an impaired host defense. In 
addition, low antibiotic-susceptibility of the infectious organism complicates effective 
treatment. These issues need to be addresses in appropriate animal models. Similarly as for 
the conventional liposome formulations, the effects that the prolonged tissue drug 
concentrations have on toxicity and development of resistance need to be addressed. 
Overall, the reviewed literature shows promising prospects for liposome-encapsulated 
aminoglycosides and warrants further investigations into the use of these formulations for 
the treatment of severe infections. 
Chapter 6 presents experiments on the therapeutic potential of SSL-encapsulated 
gentamicin (LE-GEN) in clinically relevant rat models of bacterial infections, addressing th'e 
issues of impaired host defense and low bacterial antibiotic susceptibility. The results show 
that in immunocompetent rats infected with the high gentamicin-susceptible K. pneumoniae, 
a single dose of LE-GEN is clearly superior over free GEN. Yet, complete therapeutic efficacy 
can also be obtained with multiple administration of low doses of free GEN. 
In leukopenic rats infected with the high gentamicin-susceptible K. pneumoniae, multiple 
administration of free GEN at low doses was no longer effective. Free GEN at the maximum 
tolerated dose (MTD) for 5 days was needed to obtain complete therapeutic efficacy. 
However, the addition of a single dose of LE-GEN to 5-day free GEN-treatment at low doses 
showed complete therapeutic efficacy using a 7-fold lower cumulative amount of gentamicin 
compared to free GEN-treatment alone. A single dose of LE-GEN alone is unsuccessful. This 
is probably the result of the low therapeutically active drug concentrations in the 
bloodstream after injection of LE-GEN, which are insufficient to control the rapidly occurring 
bacteremia in case of an impaired host defense. The bacteremia leads to mortality during 
treatment, in spite of substantial liposome localization in the infected left lung and 
subsequent local 'bacterial killing. Free GEN alone at low doses for 5 days is also 
unsuccessful. Probably, this dosing regimen produces sufficient drug concentrations to 
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control the rapid bacteremia, but after termination of treatment rats die as a result of 
insufficient bacterial killing in the infected left lung, leading to local bacterial outgrowth 
accompanied by septicemia. 
Thereby, the combination is efficacious compared to treatment with either GEN alone or LE-
GEN alone, since the combination acts complementary. 
In leukopenic rats infected with low gentamicin-susceptible K. pneumoniae, free GEN at the 
MTD for 5 days did not result in therapeutic efficacy. The use of LE-GEN is needed for 
achieving therapeutic success. Addition of LE-GEN to free GEN treatment using liposomes 
with a more rigid lipid bilayer resulted in 50% survival of the infected rats. By increasing LE-
GEN bilayer fiuidity, the liposomes displayed a faster release of gentamicin in the circulation. 
Rat survival increased to 100%. These results show that liposome lipid composition is an 
important determinant of therapeutic efficacy. A careful balance must be sought between 
release of the antibiotic in the circulation to obtain sufficiently high drug levels in the 
bloodstream versus liposomal drug retention in order to achieve sufficiently high levels of 
antibiotic at the infectious focus. In conclusion, in clinically relevant leukopenic rat models of 
serious bacterial infection, addition of LE-GEN to GEN treatment enhances therapeutic 
efficacy considerably. These results support further studies on liposomal formulations of 
aminoglycosides for use in immunocompromised patients with severe infections. 
In Chapter 7 a new concept in liposomal drug delivery is introduced. It is based on the 
evidence that antimicrobial agents can interact synergistically in vitro. To ensure a 
synergistic interaction in vivo, both drugs should be present at the site of infection at 
sufficiently high concentrations for an adequate period of time. By co-encapsulation of the 
drugs in a targeted drug carrier (e.g. SSL), the tissue distribution of the drugs will be 
mediated largely by the carrier. As a result, the body distribution of co-encapsulated agents 
will be similar. Moreover, encapsulation of these antibiotics in a targeted drug carrier, may 
even increase drug concentrations at the site of infection. 
The synergistically acting antibiotics gentamicin and ceftazidime were co-encapsulated into 
SSl. Therapeutic efficacy in vivo was examined by monitoring rat survival in a model of an 
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acute unilateral pneumonia caused by a high gentamicin/ceftazidime-susceptible or a 
gentamicin/ceftazidime-resistant K. pneumoniae. The results show that targeted Iiposomal 
delivery of gentamicin and ceftazidime results in a synergistic interaction of these antibiotics 
in vivo. Importantly, the synergistic interaction was present in the susceptible as well as the 
resistant K. pneumoniae model. In contrast, administration of the antibiotics in the free form 
failed to display synergy. Probably as a result of the synergistic interaction, administration of 
liposome-co-encapsulated gentamicin and ceftazidime allowed a shorter course of treatment 
as well as lower cumulative doses to obtain complete therapeutic efficacy compared to 
administration of the drugs in the free form. In future studies, it should be investigated 
whether the reduced drug exposure can also reduce the risk of the development of 
microbial resistance. 
In conclusion, the observed synergism of liposome-co-encapsulated antibiotics may open up 
new perspectives for targeted d rug delivery in serious infectious diseases. It could also have 
its impact on other pathologies, as SSL have been shown to localize preferentially in tumors 
and sites of rheumatoid arthritis, conditions for which synergistic drug combinations have 
been identified (Yokoyama, 2000; Burris 2000, Dijkmans, 1996; Isaacs, 1999; Monks, 
2000). 
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9. Samenvatting voor niet-ingewijden 
Bij een snijwondje in de vinger is een druppeltje jodium en een pleister op de wand in het 
algemeen voldoende voor een spoedig herstei. Het aanbrengen van een druppeltje jodium is 
een eenvoudig voorbeeld van 'drug targeting' (medicijnmikken), oftewel het specifiek 
afleveren van een farmacon (geneeskrachtige stofl op de plaats waar het nodig is. 
Misschien onbewust toegepast, is het doel van deze specifieke aflevering: 
,. een hoge farmaconconcentratie op de juiste plaats 
,. bescherming van de rest van het lichaam tegen mogelijke bijwerkingen en het 
beschermen van het farmacon tegen inactivatie 
,. controle over de afgifte van het fanmacon 
,. vermindering van de hoeveelheid farmacon 
Wanneer de plaats waar het farmacon nodig is onbekend of niet van buitenaf bereikbaar is, 
wordt specifieke aflevering moeilijker en kan er een nieuw doel beoogd worden: 
,. het verbeteren van de aflevering van het farmacon 
In dat laatste geval is in het algemeen een drager van het farmacon vereist, een 
zogenaamde 'drug carrier'. In de loop der tijd is een grate varieteit aan dragers ontwikkeld. 
Of een drager geschikt is voor een farmacon wordt bepaald door een aantal factoren: de 
kenmerken van de ziekte waarvoor het farmacon bedoeld is, het vermogen van de drager 
op de juiste plek aan te komen en de wijze waarop de drager het farmacon ter plaatse 
afgeeft. In het onderzoek beschreven in dit proefschrift is de bruikbaarheid van een 'drug 
carrier' in de behandeling van bacteriele infecties onderzocht. 
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Bacteriele infecties kunnen worden beschouwd als een interactie tussen een gastheer (de 
mens) en een bacterie, waar de gastheer schade van ondervindt. Infecties kunnen een 
ernstig beloop hebben. 
De reden waarom het onderzoek juist op deze ziekten is gericht, is het feit dat de k1inische 
praktijk uitwijst dat infectieziekten, met name in ziekenhuizen, niet altijd met succes 
behandeld kunnen worden. Enerzijds is dat te wijten aan een matige gevoeligheid van 
bacterien voor antibiotica, anderzijds neemt het aantal patienten met een verminderde 
weerstand toe, bijvoorbeeld als gevolg van behandeling met chemotherapie (zoals bij 
tumoren), vanwege een storing in het immuunsysteem zelf (zoals bij een HIV-infectie), of in 
geval van immuunsuppressieve behandeling (zoals bij transplantaties). Deze patienten zijn 
niet aileen gevoeliger voor infecties, ze kennen ook een slechtere ondersteuning van de 
antibioticumbehandeling door de eigen afweer. Het gevolg is dat de antibioticum-
behandeling kan falen. 
Daarom is er gezocht naar dragers die antibiotica specifiek naar infectiehaarden zouden 
kunnen vervoeren, waardoor het mogelijk zou kunnen zijn om bacterien te doden ondanks 
hun matige antibioticumgevoeligheid en/of gebrekkige ondersteuning van de behandeling 
door de afweer van de patient. Een van de farmacondragers waarvoor aanwijzingen zijn dat 
ze lokaliseren op plaatsen van infectie zijn Iiposomen. 
Liposomen zijn kleine bolletjes bestaande uit een of meer schillen van fosfolipiden die 
waterige ruimten omsluiten (Figuur 1, pagina 16). Hun grootte ligt tussen enkele tientallen 
nanometers en enkele micrometers. Stoffen die goed oplossen in water kunnen in de 
waterige ruimte(s) worden ingesloten, terwijl vetoplosbare stoffen in de fosfolipidenbilaag 
kunnen worden ingebouwd. Deze bolletjes worden, na injectie in de bloedbaan, in het 
algemeen snel herkend als lichaamsvreemd en opgenomen door cellen die het bloed 
ontdoen van lichaamsvreemde materialen, het mononucleair fagocyten systeem (MPS). Ais 
de infectie zich in deze cellen bevindt kan dit een eenvoudige manier zijn om snel, grote 
hoeveelheden antibiotica aan dit celtype af te leveren. Bevindt de infectie zich elders dan 
hindert deze snelle opname door het MPS de afievering van het antibioticum aan de andere 
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p[aatsen waar het antibioticum nodig is. Voor een minder snelle herkenning van het 
[iposoom a[s [ichaamsvreemd materiaa[ zijn er aanpassingen gedaan aan het opperv[ak van 
het [iposoom om te zorgen dat ze [anger onopgemerkt in de b[oedbaan kunnen b[ijven. Door 
op het liposoomopperv[ak een [aag po[y(ethy[een) glycol (PEG) aan te brengen (Figuur 2, 
pagina 18) is het mogelijk de circu[atietijd in het b[oed te ver[engen en zo de b[ootstelling 
van de infectiehaard aan het [iposoom te verhogen. Bakker-Woudenberg et al. hebben 
aangetoond dat deze [ang-circu[erende PEG-liposomen beter op de p[aats van infectie 
[oka[iseren dan kort-circu[erende liposomen in een model van een enke[zijdige pneumonie 
veroorzaakt door de bacterie Klebsiella pneumoniae in ratten. Dit model is ook gebruikt in 
de experimenten beschreven in dit proefschrift. In dit model worden de bacterien in de 
[inker[ong van de rat gebracht, waardoor zich daar een pneumonie ontwikke[t. De 
rechter[ong kan dienen a[s contro[eorgaan. 
Voor het verder optimaliseren van de liposomen a[s dragers voor antibiotica is het van 
be[ang vast te stellen: 
r welke factoren (aan de kant van het liposoom zowe[ a[s aan de kant van de 
gastheer) de [okalisatie van liposomen op de p[aats van infectie be"inv[oeden 
r in hoeverre [iposoma[e antibiotica een bijdrage kunnen [everen in de behande[ing 
van ernstige infecties in het geva[ van een verminderde afweer of een matige 
antibioticumgevoeligheid van de bacterie 
Deze in[eiding is beschreven in het eerste hoofdstuk. 
De vo[gende drie hoofdstukken gaan in op het eerste doer van het onderzoek. In 
hoofdstuk 2 is de inv[oed van liposoma[e factoren onderzocht door de eigenschappen van 
het liposoom te veranderen. De hoevee[heid van het opperv[akte-modificerende PEG is 
verminderd (1 mo[%) en vermeerderd (10 mo[%) ten opzichte van de hoevee[heid die 
gebruikt was (5 mo[%) in de experimenten van Bakker-Woudenberg et al. De grootte van 
het liposoom is gevarieerd (100, 280 en 360 nm), de v[oeibaarheid van de fosfolipidenbi[aag 
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(de vloeibaarheid beTnvloedt de farmaconafgifte) is veranderd en er zijn meer of minder 
negatief geladen fosfolipiden in het Iiposoom ge·incorporeerd. Het gedrag van de 
verschillende Iiposoomformuleringen is bestudeerd in ons bacteriele longinfectie-model. 
Geconcludeerd kan worden dat 1 mol% PEG-liposomen sneller uit het bloed verdwijnen dan 
de 5 of 10 mol% PEG-Iiposomen. Waarschijnlijk is 1 mol% PEG minder goed in staat het 
oppervlak van het liposoom te beschenmen tegen herkenning als Iichaamsvreemd materiaal. 
De lokalisatie in de infectiehaard was ook lager voor dit liposoomtype. 10 mol% en 5 mol% 
PEG-liposomen lieten geen verschillen zien. 
Met betrekking tot de liposoomgrootte kon worden vastgesteld dat de gratere Iiposomen 
sneller uit het bloed verwijderd werden dan het 100 nm Iiposoom, en ook een slechtere 
lokalisatie in de geinfecteerde linkerlong lieten zien. Aanpassingen aan de vloeibaarheid van 
de fosfolipidenbilaag maakte geen verschil in de verblijftijd van de Iiposomen in de 
bloedbaan of de lokalisatie op de plaats van infectie. 
Bij de incorporatie van de grootste hoeveelheid negatief geladen fosfolipiden in het liposoom 
was de uitkomst verrassend. Zoals tot nu toe blijkt gaan een kortere circulatietijd van de 
liposomen en een verminderde lokalisatie in de ge'infecteerde Iinkerlong hand in hand. Voor 
de liposomen waarin een grate hoeveelheid negatieve lading was geincorporeerd bleef de 
circulatietijd hetzelfde, maar was de lokalisatie in de infectiehaard lager. Het vermoeden 
bestaat dat de lading geen effect heeft op de circulatietijd (doordat de PEG-Iaag de lading 
afschermt), maar dat bij de lokalisatie op de plaats van infectie de negatieve lading de 
lokalisatie hindert. 
De uiteindelijke conclusie is dat een groot gedeelte van de aanpassingen aan het liposoom 
weinig of geen invloed hebben op de lokalisatiegraad op de plaats van infectie. Dit is 
waarschijnlijk het gevolg van de beschermende PEG-Iaag rand het Iiposoom. Dit betekent 
dat, mits aan bepaalde eisen met betrekiking tot deeltjesgrootte, PEG-dichtheid en 
hoeveelheid negatief geladen fosfolipiden wordt voldaan, er een uitgebreide variatie 
mogelijk is in liposoomeigenschappen zonder de lokalisatie op de plaats van infectie in 
gevaar te brengen. 
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In het derde hoofdstuk is onderzocht in hoeverre de liposoomlokalisatie wordt beTnvloed 
door de ernst van de infectie, in welke zones van de infectiehaard de liposomen vooral 
gevonden worden en of liposomen ook lokaliseren in de linkerlong wanneer een 
ontstekingsreactie wordt veroorzaakt met irriterende stoffen in plaats van met levende 
bacterien. Daarnaast is de hoeveelheid witte bloedcellen in het bloed van de ratten 
verminderd om vast te stellen of deze cellen een bijdrage leveren aan de 
liposoomlokalisatie. Hierdoor kan worden bepaald of liposoomtherapie wei geschikt is voor 
patienten met een verminderde weerstand, waarbij juist deze cellen kunnen zijn aangetast. 
Tenslotte is microscopisch vastgesteld waar de liposomen op de plaats van de infectie 
terechtkomen. Hiervoor zijn liposomen gevuld met colioTdaal goud en geTnjecteerd. Hierna 
zijn coupes van de linkerlong gesneden en, door zilver neer te laten slaan op het goud, is 
vast te stellen waar de colloTdaal-goud gevulde liposomen zijn gebleven. Gebleken is dat 
naarmate de ontstekingsreactie sterker was, de hoeveelheid vocht die vanuit de bloedvaten 
in de infectiehaard stroomde toenam en daarmee nam ook de hoeveelheid liposomen op de 
plaats van infectie toe. De vochtophoping is onderdeel van de ontstekingsreactie. Het 
vermoeden is dat liposomen door de vloeistofstroom worden meegevoerd en zo in 
verhoogde mate lokaliseren op plaatsen waar een ontstekingsreactie plaatsvindt. Of deze 
ontstekingsreactie werd veroorzaakt door levende bacterien of irriterende stoffen, bleek 
daarbij niet uit te maken. Het verminderen van de hoeveelheid witte bloedcellen maakte 
geen verschil in de hoeveelheid liposomen die in de infectiehaard terechtkwam. Dit maakt 
liposoomtherapie in principe ook geschikt voor situaties waarin de afweer is aangetast 
doordat de witte bloedcellen in aantal of functie tekortschieten. De liposomen bleken in de 
linkerlong aanwezig te zijn rond de capillairen en opgenomen door fagocyterende cellen. Of 
deze cellen de liposomen afbreken waardoor het antibioticum zou kunnen vrijkomen of dat 
hierdoor juist antibioticum verloren gaat is nog onduidelijk. 
In het vierde hoofdstuk is geprobeerd om, met aile verzamelde gegevens over de 
lokalisatie van liposomen in dit diermodel, een algemeen mechanisme te definieren achter 
het lokalisatieproces. Omdat van eiwitten in het bloed al langer bekend was dat deze 
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lokaliseren op de plaats van infectie (en daar meehelpen de infectie te bestrijden) en dat dit 
proces beschreven kan worden met een formule opgesteld door Kedem en Katchalsky, is 
deze formule als uitgangspunt genom en voor het onderzoek. De formule van Kedem en 
Katchalsky luidt: 
Het gedeelte van de formule na het plusteken beschrijft lokalisatie onder invloed van diffusie 
en dat is aileen van belang voor kleine deeltjes (zoals eiwitten). liposomen zijn daarvoor te 
groot. Het overgebleven gedeelte zegt dat de hoeveelheid van een stof die lokaliseert per 
tijdseenheid (J,) gelijk is aan de hoeveelheid vocht die per tijdseenheid in de infectiehaard 
stroomt (Jv), vermenigvuldigt met de concentratie van deze stof (C,) in dit vocht, 
vermenigvuldigt met een factor die aangeeft hoe goed deze stof uit het bloedvat in de 
infectiehaard kan stromen. De experimentele resultaten zijn in overeenstemming met deze 
formule. Hoe langer het verblijf in het bloed van een liposoom, dus hoe hoger c" hoe hoger 
de liposoomlokalisatie. En hoe meer vocht er naar de long stroomt, dus hoe hoger (Jv), hoe 
hoger de liposoomlokalisatie. Wat betreft de lage lokalisatie van de liposomen met de 
ge'incorporeerde negatief geladen fosfolipiden, zoals beschreven in het tweede hoofdstuk, 
zou dit te verklaren moeten zijn met een bemoeilijkte passage door de bloedvatwand voor 
dit type liposomen. 
Hoofdstuk 5 geeft een overzicht van klinische en pre-klinische studies met betrekking tot 
de therapeutische effectiviteit van liposomen gevuld met aminoglycosiden: een belangrijke 
klasse van antibiotica. Het vormt een inleiding op onze studies met liposomaal ingekapseld 
gentamicine (LE-GEN) (ook een aminoglycoside) in de volgende hoofdstukken. 
Hoofdstuk 6 laat resultaten zien van een studie in verschillende pneumoniemodellen in 
ratten met een oplopende moeilijkheidsgraad in behandeling. Het eerste model is relatief 
eenvoudig te behandelen: de ratten hebben een intacte afweer en de bacterien zijn goed 
158 
Samenvatting 
gevoelig voor het antibioticum gentamicine. In het tweede model is de afweer van de ratten 
verminderd en in het derde model is niet aileen de afweer aangetast maar is de bacterie ook 
laag gevoelig voor gentamicine. 
In het eerste model is een goede effectiviteit van een enkele dosis LE-GEN te zien, 
waarschijnlijk is dit een gevolg van de specifieke aflevering van het geneesmiddel aan de 
infectiehaard. Maar ook met een behandeling van slechts 3 dagen met het vrije 
geneesmiddel (GEN) is de infectie prima te behandelen. De noodzaak om het liposomale 
gentamicine te gebruiken is er dus niet. 
In het rattenmodel met de verminderde weerstand is het verloop van de longinfectie 
ernstiger. In de long zijn weinig witte bloedcellen aanwezig om de bacterien te dod en, 
waardoor de bacterien snel en in hoge aantallen in de bloedbaan komen en daar een sterke 
ontstekingsreactie kunnen uitlokken die leidt tot het overlijden van de dieren. Toediening 
van GEN gedurende 5 dagen -mits gegeven in hoge doses- kan ervoor zorgen dat de ratten 
overleven. De hoge dosis is nodig om niet aileen een adequate concentratie van het 
antibioticum in de de bloedbaan te garanderen, maar ook een voldoende hoge concentratie 
in de infectiehaard te bewerkstelligen. Eenzelfde effect kan bereikt worden wanneer GEN in 
lage doses wordt gegeven en er op de eerste dag een extra dosis LE-GEN wordt toegevoegd 
om de infectiehaard aan te pakken. Met deze combinatie overleefden aile dieren. 
In het model waarin zowel de afweer van de ratten was verminderd en de bacterien laag 
gevoelig zijn voor gentamicine geven de maxima Ie doses GEN en LE-GEN gecombineerd een 
overleving van 50%. Weliswaar bleek er bij analyse van de ge'infecteerde linkerlong een 
grate hoeveelheid gentamicine aanwezig te zijn in het ge'infecteerde weefsel. Waarschijnlijk 
was slechts een gedeelte van het gentamicine na toediening in de liposomale vorm actief. 
Daarom is de samenstelling van het liposoom gewijzigd. Zoals bekend was uit andere 
studies zorgt het verhogen van de vloeibaarheid van de liposomale bilaag gewoonlijk voor 
een snellere afgifte van ingesloten farmaca. Uit de experimenten in Hoofdstuk 2 bleek dat 
de vloeibaarheid van de fosfolipidenbilaag geen invloed heeft op de hoeveelheid liposomen 
die op de plaats van de infectie lokaliseert. Combinatie van deze vloeibare formulering van 
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LE-GEN en GEN resulteerde in het overleven van aile dieren. Liposomen kunnen dus een 
belangrijke bijdrage leveren in de therapie, met name in moeilijk behandelbare situaties. 
Het voorlaatste hoofdstuk geeft een nieuw concept weer op het gebied van de anti-
microbiele therapie met Iiposomen. Het is al langer bekend dat bepaalde antibiotica 
synergistisch (elkaar versterkend) kunnen werken, zo ook voor gentamicine en ceftazidime. 
Gentamicine verhindert de eiwitsynthese in de bacterie, maar slechts een klein gedeelte is in 
staat de celwand rond de bacterie te passeren. Ceftazidime verzwakt juist de celwand. 
Combinatie van ceftazidime dat de celwand verzwakt en gentamicine dat daardoor 
makkelijker deze barriere kan passeren leidt tot een snelle dood van de bacterien bij lage 
concentraties van combinaties van beide middelen. In het geval van een infectie is het 
probleem bij het toedienen van de beide antibiotica in de vrije vorm de onzekerheid of beide 
middelen wei op het juiste moment in passende concentraties gedurende een voldoende 
lange periode op de plaats van infectie aanwezig zijn. Door middel van Iiposomale 
inkapseling van beide antibiotica tezamen zou het mogelijk kunnen zijn beide middelen op 
dezelfde plaats op dezelfde tijd in hoge concentratie aanwezig te laten zijn. Uit de 
experimenten in ons bacteriele longinfectiemodel waarin de bacterie goed gevoelig is voor 
beide antibiotica blijkt dat de combinatie van de vrije middelen geen synergie laat zien, 
terwijl dat wei het geval is wanneer beide zijn ingekapseld in de Iiposomen en als zodanig 
worden toegediend. Ais gevolg hiervan kon met de Iiposomale formulering zowel korter als 
lager worden gedoseerd. Ook wanneer de bacterie, die de longinfectie veroorzaakt, resistent 
was voor beide antibiotica werd synergie na liposomale inkapseling van beide middelen 
gezien. 
In het laatste hoofdstuk worden de resultaten samengevat en worden suggesties gedaan 
voor voortzetting van het onderzoek. 
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Nawoord 
Dik vijf jaar geleden toen ik voor het eerst het Dr. Molewaterplein zag, kon ik er direct 2 uur 
van genieten. lk had de reistijd Leiden - Rotterdam Ee 1751a, rekening houdend met de mij 
onbekende route in het algemeen, en geruchten over onneembare hindernissen als perron 
0, de metro, de Maas en een laboratorium van 24 verdiepingen in het bijzonder, op 3 uur 
ingeschat. De zomers waren toen nog lang en heet en zo kon het zijn dat ik met zonder jas, 
zittend op het bankje voor de Erasmus, 120 minuten had om nogmaals te oefenen hoe ik 
glashard mijn geestdrift voor het onderzoek, werklust, zelfstandigheid en inventiviteit zou 
roemen, en gevraagd naar eventuele negatieve karaktereigenschappen mijn soms wat 
overtrokken perfectionisme en te grote collegialiteit met de juiste dosis bedremmeldheid zou 
brengen. Uit het feit dat ik dit nu in dit werkje op kan schrijven valt af te leiden dat ik: 
:>- het best in staat was mijn ware aard te verhullen van het legioen der 
sollicitanten (dat was toen nog zo, je stond nog in de rij voor een baan. Maar ja 
wat wilde je toentertijd ook anders met bedragen van 4 cijfers voor de komma die 
maandelijks (!) werden uitbetaald. 1600 gulden brandde in je zak als je aileen al 
dacht watje daar allemaal niet voor kon kopen) 
:>- dat het uiteindelijk tot een tot tevredenheid stemmend eindproduct is gekomen. 
Het is waar, maar houdt geen rekening met het water dat sindsdien door de Maas is 
gestroomd tussen bankje en boekje. 
Mijn moeder heeft dit boekje nooit kunnen zien. lets waar ik de eerste Rotterdamse jaren 
toch nog vurig op gehoopt had. 
Dat het er uiteindelijk toch Iigt is mede te danken aan een lange rij coli ega's, vrienden en 
familie. 
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werkbesprekingen exact de juiste vragen te stellen en goede suggesties te doen voor het 
vervolg, alsof hij de data gisteren nog had doorgenomen. Ik wit hem graag bedanken voor 
zijn inzet. 
Gert en Irma, mijn directe begeleiders, het was een voorrecht met jullie te werken. Van 
jullie enthousiasme, oog voor detail, optimisme en persoonlijke aandacht heb ik veel steun 
gehad en veel geleerd. Na een werkbespreking met jullie lagen er altijd weer meer 
onderzoekslijnen open dan konden worden onderzocht en leken de eerst wat teleurstellende 
data (met nog 1 experimentje hier en daar) al bijna een artikel. Bedankt voor jullie 
collegialiteit gedurende deze jaren, en ik vind het feit dat we nog steeds samenwerken het 
beste wat uit dit onderzoek is voortgekomen. 
Marian, een van de steunpilaren van het lab. Vanaf mijn rattenbeet op de eerste dag van 
mijn aanstelling tot de laatste inoculatie voor de synergie was je betrokken bij al mijn in vivo 
werk. Praktisch en hard meewerkend, bereid tot een onvoorzien experimentje tussendoor 
en nog aardig bovendien kan ik aileen maar zeggen: "zulke goede mensen worden maar 
weinig gemaakt". 
Samen met Wim ook nooit te beroerd om een avond of weekend op te offeren voor een 
gezellig potje injecteren, waarbij we voor een paar stellingen ratten en tegen de 1000 
injecties per week onze hand niet meer omdraaiden. 
"En wij dan?" hoor ik Susan, Liesbeth, Martin, EIs, Marcel, Diana, kleine Liesbeth, Lorna, 
Marianne; mijn stagestudenten Debbie, Corine, Angela, EIs, CO!jkun, en Renate; Tannie, 
Renata, Jan, Hanneke, Harald, Timo, Roel, Marian H, Floor en aile andere stagestudenten 
en aile overige collega's van 'beneden' en 'boven' al zeggen. "Wij hebben toch ook wei eens 
een naaldje meegeprikt, een overnachtcultuurtje ingezet, een plaatje geteld, een WK ¢ KK 
uitgevoerd, overleving gescoord en zijn aardig geweest?" 
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Mijn collega's in Utrecht wil ik ook bedanken. Alhoewel de 50:50 tijdsverdeling tussen 
Rotterdam en Utrecht met name op papier leuk oogde, maar ik praktisch toch wat vaker in 
Rotterdam vertoefde, heeft jullie dat er niet van weerhouden altijd met raad, daad en goede 
suggesties klaar te staan. Oat jullie ook aardig zijn weet ik inmiddels, als jullie 'nieuwe' 
collega, ook. 
Vrienden en (bijna) familie wi! ik bedanken voor hun niet aflatende belangstelling en 
gezellige ontspanning. 
Het feit dat mijn vader (die mij wegwijs heeft gemaakt in de wereld) en Patrick (die mij 
wegwijs heeft gemaakt in de wereld die wetenschap heet), mij ook het laatste uurtje fysiek 
terzijde willen staan geeft me het vertrouwen dat er ook nog een 'happy end' aan dit 
verhaa Itje zit. 
En van 'happy end' naar Saskia is maar een kieine stap. Haar onvoorwaardelijke steun, 
vriendschap en toekomstig jawoord maken dat ik ook de toekomst met vertrouwen 
tegemoet zie. En we leefden nog lang en gelukkig. 
Bedankt aliemaal, 
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Abbreviations 
AIDS 
ATCC 
AUC 
AUIC 
AUKC 
C 
C, 
Chol 
Cpm 
CZ 
d, 
D, 
db 
Db 
DNA 
DSPC 
DSPE 
EI 
EPC 
EPG 
GEN 
H 
HEPES 
IgG 
i.p. 
Lv. 
J, 
aquired immunodeficiency syndrome 
American type culture collection 
area under the curve 
are under the curve above the minimal inhibory concentration 
area under the killing curve 
consolidate zone 
concentration of solute 
cholesterol 
counts per minute 
(free) ceftazidime 
dose of A in combination with B needed to produce a desired effect 
dose of A alone needed to produce the desired effect 
dose of B in combination with A needed to produce a desired effect 
dose of B alone needed to produce the desired effect 
deoxyribonucleic acid 
distearoyl phosphatidylcholine 
distearoyl phosphatidylethanolamine 
early infected zone 
egg phosphatidylcholine 
egg phosphatidylglycerol 
(free) gentamicin 
hemorrhagic zone 
N-[-2 hydroxy ethyl] piperazine-N'-ethane sulfonic acid 
immunoglobulin G 
intraperitoneal(ly) 
intravenous(ly) 
fiux of solute 
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Jv 
LCL 
LE-CZ 
LE-GEN 
LE-GEN-CZ 
LL 
LPS 
MAC 
MPS 
MTD 
PBS 
PeSe 
PEG 
PHEPC 
PS 
RL 
spp. 
SSL 
TL 
l;C 
a 
172 
fluid flux 
long-circulating liposomes 
liposome-encapsulated ceftazidime 
liposome-encapsulated gentamicin 
liposome-co-encapsulated gentamicin and ceftazidime 
(infected) left lung 
lipopolysaccharide 
Mycobacterium avium complex 
mononuclear phagocyte system 
maximum tolerated dose 
phosphate buffered saline 
capillary permeability surface area product 
poly(ethylene) glycol 
partially hydrogenated egg phosphatidylcholine 
phosphatidyl serine 
right lung 
species 
sterically stabilized liposomes 
total lipid 
concentration difference across capillary wall 
reflection coefficient 


